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Prostaglandin (PG) E2 has been shown to act on at least three
distinct receptor subtypes, designated EPi, EP2 and EP3, with
recent evidence suggesting the possibility of a fourth EP-receptor
subtype. Whilst good antagonists are not available, a range of PGE
analogues of differing selectivity for the three receptor subtypes
may be used to determine which is effective in a given system.
The activity of these analogues has not yet been assessed on the
putative EP4-receptor containing preparation. This research has
involved the use of such compounds in an in vivo model of rabbit
skin inflammation, and biochemical studies on both platelets and
cultured macrophages, to determine the subtype(s) of PGE
receptor mediating the pro-inflammatory, pro-aggregatory, and
anti-inflammatory effects, respectively, of PGE2.
Whilst PGE2 alone had little effect on rabbit skin inflammation,
potentiation of vascular permeability induced by mediators of
inflammation, such as bradykinin (BK) and FMLP was observed.
The potentiation has been attributed to the vasodilator activity of
PGE2 which is typically mediated via the EP2-receptor subtype.
However the finding that compounds with both EP2- and EP3-
receptor activity were the most active, suggested that
vasodilatation was not the sole mechanism of the potentiation. A
comparison of the ability of PGE2 and the stable PGI2 analogue,
cicaprost, to induce vasodilatation and potentiate the responses to
both BK and FMLP, was consistent with this suggestion. It has
since been proposed that there is an initial EP3-mediated,
dilatation-independent component to the potentiation of BK by
PGE2.
PGE2 was shown to potentiate aggregation in human platelets
possibly through inhibition of adenylate cyclase. The potencies of
seven PGE analogues as potentiators of the PAF-induced
aggregation were assessed, and the ranking indicated that the EP3-
receptor subtype may be involved. This was supported by studies
on the adenylate cyclase second messenger system. The ability of a
series of PGE analogues to inhibit the cicaprost-induced rise in
cyclic AMP in human washed platelets was measured. The EP3-
selective agonists potently inhibited cyclic AMP production, in
comparison to the weak effect of PGE analogues selective for the
EPi- and EP2- receptor subtypes.
Evidence suggests PGE2 has a major role in the modulation of
interleukin (IL) -2 production by lymphocytes. The release of IL-1
from accessory macrophages, besides stimulating release of IL-2
from lymphocytes, also stimulates the release of PGE2 from other
macrophages. PGE2 acts as a negative feedback, inhibiting
production of IL-1 by the macrophages, and consequently IL-2 by
the lymphocytes. Human promyelocytic leukaemia (HL-60) cells
grown in suspension culture differentiate into macrophage-like
cells when exposed to a phorbol diester. Plasma membranes were
prepared from differentiated HL-60 cells by homogenisation and
sucrose density centrifugation. Of the four EP2-receptor agonists
tested, only 11-deoxy PGEi displaced binding in a manner
comparable to PGE2 itself. The lack of activity of EPi- and EP3-
selective compounds suggests that the receptor is not of either
subtype. By implication this may represent the fourth EP-receptor
subtype.
I declare that this thesis has been composed by myself and the
research has been conducted solely by me.
The results of the rabbit model of skin inflammation and
inhibition of cyclic AMP production in human platelets are
discussed in the context of contemporaneous experiments
conducted by my colleagues, as clearly referred to in the text.
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Prostanoids, that is prostaglandins (PGs) and thromboxanes (TXs),
may be synthesised de novo in almost every cell in the body, with
the exception being red blood cells. They are released in response
to stimuli, including hormones, chemical mediators, mechanical
stimuli and cell injury. The PGs and TXs are formed from the
20-carbon-containing fatty acid constituents of membrane
phospholipids, dihomo-y-linolenic acid, arachidonic acid and
eicosapentaenoic acid. These fatty acids give rise to the 1-, 2- and
3- series prostanoids respectively (Bergstrom et al, 1964,1968;
Van Dorp, 1964; Samuelsson et al, 1966,1978; Bergstrom 1967),
each referring to the number of double bonds in the side chains.
Since arachidonic acid is the predominant polyunsaturated fatty
acid present in mammalian cells, the 2-series prostanoids are the
most abundantly formed of the three (Moncada et al, 1980).
Prostanoids are formed from arachidonic acid by the
cyclooxygenase pathway (see Needleman et al, 1986;
see Williams & Higgs, 1988) as illustrated in Figure 1.1.
Leukotrienes (LTs), lipoxins (LXs) and hydroxyeicosatetraenoic
acids (HETEs) are also formed from arachidonic acid, and together
with the prostanoids constitute the eicosanoids
(see Needleman et al, 1986). The lipoxygenase enzymes
catalysing their formation do not appear to be as widely distributed
as those for the prostanoids, but have been recognised in platelets,
neutrophils and the skin.
Before enzymatic attack can occur, arachidonic acid must first be
released from the membrane phospholipid in which it is
incorporated in an esterified form (Billis et al, 1975); three
pathways have been proposed. Cleavage from the 2-position of the
phospholipid is catalysed by the action of phospholipase (PL) A2
(Flower & Blackwell, 1976; Vogt, 1978). Whilst PLA2 has been
reported to play the major role in the activation of platelets
(Broekrnan, 1986; Derksen & Cohen, 1975;
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Mahadevappa & Holub, 1986; Purdon et al, 1987), others believe
there is insufficient PLA2 activity to account for the burst of
arachidonate that occurs after platelet stimulation
(Bell et al., 1979). These groups did however detect sufficient
diglyceride lipase activity and suggested that in the platelet the
PLC pathway is responsible for the release of arachidonic acid,
forming initially diacylglycerol (DAG) from which arachidonic acid
is released by the action of this diglyceride lipase. Another study
(Billah et al, 1980) suggests the involvement of both PLC and PLA2
in sequence, with PLC producing phosphatidic acid (PA) from
phosphatidylinositol (PI), subsequent PLA2 activity releasing
arachidonic acid.
Irrespective of the phospholipase involved, free arachidonic acid is
sequentially converted to the PG endoperoxides, PGG2 and PGH2,
by PG endoperoxide synthetase (see Needleman et al, 1986), and
then to tissue specific PGs. Consequently, TXA2 is formed in
platelets (Needleman et al, 1976) and PGI2 in endothelial cells
(Moncada et al, 1976). Arachidonic acid not converted into the
eicosanoids is reesterified into phospholipid, thereby restoring the
ability to release the PG precursor upon subsequent stimulation.
It is proposed that liberation of arachidonate is mediated by at
least two distinct PLA2S in mammalian cells
(Takayama et al, 1991; Fujimori et al, 1992). The 14 kDa form
may be subdivided into group I, in mammalian pancreas, and group
II, in inflammatory exudate, according to its primary structure.
The requirement of mM Ca2+ in order to function suggests the
14 kDa form exerts its action extracellularly. Here it may have a
role in cell membrane homeostasis and digestion. Recently, the
secretory PLA2 of the group II type was isolated from rheumatoid
arthritic synovial fluid, and the gene encoding it cloned
(Seilhamer et al, 1989).
A 90 kDa form has also now been isolated and is believed to
function intracellularly. This novel cytosolic PLA2 has also recently
been cloned and expressed from the human monoblast cell line,
U937 (Clark et al, 1991). It is known to bind to membranes in a
Ca2+-dependent manner (Clark et al, 1991), and phosphorylation
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has been reported to have an important role in its agonist-induced
activation (Lin et al., 1992). There is no reported structural
similarity with the well-known mammalian secretory PLA2.
PG endoperoxide synthetase, catalysing the subsequent formation
of PGG2 and PGH2, consists of the two enzymes cyclooxygenase and
hydroperoxidase combined in a single protein unit.
Immunocytochemistry has shown cyclooxygenase to be located on
the endoplasmic and nuclear membranes in Swiss mouse 3T3
fibroblasts, but not on the mitochondrial or plasma membranes
(Rollins & Smith, 1980). Recent evidence suggests that lipid
bodies may represent additional sites of PG endoperoxide
synthetase localisation in murine fibroblasts and both human
eosinophils and monocytes (Weller & Dvorak, 1992).
A clone encoding PG endoperoxide synthetase activity has been
isolated from sheep vesicular gland (Merlie et al., 1988;
Yokoyama et al., 1988), mouse 3T3 fibroblasts (DeWitt et al., 1990)
and the human genomic library (Yokoyama & Tanabe, 1989). The
amino acid sequences encoded by the mouse and human cDNAs
demonstrated 88 % and 91 % homology with the sheep enzyme
respectively.
In addition, an mRNA for PGG / H synthetase has been isolated
from sheep tracheal mucosal epithelial cells (Rosen et al., 1989).
It is suggested that this mRNA may demonstrate high homology to
the sarcoma virus - induced mRNA recently isolated from chick
embryo fibroblasts by Xie et al (1991), though further investigation
following cloning and amino acid sequencing of the former is
necessary to verify this. In non-proliferating cells the chick mRNA
was at a low level and was nonfunctional. The protein it expressed
in proliferating cells, demonstrated 59 % homology with the sheep
PGG / H synthetase already cloned. Comparison of their respective
mRNAs suggests this may be a new inducible form of the enzyme.
Indeed, induction of a novel cyclooxygenase has recently been
reported to be responsible for endotoxin priming of rabbit alveolar
macrophages for amplified synthesis of prostanoids
(O'Sullivan et al., 1992).
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A second form of cyclooxygenase, the PGG2 synthetase component
of PG endoperoxide synthetase, is also reported to have been
isolated from human umbilical vein endothelial cells, with 61 %
homology to the previously isolated cyclooxygenase polypeptide
(Hla & Neilson, 1992). Messenger RNA for both cyclooxygenases
was also expressed in vascular smooth muscle cells, monocytes and
fibroblasts, and was differentially regulated. In addition, two pools
of cyclooxygenase have been found to exist in murine fibroblasts,
with 63 % homology between the corresponding proteins
(Winn et al., 1992). The first is a constitutive, long-lived
cyclooxygenase, the second being regulated by corticosteroids
(see page 9) and rapidly turned over.
This cyclooxygenase component catalyses the insertion of two
molecules of oxygen into arachidonic acid, giving rise to the
15-hydroperoxy compound, PGG2. The hydroperoxy group is
subsequently reduced to hydroxy, by the action of hydroperoxidase.
The resulting PGH2 then serves as the precursor for the PGs and
TXs, the conversion dependent on the specific enzyme(s) present
in a particular tissue. The PG endoperoxides, PGG2 and PGH2, are
unstable and will decompose with a half-life (ti/2) at 37 °C of
~ 4-5 min, in the absence of these enzymes.
Since there are efficient mechanisms for the inactivation of the
prostanoids, their action is normally of short duration. Initially the
prostanoids must be transported across the membrane back into
the cells where the catabolic enzymes are. The breakdown
process itself occurs in two stages. The first is a rapid prostanoid-
specific breakdown involving dehydrogenation of the carbon-15
hydroxyl group by the widely distributed 15-hydroxy prostaglandin
dehydrogenase, producing 15-keto compounds (reviewed in
Hansen, 1976). These products then enter a slower oxidation
phase. PGI2, 11 /2 at 37 °C of ~ 3 min (Dusting et al., 1977), and
TXA2, ti/2 at 37 °C of ~ 30 s (Hamberg et al, 1975), are
themselves chemically labile and rapidly decompose to the
essentially biologically inactive intermediates 6-keto-PGFia and
TXB2 respectively, before being metabolised further. The levels of
these metabolic products in biological fluids are usually taken to be
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representative of the rates of production of the individual
prostanoids, but this is complicated by the fact that there may be
many degradation products.
Besides the cyclooxygenase-derived PGs, the existence of a series
of PGF2a-like compounds which are produced in vivo in humans by
a non-cyclooxygenase, free radical - catalysed mechanism has
recently come to the fore (Morrow et ai, 1990). Reactive free
radicals may be formed pathophysiologically in disorders such as
atherosclerosis, ischaemia-reperfusion injury, inflammatory
disease, cancer and ageing. The finding that one of these
compounds, namely 8-epi-PGF2a, has biological activity, suggests
they may in fact be mediators in such conditions.
8-Epi-PGF2a was indeed found to reduce renal blood flow and the
glomerular filtration rate when infused into the rat kidney
(Morrow et al., 1990). This effect is reported to be mediated
through stimulation of PI turnover, via interaction with the
TXA2 / PGH2 receptor (Fukunaga et al, 1992). Interestingly,
8-epi-PGF2a is considered to be an antagonist at the TXA2 / PGH2
receptor on both rat and human platelets (Morrow et al, 1992a).
The contrasting profile demonstrated by 8-epi-PGF2a on these two
preparations may be reconciled by the existence of TXA2 / PGH2
receptor subtypes, or the presence of a novel receptor on the rat
vasculature at which 8-epi-PGF2a is an agonist and, like the
TXA2 / PGH2 receptor, SQ29548 is an antagonist.
It has been reported that these non-cyclooxygenase - derived PGs,
in contrast to those formed as result of cyclooxygenase activity, are
essentially stored, being formed in situ on phospholipids
(Morrow et al, 1992b). They are then released, possibly by the
action of phospholipases. A new synthetic approach using
carbohydrates has been developed for the chemical synthesis of
these epi-PGs (Rokach et al, 1992a,b). The finding that elevated
plasma levels and an increased urinary excretion of these
prostanoids occurs in hepatorenal syndrome (Moore et al, 1992)
suggests they may be involved in its pathogenesis.
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1.2 Control of prostanoid biosynthesis and action
In 1971 it was discovered that aspirin and similar drugs inhibited
the biosynthesis of PGs (Vane, 1971) and this was believed to be
the mechanism of their therapeutic efficacy. There are two stages
in the pathway of prostanoid synthesis which are susceptible to
inhibition by anti-inflammatory agents. Most commonly used are
the non-steroidal anti-inflammatory drugs (NSAIDs), such as
aspirin (Kocsis et al., 1973; Flower, 1974). Their mechanism of
action is believed to be through the inhibition of cyclooxygenase,
though they have been reported to show a differential profile of
activity on each of the two forms of cyclooxygenase previously
described (Meade et al., 1992). NSAIDs thereby prevent the
formation of PGG2 from arachidonic acid, and consequently the
PGs and TXs, though not the LTs (Vane & Botting, 1987;
Robinson 1989). In fact by inhibiting cyclooxygenase activity,
NSAIDs may actually increase LT synthesis through a build up of
arachidonic acid being channelled into the lipoxygenase pathway.
Unwanted side-effects accompanying NSAID treatment may
therefore arise as a result of the accompanying increased
production of these LTs (Lee et ah, 1986; Robinson et al., 1986).
In addition, gastric ulceration is one of the major side-effects of
NSAID therapy, occurring through inhibition of the formation of
cytoprotective PGs (Reeves & Stables, 1985). It may therefore be
more appropriate to inhibit the synthesis or action of particular
PGs or TXs, to maintain synthesis of the beneficial prostanoids and
prevent redirection of arachidonic acid to the potentially
deleterious LTs.
Cyclooxygenase inhibitors such as aspirin have shown some
anti-thrombotic activity in the clinic, however the simultaneous
inhibition of endothelial cyclooxygenase presents a theoretical
limitation to its usefulness. TXA2 is one of the most potent
inducers of platelet activation, and is involved in the development
of thrombosis (Gresele et al., 1991). Platelets, producing primarily
TXA2, are more susceptible to the inhibitory effects of NSAIDs as
compared to the endothelium, which produces PGI2. This is
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thought to be due to the fact that 60 % of the aspirin is
deacetylated to salicylate during first-pass metabolism, so that
absorbed aspirin affects platelet cyclooxygenase whilst platelets are
in the hepatic portal circulation, but the systemic plasma aspirin
concentration is then too low to affect PGI2 synthesis. In addition,
platelets cannot regenerate cyclooxygenase since they have no
nucleus (Steiner, 1970), formation of new platelets from bone
marrow stem cells, which themselves are sensitive to aspirin,
being required to restore cyclooxygenase activity. A single dose of
aspirin may therefore have an effect on platelet function lasting
well over a week.
Since PGI2 is a potent inhibitor of platelet activation, it may be of
benefit to preserve its production whilst inhibiting that of TXA2 in
conditions such as thrombosis. Given the differential sensitivity of
their production to NSAIDs, it was hoped to develop a regimen
which allowed the formation of PGI2 in the absence of TXA2. Since
much of the PGH2 for PGI2 synthesis is formed in the platelet, this
is an impossible task as any inhibition of platelet cyclooxygenase
would effectively reduce endothelial cell PGI2 production
(Patrono, 1989). Efforts were then concentrated on developing a
TX synthetase inhibitor to selectively prevent the conversion of
PGH2 to TXA2. It was reasoned that the PGH2 destined for TXA2
formation would then be redirected and consequently not only
would PGI2 synthesis be spared, it would actually be enhanced. In
addition it was expected that the platelet levels of antiaggregatory
PGD2 would also be raised. However, the PGH2 accumulated may
also interact with the platelet and vascular wall TXA2 / PGH2
receptor, thereby inducing vasoconstriction and platelet
aggregation and opposing the inhibitory effect of additional PGI2
synthesised (Gresele et al, 1984,1987).
The alternative use of a TXA2 / PGH2 receptor antagonist alone has
its limitations since it may be displaced from the receptors by high
concentrations of TXA2 generated at the localised sites of platelet
activation. Also whilst PGI2 production would be preserved, it
would not be enhanced as in the presence of a TX synthetase
blocker, nor would there be any effect on aggregation induced by
7
TXA2-independent stimulators of platelet aggregation, such as high
dose collagen or thrombin. Perhaps a combination of a
TX synthetase inhibitor and a TP-receptor antagonist would
overcome the problems arising due to administration of the
TX synthetase inhibitor alone and improve on the effect of
TXA2 / PGH2 receptor antagonists (Gresele et al., 1987). The
resulting increase in cyclic AMP as a result of such a combination
may suppress platelet aggregation induced by other stimuli,
thereby potentially reducing both TXA2- dependent and
independent platelet activation. Examples of such drugs include
ridogrel (De Clerck et al., 1989a,b; Hoet et al., 1990), picotamide
(Gresele et al., 1989) and D1542 (Brewster et al., 1992;
Brownlie et al. 1992; Snow et al., 1992).
All actions of the NSAIDs are however, not the result of inhibition
of prostanoid synthesis. 7-Oxa-13-prostynoic acid, indomethacin
and the mefenamates inhibited the effects of PGEi and PGE2 in
elevating cyclic AMP levels in human astrocytoma cells
(Ortmann & Perkins, 1977). The fenamates have been reported to
exert this additional anti-inflammatory effect at the level of the
receptor (Rees et al., 1988; Rees & Bernal, 1989;
Bernal et al., 1991). In particular, meclofenamic acid
demonstrated weak but specific blocking activity at prostanoid
EPi- and TP- receptors, as demonstrated by the antagonism of
PGE2- and U 46619 - induced contraction of the guinea-pig fundus
and rat aorta respectively (Head et al., 1992). Meclofenamate was
also shown to inhibit PGE binding and adenylyl cyclase activation in
the human myometrium (Bernal et al., 1991). In addition, at
concentrations greater than those required for inhibition of
prostanoid synthesis, NSAIDs such as aspirin, ibuprofen,
indomethacin, piroxicam and sodium salicylate, have been
demonstrated to exert an anti-inflammatory effect through
inhibition of neutrophil activation (Rampart & Williams, 1986a;
Weissman, 1987; Abramson & Weissmann, 1989).
Corticosteroids also inhibit production of the prostanoids though
they act at an earlier step in the pathway than do NSAIDs, namely
the release of arachidonic acid from phospholipid. The
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mammalian group II PLA2 is found in inflammatory exudates and is
the form susceptible to the inhibitory effect of the corticosteroids.
Several mechanisms have been reported to be involved. This
inhibitory activity was initially demonstrated on perfused
guinea-pig lungs, and since then the release of PGs from various
tissues has been shown to be reduced, but not the conversion from
exogenous arachidonic acid (Gryglewski et al, 1975). In contrast
to the NSAIDs, steroids also inhibit production of the LTs, since
these too are derived from arachidonic acid, though by the action
of lipoxygenase.
Recently it has been suggested that corticosteroids, besides their
PLA2 -inhibitory activity, also inhibit PG synthesis at the level of
cyclooxygenase (Goppelt-Struebe et al., 1989), and that the lack of
effect of the corticosteroids on conversion of arachidonic acid to
PGs previously reported may be a result of inappropriate time
periods. Dexamethasone was shown to significantly inhibit
prostanoid synthesis from exogenous arachidonic acid in bone
marrow - derived macrophages by an effect on cyclooxygenase
and / or PGE synthetase. Whilst having an effect on endogenous
PLA2, the predominant effect of dexamethasone was on the
conversion of arachidonic acid to its metabolites.
The effect of the steroids through inhibition of arachidonic acid
release is possibly mediated through the formation of an inhibitory
protein, which binds to PLA2 thereby preventing its action.
Several of these inhibitory proteins have been reported, such as
macrocortin (Blackwell et al., 1980), lipomodulin
(Hirata et al, 1980) and renocortin (Cloix et al., 1983). The term
lipocortin is now used collectively for such inhibitory proteins
(Di Rosa, 1984; Flower, 1985,1988; Rothwell & Flower, 1992).
Since corticosteroids predominantly alter gene expression, they
may block PLA2 - messenger RNA (mRNA) synthesis, and in
addition have been reported to inhibit post-transcriptional
expression of group II PLA2 (Nakano et al, 1990). A similar
inhibition of translational and post-translational cyclooxygenase
activity has also been suggested (Flower, 1992). Such an effect has
been demonstrated, in the in vivo models of human and rat
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arthritis (Sano et al., 1992). In these inflammatory joint diseases,
there was a corticosteroid-sensitive upregulation of cyclooxygenase
expression. It has been reported that the mRNA and protein of
the second cycloxygenase gene cloned is that form of the enzyme
sensitive to this inhibition by corticosteroids (Herschman, 1992;
O'Banion et al., 1992; Smith & Marnett, 1992). The ability of
dexamethasone to selectively down-regulate the expression of this
gene is thought to occur by a non-transcriptional mechanism
involving destabilisation of the corresponding mRNA
(Simmons et al., 1992).
Corticosteroids therefore appear to exert their anti-inflammatory
effect both at the level of release of arachidonic acid and its
conversion to the prostanoids. Possible mechanisms include
inhibition of transcription, and post-transcriptional effects such as
destabilisation of mRNA and synthesis of inhibitory proteins.
Lipocortins have been cloned and sequenced (Wallner et al., 1986)
and found to be related to a family of calcium and phospholipid
binding proteins, calpactins and calelectrins
(Davidson et al., 1987). The finding that inhibition by lipocortin is
substrate concentration dependent raises the possibility that they
may in fact act by binding to phospholipid and not PIA.2 as
proposed (Aarsman et al., 1987).
Regulation of nutritional lipids is an alternative to the control of
eicosanoid production besides such inhibition of enzyme activity.
The most abundant essential fatty acid in the Western diet is
arachidonic acid, which may also be formed by desaturation and
chain elongation of dietary linoleic acid. As discussed, this fatty
acid gives rise to the 2-series prostanoids. Dietary y-linolenic and
oleic acid are metabolised to dihomo-y-linolenic acid, forming
monoenoic prostanoids, and eicosapentaenoic acid, forming
trienoic prostanoids, respectively. There is competition between
these three dietary fatty acids for desaturases responsible for the
synthesis of tissue polyunsaturated fatty acids. Enrichment of the
diet with the latter two, may therefore increase the formation of
the 1- and 3- series prostanoids, at the expense of the 2-series.
An inhibitory influence is also observed at the levels of
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cyclooxygenase and lipoxygenase, where linolenic acid inhibits the
oxygenation of arachidonic acid by cyclooxygenase
(Belch et al., 1988; Hwang, 1989) and dihomo-y-linolenic acid
forms a derivative which blocks the transformation of arachidonic
acid into the leukotrienes.
Animal studies have shown diets rich in either primrose oil,
increasing the levels of y-linolenic acid, or eicosapentaenoic acid,
both exert an anti-inflammatory effect (Tate et ah, 1988). In man,
ingestion of evening primrose oil or eicosapentaenoic acid have
been shown to be of benefit in conditions of eczema and
rheumatoid arthritis. Indeed, incorporation into the diet of
evening primrose oil alone or in combination with fish oil, which
contains eicosapentaenoic acid, allowed some patients to reduce or
stop their treatment with NSAIDs. This influence of dietary fatty
acids in conditions of inflammation should prove to be useful
where patients suffer peptic ulceration or renal impairment,
thereby precluding the use of NSAIDs.
1.3 Prostanoid Receptors
Several properties of the prostanoids suggest the existence of
prostanoid receptors, including :
- high potency (Oien et ah, 1975);
- small chemical modifications having profound effects on their
potency and profile of biological activity (Pike et ah, 1967);
- different prostanoids having different effects on the same cell
type (Moncada et ah, 1976).
Distinct receptors for each of the five different naturally occurring
prostanoids PGD2, PGE2, PGF201, PGI2, TXA2, were consequently
proposed. These have been designated DP, EP, FP, IP and TP,
where the letter preceding P, for prostanoid, refers to the natural
prostanoid having the greatest potency at that receptor.
Direct evidence for prostanoid receptors initially resulted from
work conducted by Pickles in 1967, studying the effects of a series
of PGE and PGF analogues on the guinea-pig uterus, human
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myometrium and rabbit jejunum. This was supported by a later
study into the structure-activity relationships for analogues of PGA,
PGE and PGF (Andersen & Ramwell, 1974). Indeed, a binding
study suggested a PGE receptor to be present on rat adipocytes
(Kuehl & Humes, 1972). The initial classification by Gardiner &
Collier (1980) suggested three types of prostanoid receptor, \\/, X
and co, based on the results of a range of natural and synthetic
agonists in airways. Following a comparison of the potencies of
PGD2, PGE2, PGF2oc, PGI2 and the stable TX-mimetic, U46619
(Coleman et al., 1981), distinct receptors were proposed for each
(Kennedy et al., 1982, 1983; Coleman et al., 1984;
Coleman, 1988). This work has been supported both
pharmacologically (Jones et al., 1984; Tynan et al., 1984;
Whalley & White, 1980) and biochemically (Jones et al., 1984;
Robertson, 1986). It is this later classification upon which
prostanoid receptor nomenclature is now based. PG receptors
have been classified more recently based on their coupling to
signal transduction systems (Muallem et al., 1989). This group
suggests that tissue response measurement may not be
representative of the interaction of the agonist with its receptor,
especially where there is more than one PG receptor mediating
the same response, and specific antagonists for each of the
naturally occurring PGs are not available. An analysis of the results
from both methods on a common tissue would be of interest, to
determine to what extent the profiles differ.
Prostanoid receptor classification does not stop here though,
further studies having identified subtypes of the DP, EP and TP
receptors. Since this thesis is concerned with the
characterisation of EP-receptors, the evidence leading to its
subdivision into the EPi-, EP2-, EP3-, and EP4- receptors
(Coleman et al., 1985a; Coleman 1987; Coleman et al., 1987a,b,c;
Rao, 1988) will be presented.
Bennet & Posner (1971) first suggested that two subtypes of PGE
receptor may exist. This resulted from their finding that
SC 19220 and polyphloretin phosphate blocked the contractile
action of PGE2 on the longitudinal muscle of the guinea-pig ileum,
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whereas the relaxant action of PGE2 on the circular muscle was
unaffected. Since then, Coleman et al. (1980) found SC 19220 to
be inhibitory to PGE2 on only some of a range of
EP-receptor-containing tissues, such as the guinea-pig ileum and
fundus, but not the guinea-pig lung, dog saphenous vein, rabbit
aorta, dog and cat iris or cat trachea. EP-receptors which were
blocked by SC 19220 were designated EPi-receptors. The
effectiveness of this compound was limited by its low potency and
solubility, subsequently being superseded by AH 6809
(Coleman et al., 1985a) with a similar profile of action but having
both a greater potency and solubility.
This was supported by another study conducted by
Dong et al. (1986), this time involving a comparison of the effects
of the EP-receptor agonists ICI 80205, 16,16-dimethyl PGE2 and
11-deoxy PGEi with that of PGE2. Whilst ICI 80205 and
16,16-dimethyl PGE2 were more active than PGE2 as contractile
agents on bullock iris sphincter, rat stomach fundus and guinea-pig
trachea, PGE2 was the more potent relaxing agent on cat and
guinea-pig trachea, and dog hind limb arterial vessels in vivo.
11-Deoxy PGEi however showed more relaxant than contractile
potency, when compared to PGE2.
This subclassification of the EP-receptor has been confirmed and
extended by the identification of the selective agonists,
sulprostone and AY 23626. These two compounds showed a
different profile of activity on tissues not sensitive to the activity of
SC 19220 or AH 6809, leading to the division of the non-EPi
EP-receptors into two further subtypes, EP2 and EP3
(Coleman et al., 1987a,b,c). Sulprostone has a high potency at
EPi- and EP3- (chick ileum) receptors, and is inactive at
EP2-receptors (cat trachea), whereas AY 23626 is potent at
EP2- and EP3- receptors, having weak or no activity at
EPi-receptors. Similarly, Coleman et al. (1987c) using the
guinea-pig vas deferens and guinea-pig ileum circular muscle
preparations, found an effect of PGE2 which was not blocked on
either by SC 19220 or AH 6809. Sulprostone on the other hand
was shown to be highly active as an inhibitor of the twitch
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response in field stimulated guinea-pig vas deferens, whereas it
was inactive in relaxing the guinea-pig ileum circular muscle. The
action of sulprostone in inhibiting the histamine-induced acid
secretion of the rat isolated gastric mucosa showed a similar
potency to that on the vas deferens described above, and its action
was unaffected by SC 19220 (Reeves et al., 1988).
The use of such analogues having differing selectivity for each of
these three EP-receptor subtypes and the EPi antagonists, have
allowed the identification of the EP-receptor subtype(s) in a given
system to be established. Table 1.1 outlines the EP-receptor
subtypes present in various tissues, which may then be used to
determine the EP-receptor subtype activity of novel compounds.
EPi~ and EP3- receptors in general mediate contraction of smooth
muscle and EP3-receptors also mediate inhibition of transmitter
release. This may involve a rise in the intracellular Ca2+
concentration ([Ca2+]i, (Creese & Denborough, 1981) or a fall in
intracellular levels of cyclic AMP (Gutman et al., 1979).
Meanwhile, the relaxation of smooth muscle is generally mediated
by EP2-receptors. It is likely that this effect is the result of an
increase in intracellular cyclic AMP levels, such an increase
accompanying the PGE2-induced relaxation of vascular and
intestinal smooth muscle (Creese & Denborough, 1981).
More recently the possibility of a fourth EP-receptor subtype has
been reported as indicated in the table referred to above. An
investigation of the EP-receptor subtype mediating relaxation of
the rabbit jugular vein (Lawrence & Jones, 1992) suggested it to be
similar to the EP2-receptor, but the putative EP2-selective agonist
butaprost showed a low potency on this preparation as compared
to the cat trachea. The hamster uterus preparation
(Yeardley et al., 1992) enforced this requirement for a fourth
subtype. Whilst PGE2 inhibited uterine contractions and increased
intracellular levels of cyclic AMP, AH 13205, EP2-selective, and
sulprostone, EPi and EP3- selective, were inactive in these
respects. Having found AH 13205 and sulprostone to be 6,500
times and 11,000 times respectively less active than PGE2 in
relaxing pre-contracted pig saphenous vein, Louttit et al. (1992a)
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suggested the existence of an EP4-receptor. In addition, the
TP-receptor blocking drug AH 23848B, whilst demonstrating no
antagonistic activity on guinea-pig fundus (EPi-receptor
preparation), rabbit ear artery (EP2-receptor preparation) or
guinea-pig vas deferens (EP3-receptor preparation), was reported
to have a weak antagonistic activity, pA2 = 5.36, at this 'new'
receptor subtype (Louttit et al, 1992b).
Many PGE analogues have been synthesised, showing differing
selectivity for the EPi-, EP2- and EP3- receptor subtypes
(see Figures 1.2 & 1.3; structures of additional compounds used
are given in Figure 1.4). The activity of these analogues on the
putative EP4-receptor subtype is as yet not known, since the
possibility of its existence is only now emerging. For evidence of
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There are many prostanoid agonists which are analogues of PGE,
but their biological actions are not necessarily mediated through
EP-receptors. For instance, 16,16-dimethyl PGE2, ICI 80205,
MB 28767 and Wy 17186 all have TP agonist activity on vascular
smooth muscle and blood platelets which may be blocked with
GR 32191 (Lumley et al, 1989), whilst PGEi has been proposed to
act on IP-receptors (Miller & Gorman, 1979). Similarly, it is not
essential that an agonist be a PGE analogue for it to behave as an
EP agonist. Considering the stable prostacyclin analogue iloprost,
besides showing potent IP agonism on both platelets and vascular
smooth muscle, it is also a potent agonist at EPi-receptors
(Dong et al, 1986; Sheldrick et al, 1988).
To date, only EP-receptor antagonists specific for the
EPi-receptor subtype have been developed, and include the earlier
mentioned SC 19220 and AH 6809 (Coleman et al, 1985b). These
two compounds each have their limitations. The poor aqueous
solubility and low potency of SC 19220 limit its usefulness in vivo.
Although AH 6809 has a higher solubility and potency compared to
SC 19220, it also blocks DP- and TP- receptors
(Keery & Lumley, 1988) at higher concentrations, and is highly
protein bound (Coleman et al, 1985c). Diphloretin phosphate
(DPP) also possesses some EPi-receptor blocking activity, though
like AH 6809 is also believed to have antagonistic activity at both
DP- and TP-receptors. In contrast to the above mentioned
EPi-receptor antagonists, 13,14-didehydro-20-methyl
carbaprostacyclin is structurally related to the prostanoids, being a
PGI2 analogue (Fassina et al, 1985). It has been shown to inhibit
the effect of PGI2 on guinea-pig tracheal smooth muscle with a pA2
of 7.2. Since this preparation contains no IP-receptors, the
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activity of PGI2 is likely to be mediated by EPi-receptors. In the
absence of more selective antagonists then, we are currently
reliant on the PGE analogues for characterisation of the
EP-receptor subtype in a given system.
There has been some recent success in the cloning of prostanoid
receptors. Having cloned cDNA for both the human and mouse
TP-receptors (Hirata et al., 1991), whose respective proteins
demonstrated 78 % homology, cDNA for the mouse EP3-receptor
subtype was then isolated and expressed by the same group
(Sugimoto et al., 1992). The cloned PGE receptor showed
30 - 40 % homology to the TP-receptors, and has been shown to
couple to Gi. Whilst such molecular cloning techniques are
valuable in differentiating between receptors and their subtypes,
they must be complemented with functional studies to
demonstrate the biological relevance of molecular differences.
Prostanoids have been implicated in many pathological conditions
including inflammation (Lewis, 1983), cancer
(Goodwin et al., 1980), pyrexia (Milton & Wendlandt, 1971),
destruction of cartilage and bone (Lewis, 1983), thrombosis and
occlusive vascular disease (Hirsch et al., 1981), renal disease
(Scharschmidt et al, 1986), asthma (Horton, 1969) and migraine
(Lance, 1973). The development of drugs which interfere with
their synthesis or action is therefore of potentially great
therapeutic value. Consequently classification of prostanoid
receptors and their subtypes is important in order that drugs be
developed which retain the beneficial effects to the exclusion of
those that are adverse.
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Figure 1.3 Structures of PGE analogues
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GR 63799X - EP3 selective agonist
COOH
AH 23848 - EP4 selective antagonist
OH
OH










Cicaprost - stable IP-receptor agonist
Figure 1.4 Further structures
21
Table 1.1 EP-receptor subtypes and tissues expressing them.
Smooth muscle contraction is typical of EP±-recentor activation :
guinea-pig ileum
guinea-pig fundus
dog and cat fundus
rat and pig fundus
guinea-pig trachea
human myometrium
(Coleman et al, 1985a,b; Coleman, 1987)
tt
(Coleman, 1987)
(Coleman & Kennedy, 1985)
(Senior et al., 1991)
Smooth muscle relaxation is topical of EPv-receptor activation :
guinea-pig trachea






(Coleman & Kennedy, 1985)
(Gardiner, 1986; Coleman et al., 1987c)
(Coleman et al., 1985a)
(Coleman, 1987)
ii
(Gardiner, 1986; Clayton et al., 1986)
(Chen & Woodward, 1992)
The following are typical of EP^-receptor activation :
inhibition of:
twitch of guinea-pig vas deferens (Hedqvist & Von Euler, 1972)
release from adrenergic nerve terminals (Mantelli et al., 1991)
contraction of:
chick ileum (Coleman et al., 1987c)
rat and pig fundus (Coleman, 1987)
rabbit renal artery (Ahluwalia et al., 1988)
guinea-pig uterine artery (Baxter et al., 1989)
human myometrium (Senior et al., 1991)
The following man involve putative EPd-receptor activation :
relaxation of:
rabbit jugular vein (Lawrence & Jones, 1992)
hamster uterus (Yeardley et al., 1992)
pig saphenous vein (Louttit et al., 1992a,b)
inhibition of :
macrophage interleukin 1 (IL-1) release (Chapter 4, this thesis)
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Chapter 2
Characterisation of the PGE receptor mediating the pro¬
inflammatory effect of PGE2 in a rabbit model of skin
inflammation
2.1 INTRODUCTION
2.1.1 The inflammatory response
Inflammation is the body's reaction to injury, and is characterised
by redness, heat, pain and swelling. These symptoms are caused
by an increased blood supply to the infected area, an increased
capillary permeability and migration of leucocytes out of the
capillaries and into the surrounding tissue. Once in the tissue,
these cells migrate to the site of infection in response to
concentration gradients of inflammatory mediators, a process
known as chemotaxis. The polymorphonuclear (PMN) leucocytes
(neutrophils, eosinophils and basophils) are the first of the blood
leucocytes to enter the area of the inflammatory reaction, followed
several hours later by the mononuclear leucocytes (monocytes and
lymphocytes). These leucocytes engulf tissue debris, dead cells
and microorganisms and are important in the repair processes.
There are many mediators of inflammation including : amines
(histamine and 5-hydroxytryptamine (5HT)); short peptides
(bradykinin); long peptides (interleukin-1); lipids (prostaglandins
and leukotrienes); enzymes released by migrating cells and
complement. The increased capillary permeability caused by
contraction of the endothelial cells, allows the larger of these
molecules to cross the endothelium thereby gaining access to the
site of infection from the blood. Mast cells containing histamine
and 5HT are already present in the tissues.
The inflammatory reaction and concomitant immune response are
a defensive mechanism against disease-causing organisms. The
immune system confers specificity on the reaction, the
inflammatory reaction representing an effector. Sometimes this
defensive mechanism is raised to innocuous substances from
outside the body, or against tissues of the body itself such as in
asthma or rheumatoid arthritis. In these conditions
anti-inflammatory or immunosuppressive drugs are of considerable
value.
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2.1.2 Prostaglandins in inflammatory exudation
PGE2 was first identified in carrageenan-induced rat inflammatory
exudate by Willis (1969a,b), and subsequently in human cutaneous
inflammation, both as a result of exposure to ultraviolet light
(Greaves & Sondergaard, 1970) and in the condition of allergic
contact eczema (Greaves et al., 1971). Since NSAIDs have been
shown to inhibit prostaglandin synthesis in guinea-pig lung
cell-free homogenates (Vane, 1971), isolated human platelets
(Smith & Willis, 1971) and in perfused dog spleen
(Ferreira et al., 1971), with a potency comparable to that as
inhibitors of carrageenan-induced oedema, PGs are thought to have
an important role in inflammation. The significance of these
findings has been enhanced by the demonstration that PGs can
induce signs of inflammation both in rat and man
(Crunkhorn & Willis, 1969,1971a), causing increased vascular
permeability indirectly through degranulation of mast cells. The
criteria for classifying a compound as a mediator of inflammation
have therefore been met. These are: induction of the signs of
inflammation, release of the candidate substance during an
inflammatory reaction in a concentration capable of inducing
inflammation, and reduction of release by known anti-inflammatory
drugs.
Following i.v. administration of pontamine blue to the rat, the
effect of intradermally injected PGs Ei, E2, Fia and F2a was
assessed both by measurement of the mean diameter of each blue
reaction site, and by scoring their intensity on a five-point scale
(Crunkhorn & Willis, 1971a). PGEi and PGE2 showed a threshold
effect on local vascular permeability at a dose of 1 ng, and at
100 ng produced a marked increase; their potency was
comparable to other putative mediators of inflammation such as
histamine, bradykinin and 5HT. PGFia and PGF20. in microgram
doses did not produce any significant effect themselves, though
PGF2a (500 ng) was shown to inhibit the increased permeability in
response to 100 ng of either PGEi or PGE2
(Crunkhorn & Willis, 1971b). This may reflect a local control of
inflammation to minimise potential injury. Thomas & West (1973)
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however, whilst suggesting that PGEi potentiates the response to
bradykinin in the rat skin, found the response to bradykinin and
PGE2 to be only additive. Injecting the PGEs subcutaneously into
the rat hindpaw gave a similar profile of action
(Thomas & West, 1974).
Experiments carried out following i.v. administration of
mepyramine (histamine Hi-receptor antagonist) or methysergide
(5HT-antagonist), or following depletion of mast cell amines with
compound 48/80, indicate PGE2 exerts its potentiating effect in
the rat through the release of mast cell amines, with the release of
histamine being predominant (Crunkhorn & Willis, 1971a).
Mepyramine and methysergide inhibited the cutaneous response
to histamine and 5HT respectively, whilst compound 48/80 had no
effect on either. None of the three treatments altered the
response to bradykinin, whilst the PGE2-induced increase in
permeability was susceptible to all, mepyramine more so than
methysergide. The effect of compound 48/80 itself in increasing
local vascular permeability in rat skin was blocked by PGF2a
(500 ng). It was therefore suggested that PGF2« may act by
inhibiting the release of mast cell amines by both PGEi, PGE2 and
compound 48/80. Although PGAi is of much lower potency than
PGE2, blueing occurring only at doses greater than 100 ng, it
appears that it too exerts its effect through the release of
histamine, since it could be blocked by pretreatment with
mepyramine. Release of mast cell amines may therefore reflect a
common mechanism for increasing local vascular permeability in
the rat.
This cutaneous reaction to i.d. PGEi and PGE2 has also been
demonstrated in the rat hindpaw model of inflammation where the
effect of PGs on other inflammatory mediators has also been
studied (Di Rosa et al., 1971). To assess the effect of PGs
administered i.d., rats were treated with indomethacin to suppress
endogenous prostaglandin formation, such pretreatment reducing
the paw swelling induced solely by carrageenan, a phlogogen
extracted from seaweed. 100 ng PGEi and PGE2 were both shown
to potentiate the rat paw swelling induced by carrageenan, with
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PGEi being approximately 5 times more potent than PGE2. The
potentiation by PGE appeared to be fairly specific since PGF2a
(500 ng) gave no potentiation; histamine was only a weak
potentiator with 20 gg being as effective as 0.1 gg of PGEi and
bradykinin at 1 gg was ineffective. In another study
(Lewis et al, 1975) the volume of both hindpaws of each rat was
measured by mercury displacement plethysmometry. PGEi and
PGE2 produced a mild paw swelling at 100 ng, and potentiated the
response to 1 mg carrageenan, whilst PGF2a (250 ng) proved to be
ineffective both itself and in the presence of carrageenan.
This study was extended beyond the PGs themselves to their
precursor, arachidonic acid, and linolenic acid, which is not a
substrate for PG synthetase. Neither of these fatty acids produced
any oedema themselves, and it was only arachidonic acid which
potentiated the response to carrageenan. The effect of arachidonic
acid was reduced by the PG synthetase inhibitors, indomethacin,
naproxen and phenylbutazone, and may therefore be the result of
its conversion to PGs, in particular PGE2.
PGI2 has also been shown to potentiate the carrageenan-induced
rat paw swelling, though it was 10-fold less potent than PGEi
(Komoriya et al., 1978). This potentiation was not inhibited by the
presence of the NSAIDs, dexamethasone or indomethacin, but was
abolished by diphenhydramine (histamine-antagonist). Histamine
is therefore thought to be involved in the PGI2-induced
potentiation of carrageenan. In indomethacin-treated rats, the
smooth muscle relaxants PGEi and adenosine both potentiated the
paw oedema response to carrageenan, whilst papaverine was
ineffective in this respect (Thomas, 1980). PGEi and adenosine,
unlike papaverine, were ineffective in inhibiting the response to
noradrenaline in the perfused rat mesenteric circulation, therefore
it was proposed that the potentiation of oedema was unrelated to
vasodilatation. 133Xe clearance studies carried out in rat skin may
prove to be more relevant in assessing the involvement of
vasodilatation in the action of these agents.
In the absence of pontamine blue dye, the results in man were not
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as easily assessed (Crunkhorn & Willis, 1971a). PGEi and PGE2
were however found to induce a cutaneous reaction at 25 - 100 ng,
consisting of an initial wheal followed by a diffuse redness. PGFia
or PGF20C at 500 ng or 5 |ig produced a more localised but more
prolonged reaction, with no apparent potentiation of the response
when used in combination with PGE. A similar sensitivity to PGE
was therefore observed in rat and man, though no appreciable
response to PGF was evident in the rat. Perhaps release of mast
cell amines is the mechanism of action of PGE in man, as already
reported for the rat. Another qualitative study demonstrated i.d.
injection or infusion of PGE2 into man produced an immediate
weal and flare response (Ferreira, 1972). More recently a study of
a more quantitative nature investigated the effect of i.d. injection of
PAF and PGE2 into the forearm of eight healthy male volunteers
(Sciberras et al., 1987). The area of the injection site and
skin-fold thickness were used to determine flare and wheal
responses. Both PAF and PGE2 induced a dose-related effect.
Such a response to the PGs is however species-dependent, as in
the guinea-pig (Williams & Morley, 1973) and rabbit
(Ikeda et al., 1975) PGs on their own cause virtually no increase in
vascular permeability. They do however potentiate the response to
mediators such as histamine or bradykinin, which act directly on
the post-capillaiy venules to induce some oedema, and to FMLP,
C5a and LTB4, which themselves do not cause significant oedema
but in the presence of a vasodilator induce oedema dependent on
circulating leucocytes. Guinea pigs were administered i.v.
125I-guinea-pig serum albumin, followed by i.d. injection of the
inflammatory agent into the dorso-lateral skin. PGEi at 1 (ig,
which itself caused virtually no effect above saline, shifted the
dose-response to bradykinin to the left, and increased the slope.
PGEi at ng doses was also able to potentiate the response to
0.5 pg histamine, reflecting the physiological significance of this
activity. The potentiation of bradykinin and histamine observed by
the PGs has the following potency ranking: PGEi > PGE2 > PGA2 >
PGF2a- In this study PGEi, at ng doses, was also shown to
potentiate endogenous inflammatory reactions such as Type I
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(immediate or anaphylactic hypersensitivity, eg. hayfever, asthma,
urticaria), Type III (immune complex - mediated hypersensitivity,
eg. Arthus' reaction which occurs if a foreign protein is injected
subcutaneously into a rabbit or guinea pig with a high
concentration of circulating antibody against that protein), and
Type IV (cell-mediated hypersensitivity, eg. mumps, measles)
reactions.
Potentiation of bradykinin not only by PGE2 but also by arachidonic
acid has been demonstrated in rabbit skin (Ikeda et al, 1975).
Pontamine blue was administered i.v., and the diameter of the blue
skin areas measured. This protocol suggested both PGEi and PGE2
alone to be equipotent to bradykinin. However, if the dye was
extracted, the PGEi and PGE2 activities were shown to be
20 times less active at inducing plasma exudation when compared
to bradykinin, and PGFia and PGF20C 20 times less active again than
the PGE response. Diffusion of the dye in the areas of skin
receiving PG injections was responsible for the misleading results
obtained initially by comparing diameters of the injection sites.
Despite the slight response to PGE2 alone, it potentiated the
response to bradykinin (100 ng), 100 ng PGE2 increasing the
response 10-fold, and 1 gg increasing it 100-fold. Arachidonic
acid (1 jag) was also able to potentiate the response to bradykinin,
an effect which was inhibited by indomethacin. Indomethacin had
no inhibitory effect on the potentiation of the bradykinin response
to PGE2 nor on bradykinin or histamine alone. Arachidonic acid
itself produced an increase in vascular permeability, which was
less than the response to PGE2 alone, and may be a result of its
conversion to PGE2 since the effect was inhibited by indomethacin.
This was supported by the activity of the antagonist to PG action
diphloretin phosphate, in significantly inhibiting the higher doses
of arachidonic acid in increasing vascular permeability.
The arachidonic acid effect was markedly inhibited by previous
administration of pyrilamine (mepyramine in Britain). Whilst
histamine may be partly responsible for the effect of arachidonic
acid alone, it is unlikely to be involved in the potentiating effect on
bradykinin, since histamine and bradykinin in combination were
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shown to be only additive.
2.1.3 Does vasodilatation account for the action of the
prostaglandins ?
Dilatation, through the sequence of increased flow, increased
supply to the venules and increased hydrostatic pressure, may
increase the leakage of plasma proteins. In order to assess the
importance of vasodilatation in the potentiation of oedema
responses, a method for simultaneous measurement of plasma
exudation and blood flow was developed in the rabbit
(Williams, 1976a) using 131I-albumin accumulation and 133Xe
washout respectively. The 131I-albumin is administered i.v.
through an ear vein, the accumulated counts being representative
of plasma exudation, whereas 133Xe is injected i.d. at each site and
In (natural logarithm) residual radioactivity is inversely
proportional to local blood flow.
The rabbit skin inflammation model was used to study the
relationship between vasodilatation and potentiation of plasma
exudation by a series of prostaglandins and their analogues
(Williams, 1976b). The results obtained supported a link between
the two. Considering the PGs E, A, D, F and the analogues
16,16-dimethyl PGE2 and 15(S)-15-methyl PGE2, the rank order
of exudation potentiating activity of the prostaglandins correlated
with their vasodilating potency. The PGEs gave prolonged
dilatation in the skin, so that even when histamine was
administered 30 min after PGE2, the potentiation was still in
parallel with the observed increase in blood flow.
Also, other vasodilators such as ADP, isoprenaline
(Kenawy et al., 1978) and adenosine caused significant potentiation
of the histamine responses. VIP, possibly released endogenously
from mast cells, PMN leucocytes or cutaneous nerves, was able to
increase local blood flow, and whilst causing little plasma
exudation itself, potentiated the response to both bradykinin and
C5a (Williams, 1982). Indomethacin had no effect on this action of
VIP, which was more potent than that to PGE2. Even more potent
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again is the activity of pituitary adenylate cyclase activating
polypeptide (PCAP) (Warren et al., 1992). As with the other
modulators of plasma exudation described, whilst alone having no
significant effect on microvascular leakage, PCAP was shown to be a
potent dilator and potentiator of bradykinin-induced oedema,
being 100 times more potent than VIP.
It was also observed that addition of vasoconstrictors such as
angiotensin II or noradrenaline (Kenawy et ah, 1978) to histamine-
PG mixtures before i.d. injection, reduced blood flow and exudation
in parallel. Williams (1979) expanded on the study by
Ikeda et al. (1975), by measuring not only the increases in plasma
exudation induced by the PGs and arachidonate, but also the effects
of these agents on local blood flow. PGE2, PGI2, PGD2 and PGF2a
alone produced little plasma exudation in the rabbit dorsal skin.
However, PGE2 and PGI2 were potent at increasing blood flow and
potentiated plasma exudation with similar relative potencies,
whilst PGD2 and PGF2a increased local blood flow and potentiated
the response to bradykinin only at non-physiological doses.
Arachidonate alone, like the PGs themselves, gave little plasma
exudation but increased blood flow and potentiated the response to
bradykinin. A similar effect of PGE2 in the rabbit model of acute
pulmonary inflammation underlines the importance of
vasodilatation in its pro-inflammatory effect (Downey et ah, 1988).
2.1.4 Hie two mediator hypothesis
The vasodilatation and plasma exudation components of
inflammation may be considered as separate entities, as
demonstrated in rabbit skin (Williams, 1977a). Bradykinin was
shown to increase vascular permeability though it was much less
potent at increasing blood flow, the reverse being reported for
PGE2 (Williams & Peck, 1977). In combination, a greater plasma
exudation than that in the presence of bradykinin alone was
induced. The potentiation of the bradykinin response to
arachidonic acid was suppressed by locally injected indomethacin,
that to PGE2 remaining unaltered. This is consistent with the
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proposition that indomethacin suppresses inflammatory dilatation
and as a consequence inflammatory oedema, by preventing the
production of a vasodilator substance via the cyclooxygenase
pathway. Whilst indomethacin blocked the increase in blood flow
induced by arachidonic acid, it had very little effect on basal blood
flow, and so the production of vasodilator substances from
endogenous arachidonic acid is considered to be low under normal
conditions (Williams, 1979).
Further studies involving i.d. injection of B. pertussis vaccine,
which itself induces plasma exudation and an increase in blood
flow, support the two mediator hypothesis
(Williams & Peck, 1977). The administration of indomethacin
suppresses both features of the B. pertussis response. The
presence of the endogenous vasodilator mediator is indicated by
injecting bradykinin at the time of the peak response. The
exudation response to bradykinin was potentiated as a result, this
potentiation being sensitive to inhibition by indomethacin. By a
similar method the presence of the endogenous
permeability-increasing mediator was demonstrated. PGEi was
injected again at the peak response to 23. pertussis, and a
potentiated exudation occurred which was unaffected by the
presence of indomethacin.
In a similar manner the time-course of plasma exudation induced
by zymosan (100 pg, i.d.), a yeast cell wall preparation, has been
followed both in the presence and in the absence of PGI2 (100 ng)
(Williams, 1979). Since the level of PGI2 is much greater than any
endogenous vasodilator, the time-course of exudation is taken to
reflect the changes in the levels of the permeability increasing
mediator. Whilst exudation to zymosan alone was insignificant in
the first 30 min, marked potentiation was observed in the
presence of PGI2, indicating the production of a
permeability-increasing mediator, in the absence of endogenous
vasodilator. The permeability-increasing mediator reached its
peak at 30 - 60 min but exudation to zymosan did not reach its
maximum until after this time period, when presumably the
vasodilator component peaked.
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These studies are the basis for proposing that inflammation may
involve the separate production of permeability-increasing
mediators and vasodilator mediators, production of the latter being
susceptible to inhibition by indomethacin. Having established a
mechanism by which PGs could potentiate other inflammatory
mediators, an endogenous source of the natural PGs remained to
be identified.
2.1.5 PMNs provide the PGs
In vitro phagocytosing rabbit peritoneal PMN leucocytes can
produce PGs at 10 ng / 106 cells (56 % PGE2; 28 % PGF2a: 16 %
unknown) in response to killed bacteria, compared to
< 0.3 ng / 106 cells in their absence (Higgs & Youlten, 1972). The
PMNs can also convert exogenous arachidonic acid to PGs in vitro
(McCall & Youlten, 1973). Since there is an influx of these
leucocytes into inflammatory sites, an attempt was made to
correlate this influx with the finding in rabbits that exogenous
prostaglandins can potentiate inflammatory exudation in vivo
(Williams, 1976b). The experiment involved the i.d. injection of
PMN leucocytes into rabbit skin followed by bradykinin, blood flow
and plasma exudation being measured by 133Xe clearance and
131I-albumin accumulation respectively (Firrell et al., 1976). It was
found that the PMN leucocytes (5 x 106 / site) potentiated the
bradykinin-induced plasma exudation, and that this potentiation
was inhibited when indomethacin (1 pg / site) was included along
with the PMN leucocytes. The blood flow changes were consistent
with the results of experiments using exogenous PGs
(Williams, 1976b). The response of exogenous bradykinin is
therefore thought to be potentiated by endogenous PG(s), the
source of which is the PMN leucocytes.
Further evidence supporting PMN leucocytes to be the source of
PG comes from studies using PMN leucocyte-depleted rabbits.
Pretreatment with nitrogen mustard depletes circulating PMN
leucocytes by preventing replication of stem cells in the bone
marrow (Williams, 1977b). In these studies there was a marked
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reduction in B. pertussis potentiation of plasma exudation induced
by bradykinin, with no significant reduction in PGE2 potentiation.
Isolation of PMN leucocytes, and i.a. or i.v. injection into the
previously PMN leucocyte - depleted rabbit, did not however
restore responsiveness to B. pertussis. Injection of whole blood
containing PMN leucocytes proved to be more successful,
suggesting isolation of the cells has a harmful effect on their
physiological function. Potentiation was also suppressed by mixing
B. pertussis with indomethacin or dexamethasone before injection.
These results suggest the infiltrated PMN leucocytes are the
source of vasodilator, possibly a PG, which potentiates the
exudation produced by other inflammatory mediators.
Studies have shown however, that even when there is little or no
migration of PMN there is already a release of PGs by local cells
(Glatt et al, 1974), and that this release potentiates the effects of
other mediators (Moncada et ah, 1973). This source of PGs may be
the platelets (De Gaetano et al, 1989), mast cells and mononuclear
cells. Subsequent phagocytosis by PMN would then release
additional PGs, contributing further to the potentiation. Indeed
these may be the major source of the PGs, since NSAIDs were
shown to be most effective in carrageenan-induced oedema of the
rat hindpaw in the later stages of the development of the oedema,
coinciding with the influx of leucocytes (Di Rosa et al, 1971).
Assay of the mediators in inflammatory exudate produced by
carrageenan in the rat showed the release of histamine and
bradykinin in the early phase, with PGE2 being released at 2-3 hr
(Willis, 1969b). The levels of histamine and PGE2 then rose
steadily and paralleled the time-course of migration of the PMN
leucocytes into the site of injury (Di Rosa et al, 1971). The
inhibitory effect of indomethacin on carrageenan-induced oedema,
demonstrated by Moncada et al (1973), was apparent from as early
as 1 hr when there was little or no influx of PMN leucocytes,
suggesting a release of PGs by local cells potentiating the effect of
other mediators.
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2.1.6 Directly and indirectly acting inflammatory mediators
The permeability-increasing mediator in response to zymosan, is
thought to be derived from blood plasma and has been termed a
plasma activation permeability agent (PAPA) (Williams, 1978).
Zymosan (1 mg/ml) was added to fresh heparinised rabbit plasma
at 37 °C, and removed by centrifugation after 30 min. The ability
of the resulting activated plasma (P*) to cause plasma exudation
following i.d. injection, was then tested by measuring the
accumulation of i.v. administered 131I-albumin. PGEi and P* alone
each produced very little plasma exudation, and whilst PGEi with
plasma produced only a small increase, PGEi in combination with
P* increased the volume of exudate to more than 10 times that of
either alone. This latter response was comparable to that obtained
in the presence of histamine and PGEi but was not susceptible to
inhibition by the histamine antagonist, mepyramine. Zymosan
therefore appears to induce a histamine-independent PAPA. The
activity in the plasma has since been purified and identified as the
cleavage product of the fifth component of complement, C5a
(Williams & Jose, 1981).
Whilst histamine and bradykinin act directly on the venular
endothelial cells to cause plasma exudation (Gabbiani et ah, 1970),
C5a and FMLP have a different mechanism of action. The increase
in vascular permeability in response to these latter agents cannot
be induced in rabbits depleted of circulating neutrophils, whilst
the responses to histamine and bradykinin are not affected
(Wedmore & Williams, 1981). The LTs have also been shown to
exert an effect on plasma exudation, which varies depending on
the LT and the species under investigation (Williams, 1983). Dual
inhibitors of both PG and LT production may therefore have
benefits over existing drugs in controlling inflammatory conditions.
LTC4 and LTD4 increase the vascular permeability in guinea-pig
skin, as measured by Evans blue dye extravasation, but their
constrictor component restricts oedema. LTB4 on the other hand
has very little activity in the guinea-pig skin, but in the presence of
PGE2 it increases oedema formation in rabbit skin, where LTC4
and LTD4 are inactive. LTB4, like C5a and FMLP, is highly
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chemotactic (Salmon & Higgs, 1987) and in neutrophil-depleted
rabbits it has no effect.
PMN cells have a phagocytic role at the site of inflammation, where
activation by these agents results in activation of the arachidonic
acid cascade, generation of superoxide anions and release of
lysosomal enzymes. They are also involved in the control of fluid
efflux through the blood vessel wall leading to tissue oedema.
LTB4, C5a and FMLP have been shown to significantly enhance the
binding of human PMN cells to selected populations of human
dermal microvascular endothelial cells in vitro
(Reusch et ah, 1988). These neutrophil-dependent mediators may
open the junctions between the endothelial cells by inducing
swelling and aggregation of the neutrophils, as has been
demonstrated in vitro for both rabbit peritoneal and human blood
neutrophils (O'Flaherty et al., 1978).
Bradykinin reproduces several aspects of the inflammatory
processes, including increased capillary permeability, stimulation
of eicosanoid synthesis and induction of connective tissue
proliferation. Unlike many of the other biologically active
peptides, it is synthesised at the site of its action by plasma or
tissue kallikrein acting on several circulating kininogen substrates,
and is also rapidly degraded at its site of action by kininases. The
involvement of both histamine and the cyclooxygenase products in
the activity of bradykinin is controversial. Bradykinin given i.v.
increased the plasma levels of both 6-oxo-PGFia and
13,14-dihydro-15-oxo-PGF2oc. metabolites of PGI2 and PGE2
respectively, in conscious rabbits, and was inhibited in doing so by
aspirin (Warren et al., 1987). Bradykinin is believed to stimulate
the release of PGE2 and PGI2 from non-endothelial structures,
probably smooth muscle cells, as removal of the endothelium did
not significantly decrease their formation
(Forstermann et al, 1986). The PGs so formed relaxed isolated
rabbit blood vessels, and both the formation and relaxation were
sensitive to inhibition by indomethacin. Terfenadine, a
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histamine-antagonist, had no effect on the wheal and flare
response to bradykinin, and the response was only slightly
inhibited by aspirin, suggesting neither histamine nor
cyclo-oxygenase products are responsible for these cutaneous
reactions (Crossman & Fuller, 1988). This is in accordance with
the observation that co-injected indomethacin did not alter blood
flow or plasma exudation in response to bradykinin in the rabbit.
A previous report did however show significant inhibition of the
increased vascular permeability response to bradykinin in rabbit
skin by the histamine-1 antagonist, mepyramine, though no
modification of the response by indomethacin was observed
(Marceau et al, 1981). In view of the fact that bradykinin can
stimulate the production of PGs, and these are known to potentiate
the response to bradykinin in the rabbit as already reported, the
lack of effect of indomethacin in the response to bradykinin alone
is surprising. Murine macrophages and lymphocytes may also be
stimulated by bradykinin to produce inflammatory cytokines,
which cause proliferation of connective tissue and stimulation of
both eicosanoid and proteolytic enzyme release
(Tiffany & Burch, 1989).
2.1.7 The PG-inflammatorv model is not a simple one
It has been proposed that PGE and PGF do not always mimic the
inflammatory reactions, and the involvement of the
PG endoperoxide PGG2 should be considered (Kuehl et al., 1977).
MK-447 (2-aminomethyl-4-t-butyl-6-iodophenol) proved to be a
good anti-inflammatory agent in rat hindpaw oedema, being
1.6 times more potent than phenylbutazone, though 6 times less
potent than indomethacin. The differing slope of its
dose-response curve compared to phenylbutazone and
indomethacin, suggested it had a different mechanism of action. It
was indeed found to stimulate PGE and PGF synthesis, in contrast
to the PG synthetase inhibiting effect of the other two agents.
Since both inhibitors and stimulators of PGE and PGF synthesis
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were found to be anti-inflammatory, an intermediate in their
formation was thought to be important. PGG2 may serve this
purpose, its action being blocked by the PG synthetase inhibitors,
and also by the MK-447 - facilitated conversion to PGE and PGF.
Williams & Peck (1977) have suggested that the capacity of
arachidonic acid - derived products to provoke modest oedema,
and to potentiate oedema induced by bradykinin and histamine
reflects an enhanced vasodilatation. Using isolated vascular strips
a two-phase vascular response to PGG2 was observed, with an
initial constriction followed by a strong dilatation
(Bunting et al, 1976). A similar effect was obtained on
microvessels in vivo, using the hamster cheek pouch preparation
(Lewis et al., 1977). In agreement, 133Xe studies in rabbit dorsal
skin demonstrated an increase and then decrease in local blood
flow, with vasodilatation predominating (Lewis et al., 1977). It is
suggested the potentiation of the bradykinin response may be by
PGG2 itself, or indirectly through conversion to its products.
The complex nature of the inflammatory process is demonstrated
by the finding that systemic administration of the PGEs leads to
anti-inflammatory responses. This has been shown in the rat
(Fantone et al, 1980), where PGEi or its stable analogue
15(S)-15-methyl-prostaglandin Ei given i.v., both markedly reduce
the increase in vasopermeability induced by i.d. injection of
histamine, 5HT, bradykinin, C3a or compound 48/80. This was
not thought to be the result of hypotension or acute stress, and
electron microscopy showed the inhibition to be associated with
preservation of the tight junctions between the endothelial cells.
Systemic administration of l5(S)-l5-methyl-prostaglandin Ei has
in fact been demonstrated to inhibit the chemotactic factor FMLP
in activating rat PMN, an effect associated with the decreased
binding affinity of [3H]-FMLP to a specific receptor on the
neutrophil plasma membrane (Fantone et al, 1983). This
inhibition of the activation of PMN may explain, at least in part, the
anti-inflammatory effects already described.
15(S)-15-Methyl-PGEi administered orally was also shown to
suppress chronic adjuvant arthritis and acute
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immune complex - induced vasculitis in rats in a dose-dependent
manner (Kunkel et al., 1981).
PGI2 has been shown to stimulate or inhibit PMN-dependent
plasma leakage depending on whether it is administered i.d. or i.v.
(Rampart & Williams, 1986b). Locally administered PGI2 markedly
potentiated the effect on local oedema induced by C5a des Arg,
LTB4, bradykinin and histamine. This enhancing effect of PGI2 on
the PMN-dependent oedema induced by C5a des Arg and LTB4 was
reversed following i.v. administered PGI2. There was no effect on
the oedema induced by histamine or bradykinin. Similarly, the
oedema induced by FMLP was suppressed, but not that induced by
PAF. Initially, 15-methyl PGEi given systemically selectively
suppressed PMN-dependent oedema, but a threshold was reached
above which the inhibition of oedema was no longer selective and
was associated with a fall in systemic arterial blood pressure. The
site of PG generation and action is therefore important in
determining the influence on oedema formation.
Another anti-inflammatory activity of the PGs has been
demonstrated in a model of mast-cell dependent inflammation of
the hamster cheek pouch, evoked by antigen challenge
(Raud et al., 1988). Indomethacin inhibited the antigen-induced
vasodilatation and potentiated the plasma extravasation, leucocyte
accumulation and histamine release. This effect was due to
inhibition of cyclooxygenase activity, since indomethacin inhibited
the arachidonic acid induced vasodilatation without influencing the
action of histamine or acetylcholine. Topical application of PGE2
reversed the action of indomethacin.
Contrary to its inhibition of the antigen-induced reactions, PGE2
potentiated the response to histamine and LTC4. Since the
antigen response was mast-cell dependent, PGE2 may reduce the
response through inhibition of mediator-release from the
mast-cell. This study therefore demonstrates a dual action of
locally administered PGE2 in the hamster cheek pouch, by
inhibition of mediator release and enhancement of mediator
action. Following the mast-cell dependent inflammation as a result
of antigen challenge, the effect of PGE2 on mediator release
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predominates, in an anti-inflammatory fashion. A greater emphasis
on one or other of these mechanisms of action of PGE2 in different
models of inflammation, may in part be responsible for conflicting
effects reported for NSAIDs and the PGs.
This study has more recently been extended to compare the
influence of PGI2 with PGE2 on inflammation, induced by both
antigen-challenge and histamine, and to assess the involvement of
increased cyclic AMP, through forskolin-activated adenylate
cyclase, or increased cyclic GMP, through nitroprusside-activated
guanylate cyclase, in the activity of these PGs (Raud, 1990). All
four agents increased local blood flow, though forskolin and
nitroprusside were not as active as PGE2 or PGI2. Topical
administration of PGE2 or PGI2 in vasodilator concentrations
suppressed the plasma leakage induced by antigen-challenge,
whilst potentiating that to histamine. Whilst nitroprusside
potentiated the responses to both antigen and histamine,
suggesting vasodilatation in itself was not responsible for the
anti-inflammatory properties of the PGs, forskolin produced a
similar profile of activity to PGE2 and PGI2. The anti-inflammatory
effect of these latter two agents may therefore be the result of an
elevation in cyclic AMP levels. This study highlights the dual
activity of at least some PGs in inhibiting mediator release yet
enhancing mediator action, the former resulting from a
mechanism other than vasodilatation.
The PGE2-induced potentiation of the bradykinin response in
rabbit skin is complicated by the finding that in vitro PGE2 is
reported to act on at least four different subtypes, designated EPi,
EP2, EP3 and EP4. In order to better understand the mechanism
of this potentiation, PGE analogues of differing selectivity for each
of the four receptor subtypes have been tested in this model, using
both accumulation of 125I-albumin as a measure of plasma
exudation, and 133Xe clearance for measurement of changes in
local blood flow. Since vasodilatation is reported to be an
important component of this potentiation, the EP2-receptor
subtype was considered to be the most likely candidate. This
receptor is responsible for the vasodilator effects of PGE2 in
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several tissues, such as relaxation of cat and guinea-pig trachea and
rabbit jugular vein in vitro, and dog hind limb vessels in vivo. A
stable PGI2 analogue, cicaprost, was also tested in order to assess
the contribution of vasodilatation to the potentiation of the
bradykinin response. The results suggested that vasodilatation may
be too simple an explanation for the action of PGE2 in this model
of rabbit skin inflammation.
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2.2 MATERIALS and METHODS
SOLUTIONS Source
Saaatal
Pentobarbitone sodium B.P. (Vet) RMB Animal health Ltd.
60 mg / ml diluted 1:2 in sterile saline (PL 12/4040)
Heparinised-saline
0.1 ml heparin sodium (5000U / ml)
in 50 ml sterile saline (BN 9004980)
Evans blue
2.5 % in sterile saline B.D.H. Chemicals
125.1-human serum albumin
100 fiCi 123I-HSA Amersham (IM 17P)
233Xenon















Dr. R.A. Coleman, Glaxo, U.K.
Cambridge Biochemicals (PP 05 2086B)
Dr. P. Gardiner, Bayer, U.K.
Prof. Vorbruggen, Schering AG, Berlin
11
Sigma (F 3506)








2.2.1 Plasma exudation studies
This protocol is based on a method by Williams & Morley (1973).
1. Male New Zealand white rabbits (1.7 - 4.7 kg; 2.9 ±0.1 kg,
n=44) were anaesthetised with 30 mg / kg sagatal i.v. through an
ear vein, followed by an equal volume of heparinised saline to keep
the line clear.
2. The whole of the back section was shaved and demarcated
usually into 6 subsections, each containing 12 injection sites. In
those cases where the injection number was increased to 15 in
order to incorporate all necessary controls, the number of
subsections was reduced to 4.
3. 5 pCi 125I-HSA in 2 ml of 2.5 % Evans blue was administered
through the line into the ear vein, again followed by heparinised
saline.
4. After a period of 5 min, drug additions were administered
rapidly by 100 |il i.d. injection into each site. Each addition was
made to 4 or 6 injection sites according to the number of
subsections, each of fixed site pattern. These replicate injections
to each rabbit were representative of one experiment (n=l), and
avoided bias from site and animal variation.
5. The rabbit was left for 30 min, before being killed by overdose
of anaesthetic.
6. 10 ml of blood was taken by cardiac puncture and centrifuged
at 740 g (2000 rpm) for 30 min.
7. The back skin was removed from the rabbit and blood pushed
out of the vessels with a cold damp towel, to prevent inappropriate
assessment of plasma exudation due to the presence of
125I-albumin in the blood.
8. Discs of skin (16 mm) containing the injection sites were
removed with a steel punch.
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9. 3 x 1 ml aliquots of plasma were removed from the
supernatant of the intracardiac blood sample.
10. Skin and plasma samples were then counted on automatic
y-counter.
Calculation
The DPM obtained for each injection site was related to pi plasma
exudate, using the DPM per ml of plasma sample as a reference.
By simple proportion :
DPM injection site
DPM injection site = x 103 pi plasma exudate
DPM plasma sample
2.2.2 Blood flow studies
This protocol is based on a method by Williams (1976a).
133Xe is useful for the determination of blood flow as it is negligibly
bound to plasma protein and is itself inert. Due to its volatile
nature however, certain precautions are required :
- syringes for drug additions must be primed with saline and kept
on ice;
- injection sites must be punched out as soon as the skin is
removed and paraffin oil added to each.
In these blood flow studies there was a limitation of 4 subsections
each of 12 injection sites, and following addition of the drugs the
rabbit was only left for 20 min. These restrictions were necessary
in order to reduce variability of results due to the ability of 133Xe to
diffuse into surrounding tissue.
1. Male New Zealand white rabbits (2.1 - 4.0 kg; 3.0 ± 0.2 kg,
n=l 1) were anaesthetised with 30 mg / kg sagatal i.v. through an
ear vein, followed by an equal volume of heparinised saline to keep
the line clear.
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2. The whole of the back section was shaved and demarcated
into 4 subsections, each containing 12 injection sites.
3. 133Xe was added into each drug syringe behind perspex in a
fume cupboard, and administered rapidly by 100 (il i.d. injection
containing 5-10 |iCi / site. Injections were made in quadruplicate
in each rabbit, one per subsection, and were representative of one
experiment (n=l), these multiple additions avoiding bias from site
and animal variation.
4. 100 jil samples of the injection fluid were stored under
paraffin oil in sealed tubes, to provide initial 133Xe activity for
clearance calculations.
5. 20 min after the injections the rabbit was killed by overdose of
anaesthetic and the back skin removed.
6. Discs of skin (16 mm) containing the injection sites were then
immediately removed with a steel punch, immersed in paraffin oil
in polycarbonate tubes and capped.
7. Skin and injection fluid samples were then counted on an
automatic y-counter.
Calculation
Clearance of 133Xe from the tissue is dependent on and a measure
of the local tissue circulation.
% change in blood Jlow :
In 133Xe count saline-injected skin " In ^33Xe count agent-injected skin
In 133Xe count o. 1 ml injection fluid ~ in *33Xe count saline-injected skin
where In = natural logarithm.
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2.3 RESULTS
The vertical bars on the figures represent the s.e.mean.
Differences in fil plasma exudation and % change in blood flow
were assessed according to the Student's t-test, significance being
accepted with values of probability less than 0.05.
PGE2, a range of PG analogues and a TX analogue were tested in
the in vivo model of rabbit skin inflammation over the dose range
1 ng to 5 fig. None of the drugs alone, at the highest dose tested
in combination with bradykinin or FMLP, was able to induce
plasma exudation significantly different from that to saline
(Table 2.1). All drugs were given i.d.
Table 2.1 Effects of a series ofagents on plasma exudation in
rabbit skin.
Volume of exudate (fil)






Butaprost 1 fig 17 ± 4 17 ± 4
Cicaprost 1 |ig 12 ± 3 13 + 2
11-Deoxy PGE2 1-alcohol 5 fig 13 + 2 16 ± 3
Misoprostol 1 fig 23 ± 6 16 ± 3
PGE2 1 fig 18 ± 2 17 + 2
17-Phenyl-co-trinor PGE2 1 fig 16 ± 2 19 ± 4
U 46619 1 fig 15 ± 4 17 ± 4
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Bradykinin in 8 out of 10 experiments produced a response
significantly different from that to saline (Table 2.2). In those two
cases where significance was not achieved, there was one extreme
value.
Table 2.2 Skin plasma exudate produced in response to Id.
injection of bradykinin as compared to saline.





28 ± 6 (p=0.084) 16 ± 3
47 ± 5 17 ± 2
49 ± 8 15 + 5
52 ± 12 17 ± 4
55 ± 9 16 ± 3
57 ± 10 15 ± 2
57 ± 11 17 + 4
60 ± 4 19 ± 3
68 ± 14 19 ± 4
85 ± 20 (p=0.061) 13 ± 1
As a control, in experiments which were conducted in the absence
of a dose-response curve to PGE2 in combination with bradykinin,
a site was injected with 100 ng PGE2 + 0.5 pg bradykinin. The
results from such controls (133 ± 12 pi plasma exudate,
representing an increase of 129 ± 11 % over bradykinin alone;
n=19) were not significantly different from the values obtained in
the dose-response studies (116 ± 13 pi plasma exudate,
representing an increase of 163 ± 20 %; n=12).
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2.3.1 Time-course studies
The time-periods used for measurement of plasma exudation and
% change in blood flow were 30 min and 20 min respectively.
Considering plasma exudation in the case of saline, bradykinin
(0.5 pg) and PGE2 or cicaprost (100 ng each) in combination with
bradykinin, the responses to each were 93 %, 66 %, 65 % and
76 % of their maxima, as represented by 15 ± 5 pi, 49 ± 8 pi,
122 ± 17 pi and 147 ± 23 pi of plasma exudate respectively
(Figure 2.1). The response to bradykinin in the absence or
presence of PGE2 or cicaprost was significantly different from
saline, and the potentiation of the bradykinin response by PGE2 or
cicaprost significantly different from that to bradykinin alone.
The greatest % change in blood flow in response to either 0.1 ng
(+ 30 ± 15 %) or 1 pg (+ 105 ± 22 %) PGE2 was observed at 20
min after injection (Figure 2.2), that at 1 pg being a significant
increase. Determination of the % change in blood flow is
complicated by the presence of permeability-increasing mediators,
therefore studies are conducted in the absence of bradykinin,
when assessing vasodilator potencies.
2.3.2 Potentiation and blood flow studies
PGE2 and cicaprost have both been shown to dose-dependently
potentiate the response to 0.5 pg bradykinin, when administered
in combination (Figure 2.3). A significant increase over the
bradykinin alone response was observed from 0.1 ng PGE2 and
0.3 ng cicaprost to the maximum dose of each tested of 1 pg. The
results correlate well with those obtained in the previous
time-course studies (Figure 2.1).
The exudation response to bradykinin was 47 ± 5 pi, PGE2 alone
(1 pg) 18 ± 2 pi, and in combination 109 ± 19 pi; this indicates
that a more than additive response was obtained. The maximum
% increase over the bradykinin response was 167 ± 29 %
(113 ± 19 pi) at 100 ng PGE2, and 231 ± 69 % (166 ± 31 pi) at
1 pg cicaprost, but it was only at the 1 ng dose of each that there
was a significant difference between the responses to PGE2 and
cicaprost in combination with bradykinin.
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Considering the % change in blood flow induced by PGE2 and
cicaprost alone (Figure 2.4), significance is achieved at 1 ng and
maintained through to 1 pg. At 100 ng and 1 pg, the increase in
blood flow induced by PGE2 (107+ 22 % and 110 ± 22 %
respectively) is significantly greater than that resulting from
cicaprost at the same doses (86 ±21 % and 93 ± 23 %
respectively). The results represented here for 0.1 ng (24 ±16 %)
and 1 pg (110 ± 22 %) PGE2 in increasing % blood flow, correlate
well with those obtained during the time-course studies
(30 ±15 %, 105 ± 22 % respectively) (Figure 2.2).
Another inflammatory mediator, FMLP, alone
(5 x 10"11 moles / site; 22 ng) induced much lower plasma
exudation, 18 ± 3 pi, (Figure 2.5) compared to that for bradykinin,
47 ± 5 pi (Figure 2.3), and the response was not significantly
different from that to saline, 13 ± 2 pi. Whilst not significantly
inducing plasma exudation themselves, PGE2 and cicaprost, as in
the presence of bradykinin, did however enhance the response to
FMLP, being most significant at the lower doses with only PGE2
maintaining significance at 1 pg (27 ± 5 pi = +108 ± 36 %). The
responses to PGE2 and cicaprost in the presence of FMLP reached
levels not much more than additive, and were not significantly
different from each other at any of the doses tested.
Butaprost (Figure 2.6) at 1 ng and 10 ng doses did not increase the
response to bradykinin, and at 100 ng the increase was slight.
Significance was achieved only at the highest dose tested of 1 pg,
represented by 96 ± 17 pi, an increase of 94 ± 21 % over the
bradykinin control.
The response to 11-deoxy PGE2 1-alcohol is also represented in
Figure 2.6. At 5 pg, 11-deoxy PGE2 1-alcohol increased the
bradykinin-induced plasma exudation from 28 ± 6 pi to 38 ± 6 pi,
an effect which is at most additive. A significant difference from
bradykinin alone was only achieved in the presence of 500 ng
11-deoxy PGE2 1-alcohol, with 33 ± 7 pi representing an increase
of 22 ± 4 %.
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11 -deoxy PGE2 1 -alcohol did not significantly alter local blood flow
(Figure 2.7) up to the maximum dose tested of 5 pg. These studies
were carried out in rabbits in which significant increases in blood
flow were observed by PGE2 and cicaprost at doses as low as 1 ng
(Figure 2.4).
The effect of pretreatment with 11-deoxy PGE2 1-alcohol
(5 pg, 5 min) is demonstrated in Figure 2.8. The significant
increase in plasma exudation over bradykinin achieved by 1 ng
PGE2, is absent following this pretreatment. Whilst the absolute
values for PGE2 (in the absence of 11-deoxy PGE2 1-alcohol
pretreatment) in combination with bradykinin were greater than
those achieved previously (Figure 2.3), this may be accounted for
by an increase in the bradykinin control response, 60 ± 4 pi here
compared with 47 ± 5 pi in Figure 2.3. This is reflected by the
similar % increases over bradykinin alone when comparing both
sets of experiments.
11-deoxy PGE2 1-alcohol pretreatment increased both saline and
bradykinin controls, the latter achieving significance. In order to
test for significant differences, the results following pretreatment
were assessed relative to the 11-deoxy PGE2 1-alcohol - bradykinin
control. When expressed as % increase over the response to
bradykinin alone, pretreatment with 11-deoxy PGE2 1-alcohol
doubled the response to 1 ng PGE2 in combination with bradykinin
from 33 ± 10 % to 76 ± 11 %, and increased the response slightly
at 10 ng PGE2 from 91 ± 10 % in the absence of
11-deoxy PGE2 1-alcohol to 115 ± 17 % in its presence. The %
increases at 100 ng + bradykinin and 1 pg PGE2 + bradykinin were
similar in the presence or absence of 11-deoxy PGE2 1-alcohol
pretreatment.
However, if expressed relative to the
11-deoxy PGE2 1-alcohol - bradykinin control, which represents
an increase of 66 ± 11 % over the response to bradykinin alone,
the % increases are considerably less following pretreatment.
Since the response to 11-deoxy PGE2 1-alcohol pretreatment may
have been additive, 10 pg PGE2 + bradykinin was included in the
experiment to check if the maximum response had been reached.
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This combination gave 148 ± 49 pi plasma exudated, representing
an increase of 144 ± 84 % over the response to bradykinin alone.
Preliminary studies carried out with 11-deoxy PGEi (n=2) showed
a potentiation of the response to bradykinin. The response to
11-deoxy PGEi alone at 2.5 pg was 19 pi as compared to saline,
18 pi, whilst bradykinin alone resulted in 71 pi of plasma exudate.
In combination with 2.5 pg 11-deoxy PGEi, the response to
bradykinin was potentiated to 145 pi, representing an increase of
104 % over the bradykinin control alone.
Misoprostol (Figure 2.9) potentiated the response to bradykinin,
increasing the response significantly over that to bradykinin alone
at doses of 100 ng and 1 pg. The maximum plasma exudation to
misoprostol and bradykinin in combination was 156 ± 17 pi at
1 pg, which is an increase of 194 ± 30 %. At 1 ng and 10 ng doses,
the responses to misoprostol + bradykinin were only marginally
greater than that to bradykinin alone.
The influence of sulprostone and 17-phenyl-co-trinor PGE2 on the
response to bradykinin, were tested in the presence and absence
of AH 6809 (10 pM, 5 min pretreatment) (Figure 2.10). The
response to bradykinin was not significantly altered by either
sulprostone or 17-phenyl-co-trinor PGE2, nor the AH 6809
pretreatment. AH 6809 did however increase both the saline and
bradykinin responses, that to saline being significantly increased in
both the sulprostone and 17-phenyl-co-trinor PGE2 studies, whilst
that to bradykinin was only significantly increased in the
17-phenyl-co-trinor PGE2 study, p=0.070 in the sulprostone study.
Preliminary studies into the effect of 17-phenyl-co-trinor PGE2 on
a potentiated system (n=2), have also been carried out. PGE2 at
100 ng increased the response of bradykinin to 148 pi plasma
exudate, from 71 pi in its absence, an increase of 113 %.
1 pg 17-Phenyl-co-trinor PGE2 reduced this potentiation slightly to
138 pi (+ 93 %). Following pretreatment with AH 6809
(10 pM, 5 min), this slight fall in response was not apparent,
though more experiments are required to assign any significance
to this 17-phenyl-co-trinor PGE2 effect.
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Studies with U 46619 were conducted to determine the influence
of this TP-receptor agonist on a PGE2-potentiated bradykinin
response (Figure 2.11). In the absence of U46619, the response to
1 ng PGE2 in combination with bradykinin (58 ± 13 pi) was small
but significantly different from that to bradykinin alone
(52 ± 12 pi). However, if the dose of PGE2 was raised 100-fold, an
increase of 161 ± 31 % over bradykinin alone was observed,
represented by 124 ± 17 pi skin plasma volume. U46619 did
significantly reduce the response of 100 ng PGE2 + bradykinin to
90 ± 17 jLil, 81 ± 23 % over bradykinin alone, a reduction of
28 ± 10 % of the control 100 ng PGE2 + bradykinin response.
PGE2 was shown to significantly increase the response to both
0.5 pg and 1 pg bradykinin (Figure 2.12). The bradykinin
responses alone were not significantly different from each other, at
47 ± 5 pi and 55 ± 9 pi respectively. The PGE2 responses in
combination with bradykinin were only significantly different from
each other at the 1 ng dose. The correlation between potentiation
of the bradykinin response by 1 ng PGE2 and the bradykinin
response alone was tested and not found to be significant
(Figure 2.13).
Preliminary studies with cicaprost in the presence of 1 pg
bradykinin (n=2), demonstrated potentiation of the response
(86 pi) at the lowest dose of cicaprost tested, 1 ng
(144 pi, + 97 %). A dose-dependent increase in pi plasma
exudated was obtained up to the maximum dose of cicaprost
tested, 1 pg (197 pi, + 206 %). Whilst absolute values vary, the %
increases over bradykinin alone are similar to those obtained with
PGE2 in place of cicaprost (Figure 2.12), and cicaprost with 0.5 pg
bradykinin (Figure 2.3). More experiments would be required in
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Figure 2.1 Time-course of gl plasma exudated in response to saline,
bradykinin and PGE2 or cicaprost in combination with bradykinin
(n=4).
* denotes significant difference from saline response within the
same time period (p<0.05).
1 denotes significant difference from bradykinin response alone
within the same time period (p<0.05).
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Figure 2.2 Time-course of% change in blood flow induced
by low dose (0.1 ng) and high dose (1 gg) PGE2 (n=4).





Figure 2.3 Dose-response to PGE2 and cicaprost (n=4-12) in
potentiating plasma exudation induced by 0.5 pg bradykinin.
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Figure 2.4 Dose-response comparing % change in blood flow
induced by PGE2 and cicaprost (n=4-10).
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Figure 2.5 Dose-response (n=4-8) to PGE2 and cicaprost in
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Figure 2.6 Potentiation of 0.5 pg bradykinin-induced plasma
exudation by butaprost (n=3-4) and 11-deoxy PGE2 1-alcohol (n=4).
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Figure 2.8 Effect of 11-deoxy PGE2 1-alcohol (5 min pretreatment
with 5 (ig) on a system potentiated by PGE2 in combination with
0.5 pg bradykinin (n=4).
* denotes significant difference from bradykinin response alone
(p<0.05).
1 denotes significant difference from bradykinin response following
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Figure 2.9 Potentiation of 0.5 pg bradykinin-induced plasma
exudation by misoprostol (n=4).
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Figure 2.10 Effect of sulprostone (n=3) and 17-phenyl-co-trinor PGE2
(n=4) on plasma exudation induced by 0.5 pg bradykinin, and the
influence ofAH 6809 (10 pM, 5 min) thereon.
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□ 1 ng PGE2
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Figure 2.11 Dose-response to U46619 (n=4) on lng and 100 ng
PGE2-induced potentiation of plasma exudation to 0.5 gg bradykinin.
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Figure 2.12 A comparison of the potentiation by PGE2 of plasma
exudation induced by 0.5 gg (n=4-12) and 1 gg (n=4) bradykinin.
* denotes significant difference from 0.5 gg bradykinin response alone
(p<0.05).
Si denotes significant difference from 1 gg bradykinin response alone
(p<0.05).
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Figure 2.13 % increase over bradykinin response by 1 ng PGE2 and
0.5 pg bradykinin in combination versus the bradykinin response alone
expressed as pi plasma exudate.
63
2.4 DISCUSSION
In this in vivo rabbit model of skin inflammation, locally injected
prostaglandins, whilst alone having no significant effect on vascular
permeability, potentiated the plasma exudation induced by
inflammatory mediators. The time-course of plasma exudation
(Figure 2.1) indicated that a time-period of 30 min provided
appreciable but submaximal response to both 0.5 pg bradykinin and
100 ng PGE2 + 0.5 pg bradykinin. This is necessary in assessing
potentiation or inhibition of such responses by additional agents.
The slight plasma exudation induced by PGE2 (Table 2.1) and the
bradykinin responses listed (Table 2.2), are comparable to those
reported elsewhere (for example Williams & Peck, 1977), where
PGE2 (300 ng) and bradykinin (300 ng) gave 8 pi and 40 pi skin
plasma exudate respectively. PGE2 has been shown to significantly
potentiate the response to 0.5 pg bradykinin (Figure 2.3).
Approximately one third of the maximum bradykinin-potentiating
response to PGE2 was achieved at 1 ng.
The effects of butaprost and 11-deoxy PGEi, which are selective
EP2-receptor agonists mediating vasodilatation through increases
in cyclic AMP, predicted the involvement of this receptor subtype.
The lower potency of butaprost, as compared to PGE2, in
potentiating the response to bradykinin was surprising
(Figure 2.6), since vasodilatation was reported to be responsible for
the potentiating effect of PGE2, and is typically mediated via the
EP2-receptor subtype. Whilst the actual skin plasma volume
approached the maximium achieved with PGE2, the % increase
over bradykinin alone was only slightly greater than half.
Preliminary experiments with 11-deoxy PGEi, showed it to be
active in potentiating the response to bradykinin. Whilst butaprost
produced no significant increase until the 1 pg dose,
11-deoxy PGEi appeared to dose-dependently potentiate the
response to bradykinin, a third of the maximium response being
achieved at 50 ng.
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11-deoxy PGE2 1-alcohol, another EP2-selective agonist, was less
potent than butaprost (Figure 2.6). 0.1 gg - 5 gg
11 -Deoxy PGE2 1 -alcohol produced only small increases of plasma
exudation and only at 0.5 gg was the effect statistically significant.
A similar % increase over bradykinin control was achieved by 1 ng
PGE2. It may be that 11-deoxy PGE2 1-alcohol is behaving as a
partial agonist. In order to test this theory, the effect of a 5 min
pretreatment with 5 gg 11-deoxy PGE2 1-alcohol on the ability of
PGE2 to potentiate the response to 0.5 gg bradykinin was
investigated (Figure 2.8).
Whilst in the absence of 11-deoxy PGE2 1-alcohol, PGE2 was able
to significantly potentiate the response to bradykinin over the
range 1 ng to 1 gg doses, following 11-deoxy PGE2 1-alcohol
pretreatment the potentiation at 1 ng no longer achieved
significance. This may reflect a partial agonist effect on low dose
PGE2. The analysis of such a study is complicated by the
observation that following pretreatment, the bradykinin control
was significantly increased (p<0.05). This may be the result of
double injections into sites receiving pretreatment, and with
hindsight, may have been accounted for by injecting saline into
those sites not receiving pretreatment.
The increase induced by 11-deoxy PGE2 1-alcohol pretreatment is
similar to an effect of 3 ng PGE2 + bradykinin, as estimated from
the dose-response relationship to PGE2 shown in Figure 2.8.
Assuming simple addition of effects, 5 gg 11-deoxy PGE2 1-alcohol
in combination with 3 ng PGE2 + bradykinin should equal 4 ng
PGE2 + bradykinin, which it does. Therefore, since there is no
antagonism between 11-deoxy PGE2 1-alcohol and PGE2 here, the
former is not behaving as a partial agonist in this system. As a
control, 10 gg PGE2 + bradykinin was included and gave similar
responses both in the absence and presence of
11-deoxy PGE2 1-alcohol pretreatment.
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The EP2- and EP3- selective agonist misoprostol, in combination
with bradykinin, was the only analogue to produce a maximum
response (194 %) comparable to that for PGE2 (167 %)
(Figure 2.9). However, whilst at 1 ng, PGE2 significantly
potentiated the response to bradykinin, significance was not
achieved with misoprostol until the 100 ng dose. The possibility of
EP3-receptor involvement was addressed using sulprostone, an
EPi- and EP3- receptor agonist. In an effort to dissociate action at
these two receptor subtypes, studies with sulprostone were
carried out in the presence and absence of a 5 min pretreatment
with the EPi-receptor antagonist, AH 6809. Sulprostone alone did
not significantly increase the response to bradykinin at doses up to
1 gg. There did not appear to be any inhibitory influence of an
EPi-receptor system on an EP3- mediated effect, since AH 6809
did not significantly alter the % increase over control, as
calculated relative to the bradykinin response following AH 6809
pretreatment. This was considered the best analysis for
significance, since AH 6809 pretreatment itself significantly
increased the bradykinin response, as discussed previously for
11-deoxy PGE2 1-alcohol pretreatment.
In order to study the effect of an EPi-selective agonist on the
bradykinin response, 17-phenyl-co-trinor PGE2 was tested in this
model (Figure 2.10). A similar profile to sulprostone was observed,
in that there was no potentiation of the response to bradykinin,
and AH 6809 pretreatment did not significantly alter these results.
It was reasoned that a possible EPi-mediated inhibitory effect may
only be evident on a potentiated system. Preliminary studies have
therefore been carried out using 100 ng PGE2 + 0.5 fig bradykinin
to potentiate the response to bradykinin, pretreatment with
AH 6809 being used to determine its influence on any
17-phenyl-co-trinor PGE2 effect. At 1 jig 17-phenyl-(o-trinor PGE2,
there was a slight reduction in the response to PGE2 + bradykinin,
an effect which appeared to be blocked by AH 6809 pretreatment.
In order to assign significance to this slight EPi-mediated
inhibitory effect, further studies are required.
66
Some PGE analogues such as MB 28767, whilst being selective for
the PGE subtypes, also have agonist activity at the TP receptor.
The TP-receptor agonist U46619 at a dose of 1 pg, significantly
inhibited the exudation response to 100 ng PGE2 + bradykinin,
and reduced that to 1 ng PGE2 + bradykinin (Figure 2.11). The
small increase over bradykinin-induced plasma exudation by 1 ng
PGE2 may have prevented detection of any significant reduction by
U46619 in this system. Nonetheless, this inhibitory influence via
the TP-receptor raises the possibility that the full potentiating
response to MB 28767 is not seen.
Since the bradykinin exudation responses vary between
experiments, the influence of this variation on the potentiation
observed by PGE2 or its analogues, was of concern. A comparison
of the potentiation of the response to both 0.5 pg and 1 gg
bradykinin (Figure 2.12), have shown significant differences to
occur only at the 1 ng dose. Since these were unpaired
experiments, 100 ng PGE2 + 0.5 pg bradykinin was included as a
control in the 1 gg bradykinin studies. This was in fact found to be
significantly different from 100 ng PGE2 + 1 gg bradykinin.
The responses to 0.5 gg and 1 gg bradykinin in these studies were
not significantly different from each other, and certainly do not
represent the span over which the responses to bradykinin have
been found to vary. Perhaps then, a greater fold difference in
doses of bradykinin would be more representative, or indeed a
dose-response to bradykinin in the presence of one submaximal
dose of PGE2. Ideally a dose-response curve to bradykinin in
advance of test agents would allow the choosing of a bradykinin
dose producing a similar effect in each experiment, but this is
obviously not possible. Even incorporating a dose-response curve
to bradykinin into a study to determine where the response lies in
relation to the maximum, would only serve to limit the number of
test injection sites in the study. Such differences in control
response may be the result of variations in temperature or indeed
seasonal variations in the rabbits themselves. Indeed, the absence
of TP receptors from rabbit aorta over a six month period, has
previously been reported (Tymkewycz et al, 1991).
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An alternative to looking at potentiation of an increased bradykinin
dose, is to determine the relationship between response
magnitude to bradykinin and the potentiation thereof. This is of
importance since response magnitude may be more relevant than
bradykinin dose. A graph was plotted of % increase over
bradykinin response by 1 ng PGE2 and 0.5 |ig bradykinin in
combination, against bradykinin response expressed as (il plasma
exudate (Figure 2.13). Analysis of the data points showed no
significant correlation suggesting the degree of potentiation to be
independent of the bradykinin response alone, over the range
observed for this dose of bradykinin.
The potentiation induced by PGE2 has been suggested to result
from its vasodilator activity (Williams & Morley, 1973). Previous
studies have investigated this by comparing the ability of PGE2 with
that of PGI2, to both increase blood flow and potentiate plasma
exudation in the model of rabbit skin inflammation
(Peck & Williams, 1978; Williams, 1979). PGE2 and PGI2 were
potent at increasing blood flow, and showed a similar potency in
potentiating the response to both bradykinin and zymosan.
However, PGI2 is unstable -with a ti/2 at 37 °C of ~ 3 min
(Dusting et al., 1977). Consequently I have compared the action of
PGE2 with that of a stable PGI2 analogue, cicaprost, which has
considerable specificity for the IP receptor. Similar increases in
blood flow were demonstrated with cicaprost as compared to those
reported for PGI2 (Williams, 1979), though whilst this paper
reports PGE2 to be 10-fold more potent than PGI2, I have found it
to be essentially equiactive with cicaprost. The results reported
here for the potentiation of the bradykinin response are in
agreement with those reported by Williams (1979) for that to
PGE2 and PGI2. It is interesting that in the paper by
Peck & Williams (1978), whilst the increases in blood flow are
reportedly much greater for both PGE2 and PGI2 than that
reported by Williams (1979), there is no correspondingly greater
increase in the volumes of exudate.
Here the maximum increase in blood flow in response to 0.1 ng or
1 (ig PGE2 was obtained following a 20 min time-period
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(Figure 2.2). This is taken to be representative of the vasodilating
capacity for the doses of PGE2 tested, and subsequent
measurements are taken following this regimen, when assessing
the contribution of a vasodilator component to the potentiation of
exudation by other inflammatory modulators. Cicaprost was shown
to dose-dependently potentiate the response to bradykinin
(Figure 2.3), the response being significantly different from that to
PGE2 only at the 1 ng dose, when more than 50 % of the maximal
response to either was produced. Whilst significant increases over
the bradykinin response were evident from 0.1 ng PGE2 and 0.3 ng
cicaprost, significant increases in blood flow were only
demonstrated from 1 ng of either (Figure 2.4). In the absence of a
significant increase in blood flow then, there was potentiation of
the response to bradykinin by PGE2 at 0.1 ng and 0.3 ng, and
cicaprost at 0.3 ng. Perhaps vasodilatation itself is not wholly
responsible for the potentiation of the bradykinin response by
these two agents, and another common factor is responsible for
their potentiating activity at the lower doses. Also, the
significantly greater increases in blood flow induced by PGE2 at
100 ng and 1 pg as compared to cicaprost, did not result in a
significant difference in their responses to bradykinin. Indeed,
whilst no significant increase was detected between the
potentiation of bradykinin induced by PGE2 as compared to
cicaprost at 100 ng or 1 pg, it was cicaprost and not PGE2 that
produced the greater absolute increase in skin plasma exudate,
and the greater % increase over the response to bradykinin alone.
The responses of PGE2 and cicaprost in combination with the
leucocyte-dependent chemoattractant, FMLP were only
significantly different from that to FMLP alone at the lower doses,
and there was no significant difference between the response of
FMLP to either, at any of the doses tested. PGE2 and cicaprost
therefore, in the absence of a significant increase in blood flow,
significantly potentiated the response to FMLP. FMLP has been
reported to produce a small plasma exudation, which is not
dependent on histamine release and may be potentiated by PGE2
(Hellewell et al, 1989). In potentiation of the FMLP response,
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there does not appear to be a good correlation between the dose of
PGE2 or cicaprost, and the increase in pi skin plasma volume
exudated at the lower concentrations. Full dose-response curves
were not conducted in the same rabbits, the range 0.1 ng to 1 ng
being carried out separately from 1 ng to 1 pg. The response to
1 ng of either PGE2 or cicaprost was greater in the former, which
were conducted (end July - beginning August) six months after
those at the higher doses (end January - beginning February),
highlighting the problem with seasonal and temperature variations
already mentioned. The results at 1 ng were averaged and
therefore lie between the higher response at 0.3 ng and the lower
response at 10 ng for either PGE2 or cicaprost.
11-Deoxy PGE2 1-alcohol produced an increase in plasma
exudation at 500 ng (Figure 2.6). This represented a significant
increase over that to bradykinin alone, and occurred in the
absence of any significant alteration in blood flow (Figure 2.7)
highlighting the possible existence of another mechanism besides
vasodilatation in the potentiation of inflammatory mediator action.
In summary, the effect of the drugs tested on this in vivo model of
rabbit skin inflammation, suggests an EP2-like receptor subtype to
be involved in the potentiation of the inflammatory response
induced by mediators such as bradykinin. There are discrepancies
between the changes in blood flow and plasma exudation which
suggest that whilst vasodilatation may be important in the
potentiation response, it does not appear to be the sole
mechanism by which the effect is mediated.
These studies have been complemented and furthered by the work
of a colleague, which gives a greater insight into the mechanisms
involved in PGE2-induced potentiation. The EP3-component of
PGE2 activity was additionally examined using the EP3-selective
analogue, MB 28767, following inhibition of its TP-receptor activity
by GR 32191 (Armstrong et al., 1990). At 1 ng MB 28767
significantly increased plasma exudation to +78 % but there was no
further increase up to the maximum dose tested at 1 gg. This may
reflect MB 28767 overcoming the TP-receptor block at the higher
doses, agonist activity at this receptor exerting an inhibitory
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influence on the potentiation as demonstrated by the experiments
with the TX-mimetic, U46619 (Figure 2.11). However
sulprostone, which is a very weak TP-receptor agonist, showed a
similar effect. Misoprostol, like PGE2, was shown to be a potent
vasodilator, which may correlate with its ability to potentiate
exudation (Figure 2.9). MB 28767 however, did not cause
dilatation, though it was able to potentiate the response to
bradykinin, as described.
The plasma exudation and dilatation results of the PGE analogues
tested, taken in combination, suggest both EP2- and EP3- mediated
events may be involved in this pro-inflammatory activity of PGE2.
The lack of activity of 17-phenyl-co-trinor PGE2 in potentiating the
bradykinin response (Figure 2.10), suggests the EPi-receptor is
not involved, though the preliminary results on a potentiated
system (see results section) may indicate an inhibitory component
by this receptor subtype. It was concluded that the high potency
component may reflect an EP3-mediated activity, which would
appear to be unrelated to vasodilatation. The potentiation of
bradykinin exudation seen with agonists having EP3-activity, may
therefore result from bradykinin-induced dilatation potentiating an
EP3-induced neutrophil-dependent exudation, as shown for LTB4
(Bray et al, 1981).
As reported earlier, the increase in plasma exudation by 1 ng PGE2
was significantly greater in combination with 1 gg bradykinin as
compared to 0.5 pg. This may reflect a greater dilatation at 1 pg
bradykinin increasing the response of an EP3 component of
potentiation, as represented by low concentrations of PGE2. The
lower potency component is proposed to be an EP2-mediated
vasodilatation, which may differ from that previously characterised
by the high potency of butaprost. This would explain the
observation that of all the analogues tested, misoprostol, having
both EP2- and EP3- receptor activity, produced a similar maximum
to that obtained with PGE2 in potentiating the response to
bradykinin.
Cicaprost, a potent vasodilator and PGI2 analogue, has been shown
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to potentiate plasma exudation induced by the EP3~selective
analogues MB 28767 and sulprostone, but not the EP2-selective
analogues butaprost and 11-deoxy PGEi, in the absence of other
inflammatory mediators (Armstrong & Jones, 1991). In order to
determine if the EP3-mediated effect is neutrophil-dependent,
experiments were carried out on rabbits rendered leucopoenic
with nitrogen mustard. Following such pretreatment, the
potentiation by cicaprost of MB 28767 and sulprostone was
prevented, whilst the potentiation of the bradykinin response was
unaltered. This supports the proposition that PGE2 may exert part
of its pro-inflammatory action via an EP3 receptor-mediated,
leucocyte-dependent mechanism.
A comparison of the effect of EP2- and EP3-selective agonists on a
neutrophil -dependent (FMLP) and -independent (bradykinin)
inflammatory mediator, gives further strength to the proposal that
two different mechanisms are involved in the potentiation of
plasma exudation by PGE2 (Armstrong et al, 1991). The response
to FMLP was potentiated by the EP2-selective agonists,
11-deoxy PGEi, butaprost, mexiprostol and
11-deoxy PGE2 1-alcohol, and correlated with their ability to
increase local blood flow. The EP3-selective agonists, MB 28767,
sulprostone and GR 63799X, were unable to potentiate the
response to FMLP, with neither the PGs nor FMLP able to increase
local blood flow. This was in contrast to the potentiation observed
with bradykinin, which itself was able to increase local blood flow.
PGE2, PGEi, 6-keto-PGEi and PGD2, but not PGF2a, PGI2 and its
analogues, have all been shown to inhibit PMN superoxide
production in response to FMLP (Gryglewski et al., 1987). PGE2
and 6-keto-PGEi may reduce the FMLP-induced response through
occupation of the FMLP receptor. In addition PGD2 and the PGEs
are thought to have a common mechanism of action through
interaction with different binding sites (Rossi & O'Flaherty, 1989).
The mechanism of this action of the PGEs is suggested to be the
result of an increase in cyclic AMP, which neither PGI2 nor
cicaprost are capable of inducing (Hecker et al, 1990). Having
shown the EP3-mediated effect to be dependent on the
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presence of circulating neutrophils, the effect of the PGE
analogues on chemotaxis is now being investigated. Also, the
subtypes of PGE receptor present on the neutrophil are being
further characterised through both binding and second messenger
studies.
Whilst vasodilatation is obviously an important component of the
potentiation of inflammation induced by PGE2, this study has
suggested that it is not the sole mechanism of action of PGE2.
Indeed, subsequent studies have indicated the chemotactic nature
of the EP3-selective analogues on the neutrophil to be important.
In a previous study, PGE2 and PGI2, both at a dose of 10 ng, were
found to be equiactive in potentiating plasma exudation, yet PGE2
was shown to be more active than PGI2 in increasing blood flow
(Williams, 1979). This is thought to reflect a different time-course
of action for the PGs, with PGE2 peaking before PGI2, or
alternatively, there is another component to their potentiating
ability which is more active with PGI2 than PGE2. In addition to
the vasodilatory component, it has also been suggested that PGE2
may sensitise agonist receptors on vascular endothelial cells, or
exert its effect through modulation of endothelial cell cyclic AMP
levels (Williams & Morley, 1973). Binding and second messenger
studies with cultured endothelial cells may therefore be the next
step in further understanding the mechanisms of the
pro-inflammatory action of PGE2.
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Chapter 3
Inhibition of cyclic AMP production in human platelets
by PGE analogues
3.1 INTRODUCTION
3.1.1 Prostaglandins and platelet aggregation
In the early years of prostaglandin research, arachidonic acid was
shown to induce platelet aggregation and this was accompanied by
prostaglandin formation (Ingerman, 1973). NSAIDs were also
shown to inhibit irreversible platelet aggregation and the
production of PGE2 and PGF20C (Smith & Willis, 1971;
Kocsis et al., 1973). However, these prostaglandins could not
themselves induce platelet aggregation nor surmount the
inhibitory effect of aspirin, though pre-incubation with arachidonic
acid prevented the inhibitory effect of aspirin on collagen-,
adrenaline- and ADP-induced platelet aggregation
(Leonardi et al., 1972). Therefore the existence of a potent
inducer of platelet aggregation was proposed, whose enzymatic
generation from arachidonic acid is suppressed by NSAIDs
(Willis & Kuhn, 1973), but whose nature is distinct from PGE2 and
PGF2a (Vargaftig & Zirinis, 1973). Subsequently, the isolation and
structure of two prostaglandin endoperoxides, PGG2 and PGH2,
formed during prostaglandin biosynthesis was reported. These
agents induced aggregation of human platelets
(Hamberg et al., 1974).
However, it soon became apparent that further metabolism to an
even more potent aggregator was possible (see Figure 1.1). The
product TXA2 has a unique strained acetal structure which readily
hydrolyses under neutral conditions (ti/2 ~ 30 s, 37 °C) to give the
inactive TXB2 (Hamberg et al., 1975). A microsomal thromboxane
synthetase system was subsequently identified and characterised
from both human and horse platelets (Needleman et al., 1976).
This enzyme was able to convert the prostaglandin endoperoxides
into TXA2 which proved to be more potent in contracting strips of
rabbit aorta. It was not long after that another enzyme was
isolated, this time in microsomes prepared from rabbit or pig
aorta. Interestingly this enzyme converted the prostaglandin
endoperoxides into yet another unstable substance, PGI2
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(see Figure 1.1). originally termed PGX, (Johnson et al., 1976),
with opposing biological activities to TXA2 (Moncada et al., 1976).
3.1.2 Inhibition of platelet aggregation - who shares what
receptor?
PGE2 and PGEi have both been shown to raise cyclic AMP levels
and inhibit ADP-induced platelet aggregation, though PGEi was the
more potent of the two (McDonald & Stuart, 1974). PGI2 however,
was found to be much more potent than PGEi in inhibiting platelet
aggregation, and is in fact the most potent inhibitor of human
platelet aggregation in vitro so far described
(Moncada et al., 1976). It also is a potent stimulator of cyclic AMP
accumulation in human platelet-rich plasma and a direct stimulator
of platelet microsome adenylate cyclase, with an e.m.r. of 0.1
relative to PGEi (Gorman et al., 1977).
Following the report that PGD2 could also elevate platelet cyclic
AMP levels (Tateson et al., 1977), the possibility of a common
receptor was addressed. The sensitivity of PRP from horse,
human, rabbit, rat and sheep to PGEi followed more closely the
sensitivity to PGI2 than to PGD2, suggesting there may be a
common site for PGEi and PGI2 (Moncada et al., 1977). However,
distinct receptors were believed to exist on the platelet for PGI2
and PGD2 (Siegl et al., 1979a,b; Siegl, 1982). This was supported
by binding studies on normal citrated human PRP, which revealed
PGEi to be 20-fold less potent than PGI2 in displacing [3H]-PGl2,
whilst PGD2 was ineffective despite being more potent than PGEi
as an inhibitor of ADP-induced aggregation in vitro. Also,
di-4-phloretin phosphate blocked the inhibitory effect of PGD2 but
not PGEi or PGI2 in human platelet aggregation
(Westwick & Webb, 1978). The inhibition of irreversible,
monophasic, ADP-induced aggregation by PGI2 and PGD2, was
found to be additive (Andersen et al., 1980), which is consistent
with the presence of two structurally distinct receptors governing
the same adenylate cyclase.
Further evidence for a common PGEi / PGI2 receptor comes from
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desensitisation studies to elevation of cyclic AMP in human PRP
(Miller & Gorman, 1979). Whilst PGEi and PGI2 reciprocally
desensitise to subsequent challenge, PGD2 desensitises platelets to
later challenge by PGD2 but not PGEi or PGI2. This PGEi / PGI2
receptor has since been purified from human blood platelets and
binding of [3H]-PGEi displaced by PGI2 but not PGD2
(Dutta-Roy & Sinha, 1987). PGEi and PGE2 may also share a
receptor on the human platelet having a similar potency in
displacing [3H]-PGEi from its high affinity binding sites in the
platelet suspension (McDonald & Stuart, 1974), but not PGD2 from
its own receptor (Bonne et al., 1981). This is distinct from the
PGEi / PGI2 receptor already discussed, since specific binding of
[3H]-PGE2 to its site was displaced by PGE2 and PGEi, but not by
PGI2 (Eggerman et al., 1986).
3.1.3What is the role ofPGEg in platelet aggregation ?
Kloeze's first report (1969) of the stimulatory activity of PGE2 on
ADP-induced platelet aggregation in the rat, in contrast to its
inhibitory effect towards human platelets, prompted a
reexamination of PGE2 activity by Shio and Ramwell (1972). They,
and others since, found PGE2 to be distinct from other
prostaglandins in that at low concentrations it potentiates human
platelet aggregation induced by ADP or arachidonic acid, yet at
higher concentrations platelet inhibition is observed
(Shio & Ramwell, 1972; Vargaftig & Chignard, 1975).
Maclntyre & Gordon (1975) found PGE2 to reproducibly enhance
aggregation in heparinised PRP from both rat and man, and indeed
to directly induce aggregation in pig heparinised PRP. PGE2 often
shows a dual effect on aggregation, inhibiting primary aggregation
and stimulating release (14C-5HT loading technique) in secondary
irreversible aggregation (Shio & Ramwell, 1972;
McDonald & Stuart, 1974; Andersen et al., 1980).
Andersen et al. (1980) have suggested the aggregation-potentiating
effect of PGE2 occurs at concentrations as low as 10-20 nM, and is
therefore of physiological significance.
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The pro-aggregatory effect of PGE2 is reported to be responsible
in part for the lack of sensitivity of platelet aggregation to five
different thromboxane synthetase inhibitors in non-responders
(Gresele et al., 1988). Inhibition of thromboxane synthesis results
in the accumulation of the PG endoperoxides which may be
metabolised further to PGD2, PGE2 and PGF2a, or under the
influence of endothelial PGI2 synthetase be converted into PGI2.
There is also the potential for the PG endoperoxides themselves to
stimulate platelet aggregation, through interaction with the
TP-receptor.
In vitro, inhibition of arachidonic acid - induced platelet
aggregation in responders due to the presence of such inhibitors
was observed, and PGE2 was mostly anti-aggregatory. However, in
those cases where the thromboxane synthetase inhibitors did not
inhibit the arachidonic acid - induced platelet aggregation, PGE2
was found to be pro-aggregatory at similar concentrations of
50 - 500 nM. Neutralisation of endogenously produced PGE2 by an
anti-PGE2 serum, transformed nonresponders into responders,
indicating the involvement of the pro-aggregatory PGE2 in the
arachidonic acid - induced aggregation response, obtained in the
presence of the thromboxane-synthetase inhibitors in
non-responders. The response of the platelets is thought to be
dependent on the balance between PGD2 and PGE2, since if PGD2
formation is enhanced by the addition of serum albumin,
non-responders to the TX synthetase inhibitor dazoxiben are
induced to respond (Gresele et al, 1984).
The pool of platelets were equally sensitive to the effects of
forskolin or dibutyryl cyclic AMP, suggesting no change in the
sensitivity of the catalytic unit between responders and
non-responders. Further, in the absence of any specific receptor
effect, the difference in response to the thromboxane synthetase
inhibitors is thought to be at the level of coupling between the
EP-receptor and the adenylate cyclase unit. With the additional
presence of a TP-receptor antagonist there were no
non-responders, suggesting the action of the accumulated PG
endoperoxides in response to the inhibition of thromboxane
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synthetase are responsible for the altered effects to PGE2 and
pgi2.
3.1.4 Regulation of adenylate cyclase
Early reports have suggested that the potentiation of aggregation
by low concentrations of PGE2 is due to a decrease in cyclic AMP
content of the platelet, with an increase at the higher
concentrations inhibiting aggregation (Salzman et al, 1972). Thus
Gray and Heptinstall (1985) demonstrated potentiation of
ADP- and collagen- induced aggregation by 10~8 - 10~6 M PGE2 and
inhibition at 10~5 M. Interestingly with adrenaline-induced
aggregation, only the inhibitory component of PGE2 was present.
However, PGE2 could also reverse the inhibitory effect of PGI2 on
adrenaline-induced aggregation. Since adrenaline itself inhibits
adenylate cyclase in human platelets (Zieve & Greenough, 1969;
Salzman & Levine, 1971), this may possibly prevent further
depression by PGE2 and therefore potentiation of aggregation was
not demonstrated. PGI2 inhibited the adrenaline-induced
aggregation through elevation of cyclic AMP (Gorman et al, 1977),
thereby permitting the reversing action of PGE2 through
subsequent inhibition of cyclic AMP formation.
As PGEi acts on the IP receptor as already discussed, by analogy
the reversal of the inhibitory effect of PGI2 on adrenaline-induce
aggregation by PGE2 may reflect a degree of competition with PGI2
for the inhibitory IP receptor, at which PGE2 is the weaker agonist
(Miller & Gorman, 1979). However, PGE2 is an effective
antagonist to PGEi, PGD2 and PGI2 (Andersen et al., 1980;
Bonne et al, 1981) and inhibits the increase in cyclic AMP
induced by adenosine and sodium fluoride (Bonne et al, 1981),
suggesting a separate receptor for the potentiation of aggregation
by PGE2.
The prostaglandins PGI2 and PGD2 have been shown to produce a
time- and dose- dependent inhibition of their own rapid activation
of adenylate cyclase in platelet lysates (Ashby, 1986) similar to
previous reports of PGEi in intact platelets (Mills & Smith, 1972).
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This may indicate the presence of a low affinity inhibitory PG
receptor and subsequently a two receptor model was proposed to
explain prostaglandin regulation of adenylate cyclase
(Ashby, 1988,1989).
The fall in cyclic AMP level was shown to be independent of
phosphodiesterase (PDE) activity. Platelet PDE may be activated by
phosphorylation due to the action of cyclic AMP - dependent
protein kinase (Grant et al, 1988; MacPhee et al, 1988). Such
activation of PDE is however rapid (Alvarez et al, 1981) and in the
presence of a PDE inhibitor there is still a time-dependent fall in
the cyclic AMP level.
By following the time-course of cyclic AMP metabolism in the
intact cell, Ashby (1990) suggested distinct stimulatory and
slow-acting inhibitory receptors differing in affinity for each of the
prostaglandins. This proposal is supported by binding studies
reporting two classes of prostaglandin binding site on platelet
membranes (Schafer et al, 1979; Siegl et al, 1979a,b;
Siegl, 1982). The model that Ashby proposes does not require
that any of the prostaglandins binds to the same receptor, the
desensitisation which he refers to being at the level of the
G proteins, reflecting more a physiological antagonism.
3.1.5 Physiological role of the prostanoids
It has been proposed that the arachidonic acid metabolites have a
role in the regulation of platelet interactions with the blood vessels
(Maclntyre, 1979). Prostaglandins not normally produced by the
platelets, such as PGEi and PGI2, modify platelet function when
added exogenousfy or formed endogenousfy by the lungs or
vasculature, and released into the circulation. Studies conducted
by Kloeze (1969) on platelet-rich rat blood plasma, indicated that
PGEi, which we now know to be acting through the IP-receptor,
inhibited the ADP-induced platelet aggregation through a rise in
cyclic AMP. The relationship of the platelet with the blood vessel
is such that in the case of a normal undamaged vessel, the
endothelium plays an active part in the prevention of thrombus
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formation. Part of this may be due to the generation and release of
PGI2 to balance the opposing action of released prostaglandin
endoperoxides which stimulate platelet aggregation
(Gryglewski et al., 1976). The endothelial cells may form this PGI2
utilising PGH2 released from activated platelets in close association
with the vascular endothelium (Bunting et al., 1976). Platelet
aggregation in vivo is thought to be regulated in part by a balance
between platelet TXA2 and endothelial PGI2.
The main physiological role of platelets is the triggering of
haemostasis where they are important for healing damaged blood
vessels (Mustard & Packham, 1970). If a vessel is cut or injured
the endothelium will be damaged and the subendothelial tissue
exposed. As a result of their strong affinity for collagen, platelets
adhere to the exposed subendothelial tissue in the damaged area
and become activated. The release reaction following shape
change and aggregation will recruit more circulating platelets and
a plug will form as a consequence. Along with vessel constriction,
this plug maintains haemostasis in the small vessels until the
platelet plug is reinforced by fibrin. This sequence of events may
be inappropriately triggered in a number of pathophysiological
conditions including tumour cell metastasis, asthma, migraine,
atherosclerosis, and most prominently, thrombosis. A bleeding
disorder will result if platelets cannot aggregate or if the platelet
count is low, as in thromocytopenic purpura. It is in these
circumstances where drugs which influence the aggregation
process may be of therapeutic value.
3.1.6 The mechanism ofplatelet aggregation
The response of a stirred suspension of platelets to an activating
agent progresses from shape change, through aggregation, to
release of granule contents, and occurs in response to a variety of
different agonists (reviewed in Seiss, 1989). Quantitative studies
of shape change and aggregation have been facilitated by the
invention of the platelet aggregometer by Born in 1962. Light
passing through the platelet suspension is detected by a photocell
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connected to a chart recorder. Shape change results in a small,
rapid reduction in light transmission and a disappearance of
oscillations as the platelets become spherical and extrude
pseudopodia. The disc shape characteristic of the resting state of
the platelet is maintained by a ring of microtubules around the
edge below the plasma membrane. The rounding of the platelet is
associated with constriction of the ring of microtubules and
centralisation of the organelles within the ring. Cytoplasmic
actin- and myosin- like proteins also cross-react. Shape change is
not a prerequisite for aggregation, as adrenaline can cause
aggregation without shape change and cytochalasin B inhibits
shape change but not aggregation. When aggregation occurs there
is an increase in light transmission dependent on extracellular
Ca2+ and fibrinogen, which forms bridges between platelets, and
only occurs if the platelet suspension is stirred rapidly enough
(1000 rpm) to allow the platelets to collide. The rate and extent
of the increase is dependent on the concentration of the
aggregatory agent. Fibrinogen binding to activated platelets and
the subsequent cross-linking gives rise to the reversible primary
agregation obtained with weak aggregatory agents, or a low
concentration of the stronger agonists. Stronger stimuli give rise
to secondary irreversible aggregation associated with prostaglandin
endoperoxide or thromboxane synthesis, and release of granule
contents.
Platelets contain three types of storage granules whose contents
are released upon activation. Dense granules containing 5HT, ADP,
ATP, Ca2+ and Mg2+, influence vascular tone and the
thrombus-forming ability of other platelets. a-Granules contain
proteins which influence blood vessel function and the clotting
cascade, such as platelet factor 4, (3-thromboglobulin,
platelet-derived growth factor (PDGF), thrombospondin and
fibrinogen. PDGF is secreted by platelets when serum is formed
from plasma and gives serum its property of stimulating or
sustaining growth of cells in culture. The contents of the
lysosomal granules are only released after platelets are stimulated
with powerful aggregating agents such as thrombin and high
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concentrations of collagen. The irreversibility of the secondary
aggregation may be due to the stabilisation of the fibrinogen
bridges by thrombospondin, the adhesive protein released from
the a-granules.
Besides the contents of the granules, activated platelets can
release physiologically active substances, which are newly
synthesised rather than stored. Platelet activating factor
(PAF-acether, PAF) is generated from most inflammatory cells
when they are activated, and from platelets by the action of
thrombin. PAF produces many of the phenomena of inflammation
including induction of local platelet aggregation
(Chignard et al., 1979). The effects are produced at low
concentrations (1-10 nM) and though human platelets do not
produce detectable amounts on physiological activation, PAF is
important in bronchial hyperresponsiveness, the delayed phase of
asthma and may also have a role in arterial thrombosis and
endotoxic shock (Braquet et al., 1987). Since aspirin inhibits the
second wave of aggregation, first shown by O'Brien (1968), the
endoperoxides have been implicated in the release reaction
(Samuelsson et al, 1976). Generally it is the act of aggregation
rather than the agonist itself which causes prostaglandin synthesis
and release, as unstirred platelets or those prevented from
aggregating by treatment with an antibody to glycoprotein
lib / Ilia, thought to be the fibrinogen receptor, do not release
their granule contents, whereas centrifugation of activated
platelets will cause release (Balduini, 1988). Thrombin is the
exception, in that the resulting TXA2 formation and release appear
unrelated to aggregation. Other substances released from platelets
are factors which increase vascular permeability, factors
chemotactic for white blood cells and platelet-derived growth
factors which can cause proliferation of fibroblasts, vascular
endothelial cells and vascular smooth muscle cells.
There are several forms of positive feedback control in the
aggregation of platelets. Activation may be enhanced due to the
release of ADP from the dense granules. Following induction of
arachidonic acid metabolism, the stimulatory PGG2, PGH2 and
TXA2 further enhance aggregation and cause this release reaction
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(Malmsten et al, 1975). Indomethacin was shown to inhibit the
PGG2 formation and the release reaction induced by collagen, ADP,
adrenaline and thrombin, but had no effect on the PGG2-induced
release reaction. The aggregating effect of PGG2 was however
abolished by furosemide, a competitive inhibitor of ADP-induced
primary aggregation. The results suggest these aggregating agents
require PGG2 (and / or PGH2) synthesis for induction of the release
reaction, the resulting ADP promoting the aggregation. Strong
stimuli such as collagen or thrombin may also induce the synthesis
and release of PAF which, as discussed, causes platelet aggregation
at a low concentration. All these agents are important in activating
more platelets to increase the size and effectiveness of the
thrombus. How this positive feedback is limited is not well
understood. Dilution by the flow of blood past the thrombus may
limit their effective concentration, and the PGI2 released by
stimulation of the vessel wall will be exerting opposing inhibitory
effects on the platelets.
3.1.7 Second messengers
The most important stimuli for platelet aggregation in vivo include
collagen fibres to which the platelet is exposed following vascular
damage, ADP released from damaged cells and thrombin which is
formed rapidly from circulating prothrombin at the sites of platelet
adherence. Stimulatory agonists including collagen, thrombin,
PAF, vasopressin and TXA2, activate phospholipase C (PLC), which
hydrolyses phosphatidyl-inositol 4,5-bisphosphate (PIP2)
(Agranoff et al, 1983) producing the second messengers inositol
triphosphate (IP3) and diacylglycerol (DAG) (see Figure 3.1.1). IP3
causes Ca2+ release from the dense tubules and DAG activates
protein kinase C (PRC) (Drummond & Maclntyre, 1987).
However, subsequent action of DAG kinase may result in the
formation of phosphatidic acid (PA), from which free arachidonic
acid may be released by the action of a PA-specific PLA2
(Billah et al, 1981). PA may additionally be produced as a result of
the PLD-induced hydrolysis of PC, as demonstrated for thrombin in
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human washed platelets (Rubin, 1988). Alternatively, sequential
action of DAG lipase and monoacylglycerol lipase may directly
produce arachidonic acid (Bell et al, 1979). The cyclooxygenase
products of this arachidonic acid exert a positive feedback on the
platelet aggregation as already described.
Adrenaline and ADP may activate PLC indirectly through formation
of TXA2, since cyclo-oxygenase inhibitors or TX receptor blockers
strongly reduce the inositol phosphate production in response to
these agonists (Sweatt et al, 1986a). Multiple forms of PLC activity
have been described for the soluble (Mauco et al, 1979;
Rittenhouse-Simmons, 1979; Billah et al, 1980) and particulate
(Banno et al, 1988) extracts of human platelets.
The involvement of Ca2+ in platelet activation results from studies
using the Ca2+ ionophore A23187, which mimics stimulatory
agonists in causing shape change, aggregation and the release
reaction (Feinman & Detwiler, 1974). Tsien et al (1984)
revolutionised the measurement of [Ca2+J and its role in
stimulating response coupling, by the invention of a fluorescent
Ca2+ indicator, quin-2, and its more sensitive successor fura-2. In
their esterified form they enter the intact cell and following
deesterification become trapped. Ca2+ studies have also
progressed through the use of the photo-protein aequorin and
measurement of 45Ca2+ fluxes. An increase in [Ca2+]i was thought
to be the common activator for platelet shape change, aggregation
and release, as shown for ADP using quin-2 loaded human platelets
(Hallam & Rink, 1985). Influx of Ca2+ across the plasma
membrane was thought to be the major contributor to this
increase, since it was markedly reduced in the absence of
extracellular Ca2+ or in the presence of the Ca2+ chelator, EGTA.
The small increase under these conditions would be the result of a
release from internal stores. The Ca2+ content of the organelles is
10-20 mM but much of this is reversibly bound to a
calsequestrin-like molecule, so that the free [Ca2+] is several
100 pM. The entry of extracellular Ca2+ is regulated by the state of
filling of the discharged intracellular store.
By measuring both quin-2 fluorescence and the optical density of
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the suspension in the presence of the selective Ca2+ ionophore,
ionomycin, the threshold [Ca2+h for shape change was found to be
300 nM, becoming maximal at 800 nM with aggregation occurring
at 1 |TM. However, maximal shape change using ADP as the
stimulus occurred at [Ca2+h < 200 nM, producing an aggregatory
response at [Ca2+h < 1 pM. This ability of ADP to induce both
shape change and aggregation with a smaller increase in [Ca2+h
than that required by the calcium ionophore, ionomycin, suggests
additional excitatory mechanisms besides the increase in [Ca2+]i
are involved in the response to ADP. A similar effect had
previously been described for thrombin and PAF, which were able
to produce aggregation and secretion even when [Ca2+h was
suppressed. It was suggested that the DAG formed as a result of
PIP2 hydrolysis may be responsible for this Ca2+-independent
activation (Rink et al., 1983), l-oleoyl-2-acetyl-glycerol (OAG)
inducing secretion and aggregation without raising [Ca2+h above
the basal concentration of 100 nM. OAG acts through the
stimulation of PKC and indeed TPA, another activator of PKC, was
also a potent stimulus for secretion and aggregation. An increase
in [Ca2+]i which itself was unable to produce an effect, enhanced
the response to both OAG and TPA. Therefore, a combination of a
rise in [Ca2+h induced by IP3 and the action of DAG through the
activation of PKC, together appear to be responsible for the
response of the platelets to thrombin and PAF. The synergism
between Ca2+ and DAG may explain why some agonists cause
responses with smaller rises in [Ca2+h than expected using
ionophores, as described for ADP.
Agents whose action is to induce or augment platelet aggregation
may also be associated with a decrease in the platelet content of
the cyclic nucleotide, cyclic AMP (see Figure 3.1.1). Various
aggregatory hormonal factors such as adrenaline, ADP
(Cooper & Rodbell, 1979), platelet-activating factor
(Haslam & Vanderwel, 1982), vasopressin (Vanderwel et al, 1983)
and thrombin (Aktories & Jakobs, 1984) have been shown to
inhibit adenylate cyclase in the platelet particulate fraction.
Besides the PLC pathway and the inhibition of adenylate cyclase,
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there is evidence that increased Na+ / H+ exchange may play a role
in the activation of platelets by adrenaline and ADP
(Home et al, 1981) via the sequential formation of TXA2 and IP3
(Sweatt et al, 1986a,b). It has been proposed that elevation of
pHi, as a result of the effect of ADP on Na+ / H+ exchange,
stimulates PLA2 giving rise to TXA2, and consequently IP3 through
activation of PLC. This IP3 in turn mobilises Ca2+ from intracellular
stores, resulting in the observed platelet aggregation. However,
the ADP-induced dose-dependent Ca2+ mobilisation in fura-2
loaded platelets was not affected by indomethacin. It was however
inhibited by > 65 % in indomethacin-treated platelets by the
Na+ / H+ exchange inhibitor, ethylisopropylamiloride, an effect
which could be overcome by artificially raising the pHi. The effect
of U46619, a stable TXA2 mimetic, on Ca2+ mobilisation was
similarly sensitive to EIPA. These results therefore show that
Na+/H+ exchange is a common step in platelet activation by the PG
endopeoxides / TXA2 and ADP, and appears to enhance Ca2+
mobilisation independently of PLA2 activity.
Inhibitory agonists act via elevation of intracellular cyclic AMP or
cyclic GMP (Mills & Smith, 1971) (see Figure 3.1.2). Certain
agents that elevate either cyclic AMP (PGEi, PGI2, forskolin) or
cyclic GMP (organic nitrates, sodium nitroprusside,
endothelium-derived relaxing factor (EDRF)) inhibit both vascular
smooth muscle cells and platelet aggregation. The effect of a rise
in cyclic AMP, accomplished either by inhibition of cyclic AMP
phosphodiesterase or stimulation of adenylate cyclase, is to inhibit
nonspecifically and noncompetitively platelet activation induced by
aggregating agents, including Ca2+ ionophores, and to cause
disaggregation if aggregation has already occurred (reviewed in
Huang & Detwiler, 1986). It is of physiological significance that
sodium nitroprusside and PGI2 act synergistically to inhibit platelet
aggregation (Levin et al., 1982) since EDRF and PGI2 are released
together from the endothelium. EDRF is in fact nitric oxide, the
effector molecule of the nitrovasodilators (reviewed in
Moncada et al, 1991).
The anti-platelet effect of nitrovasodilators was accompanied by a
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large dose-dependent increase in cyclic GMP, and a smaller
increase in cyclic AMP, which could both be blocked or reversed
by the addition of the nitric oxide binding haemoglobin
(Waldman & Murad, 1987). MB 22948, the selective inhibitor of
cyclic GMP phosphodiesterase, potentiated the increase in both
cyclic GMP and cyclic AMP caused by sodium nitroprusside. There
is therefore an interaction between the guanylate and adenylate
cyclase systems in the platelet, and it is suggested that cyclic GMP
is inhibiting cyclic AMP phosphodiesterase by the phosphorylation
of a cyclic GMP-dependent protein kinase
(Maurice & Haslam, 1990). In effect cyclic AMP levels are
elevated, thereby promoting the cyclic GMP-induced platelet
inhibition.
The response of the platelet to stimulatory or inhibitory agonists is
thought to be mediated largely by the phosphorylation of proteins
(Rink & Hallam, 1984; Cohen, 1988; Rink & Sage, 1990).
Aggregation can still occur, though it is much reduced, in the
presence of non-specific inhibitors of protein kinase. This implies
there is also a phosphorylation-independent pathway of platelet
activation mediated by Ca2+ (Watson & Hambleton, 1989).
Inhibitory agonists exert their effect by stimulating a specific
pattern of protein phosphorylation in human platelets mediated by
cyclic AMP- and cyclic GMP- dependent protein kinases
(Waldman et al, 1987). The activation of cyclic AMP - dependent
protein kinase results in the phosphorylation of a protein which
increases Ca2+ uptake, representing the major mechanism of
inhibiting platelet function. This protein kinase may also inhibit
PIP2 hydrolysis, thereby inhibiting Ca2+ release as a result of IP3
formation. Nitroprusside, through the increase of cyclic GMP
levels, is a more effective inhibitor of platelet responses to
different agonists rather than Ca2+ ionophores or phorbol ester,
suggesting its main inhibitory action is at the generation of
stimulatory second messengers.
The signal emitted from the activated receptor is transduced
through the plasma membrane by GTP-binding proteins
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(Gilman, 1987; Smith et al., 1987). G-proteins are composed of
three subunits a, (3 and y and are associated with the plasma
membrane. The a-subunits for the stimulatory (as) receptor and
the inhibitory (aj receptor are non-identical but highly
homologous. These hydrophilic subunits bind guanine nucleotides
GDP and GTP, possess GTP-ase activity and have recognition sites
for the enzyme or effector protein whose activity they regulate.
The activity of the a-subunit is controlled by the hydrophobic (3y
complex, which is only separated under denaturing conditions. In
the resting state GDP is bound to the G-protein maintaining its
inactive form in association with the receptor. Following agonist
binding to its specific receptor, GDP is exchanged for GTP and the
G-protein dissociates into the (3y complex with the active a-subunit
modulating effector activity. The intrinsic activity of the a-subunit
hydrolyses GTP to GDP, promoting dissociation from effector and
reassociation with the (3y subunits. Stable GTP analogues, GTPys
and GMP-PNP allow prolonged activation of G-proteins since they
are non-hydrolysable, maintaining the a-subunit in its active form.
Prostanoids act via receptors that are directly coupled to specific
G-proteins, the biochemical outcome of receptor occupancy
depending on the nature of the G-protein with which the occupied
receptor is able to interact. Bacterial toxins covalently modify the
G-proteins by addition of an ADP-ribose group from NAD to specific
sites on the a-subunit, and consequently are useful tools in
determining the involvement of G-proteins in signal transduction.
Cholera toxin (CTX) blocks the GTPase activity of as thereby
maintaining it in its active form. Pertussis toxin (PTX) blocks the
agonist-induced inhibitory effect of ai by stabilising the ai-GDP/Py
complex and uncoupling Gi from the receptor (Ui, 1984).
There is evidence of a role for G-proteins in activation of PLC from
both permeabilised platelets and human platelet membranes
(Nozawa et al., 1989). Stable GTP analogues reduce [Ca2+]i
necessaiy for platelet activation (Haslam & Davidson, 1984) and
cause an increase in DAG formation and concomitant hydrolysis of
phosphoinositides (Lapetina, 1986; Brass et al, 1986). There
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appears to be differing opinions as to whether there is a similarity
between this G-protein mediating receptor coupling to PLC (Gp)
and the Gi inhibiting adenylate cyclase in platelets.
Brass et al. (1986) and Williams et al. (1990) both report on a
PTX-sensitive G-protein to be involved in the regulation of
thrombin-induced phosphoinositide hydrolysis. This similarity of
Gi and Gp is supported by a study using an antibody to the oq
subunit of Gi isolated from bovine brain, which is shown to
cross-react with the protein involved in the formation of IP3 and
DAG as a result of collagen-induced platelet activation
(Walker & Bourguignon, 1990). In contrast, Lapetina (1986)
suggests that not only does PTX not inhibit the hydrolysis of
phosphoinositides in response to thrombin, it increased
hydrolysis, thereby suggesting an inhibitory influence of Gi on this
platelet response to thrombin.
A report that thrombin stimulates PLC and inhibits adenylate
cyclase, whereas adrenaline only inhibits adenylate cyclase, tends
to suggest the G proteins mediating these two pathways cannot be
the same (Haslam et al., 1990). In the same study PTX or NEM,
which has been shown to inactivate inhibition of adenylate cyclase
by adrenaline (Jakobs et al., 1982), almost completely blocked the
inhibition of adenylate cyclase induced by adrenaline, whereas the
response to thrombin in stimulating PLC was reduced by 50 % as
was the inhibitory influence on adenylate cyclase. Since they have
identified a guanine-nucleotide independent PLC activity in the
presence of high concentrations of Ca2+ which could be partially
inhibited by PTX or NEM, they conclude that most of the
thrombin-stimulated PLC activity does not in fact require
functional Gj. In relation to the stimulation of the PLC pathway by
PAF and the TP-receptor agonist, U44069, Houslay et al. (1986)
support not only the lack of involvement of a PTX-sensitive
G-protein but also that of Gs through studies with both PTX and
CTX. It has been suggested that there is a heterogeneous
population of Gp proteins (Cockcroft, 1987). The PTX-insensitive
Gp is distinct from Gi, with immunochemical studies suggesting
the PTX-sensitive form is not actually identical to Gi.
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Brass et al. (1988) suggest that platelet TXA2 receptors are
coupled to a toxin-resistant form of G protein distinct from the
one that is coupled to thrombin receptors, though both agonists
stimulate phosphoinositide metabolism. Therefore more than one
G protein appears to couple receptors to PLC, which may account
for some discrepancies.
Adenylate cyclase in platelets is regulated by the G-proteins Gs and
Gi (Stiles & Lefkowitz, 1982; Gilman, 1984; Houslay, 1984;
Katada et al., 1984). Gi inhibits adenylate cyclase directly via ai,
and/ or indirectly through the binding of (fyi to as so inactivating
the latter. Small molecular weight GTP-binding proteins have also
been isolated from human platelet membranes
(Ohmori et al., 1989; White et al., 1990). They may have a role in
the coupling to PLC of the murine monoclonal antibody AG-1,
which causes platelet activation (Kroll et al., 1990). This antibody
is generated by immunising mice with washed platelets from
patients with platelet-type von Willebrand disease, a rare bleeding
disorder in which von Willebrand's factor, normally synthesised by
vascular endothelial cells and present in the platelets, is missing.
There is a negative correlation between the ability of aggregating
agents to inhibit adenylate cyclase and stimulate PI turnover, so
that agents that are potent activators of PLC, such as thrombin, PAF
and vasopressin, are poor inhibitors of adenylate cyclase, whereas
potent inhibitors of adenylate cyclase, such as ADP and adrenalin,
activate PLC weakly. Receptors then, cannot be coupled
simultaneousy to Gi and the G-protein controlling phospholipase
activity, and the receptors for different aggregating agents may
bind preferentially to one or the other. However if, as some groups
are reporting, there is a functional similarity between these two
G-proteins then some other factor may determine which receptors
couple to which effector systems.
The stimulatory and inhibitory second messenger systems
influencing platelet aggregation have been shown to interact with
each other. In human platelets for instance, a rise in cyclic AMP
inhibited the formation of inositol phosphates and diacylglycerol
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(Nishizuka, 1984; Jakobs et al., 1986). Since an increase in cyclic
AMP reverses the rise in cytoplasmic Ca2+ caused by aggregating
agents (Zavoica & Feinstein, 1984; Paul et al., 1990), there must
be an effect on Ca2+ sequestration in addition to the inhibition of
Ca2+ mobilisation as a result of the inhibition of IP3 formation.
Protein kinase A, activated by cyclic AMP, was shown to inhibit PLC
in human platelets (Walker & Watson, 1992).
Studies have suggested cyclic AMP to inhibit guanine
nucleotide-induced activation of phosphoinositide-specific
phospholipase C in human platelets (Yada et al, 1989). This
inhibition is reported to be mediated by A-kinase phosphorylating
a membrane protein rather than the GTP-binding protein or PLC
itself, possibly resulting in the uncoupling of the GTP-binding
protein from PLC.
PKC, activated by diacylglycerol, reciprocally interferes with the
adenylate cyclase system. This may involve phosphorylation of the
Gia subunit, thereby removing the stimulatory influence on
aggregation occurring through the inhibition of adenylate cyclase
(Jakobs et al., 1986). The phosphorylation by PKC does not
however, affect the ability of hydrolysis-resistant GTP analogues to
inhibit adenylate cyclase, suggesting the receptor-Gi interaction is
altered, rather than the Gi-adenylate cyclase. The GTPase activity
of Gi may be the target (Gutierrez-Venegas & Garcia-Sainz, 1991).
In contrast, Williams et al. (1987) suggest a predominant effect of
PKC on the stimulation of cyclic AMP formation in intact platelets.
Since the former study involved the use of membranes prepared
from TPA-treated platelets, the observed differences may reflect
the nature of the preparation. A rise in [Ca2+]j may also inhibit
both basal and PGEi-stimulated adenylate cyclase in human platelet
membranes, and the Ca2+ influx induced by the ionophore A23187
markedly inhibits the PGE1 -stimulated rise in cyclic AMP in intact
platelets (Rodan & Feinstein, 1976).
Studies in our laboratory indicated that several PGE analogues
could induce irreversible platelet aggregation (in part) through
their interaction with TP-receptors (Jones et al., 1979,1982). The
presence of a 16-phenoxy group is particularly effective in
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enhancing TP-receptor agonist potency. However the 16-phenoxy
analogue, sulprostone, produced only small, slowly developing
aggregation waves, but did enhance aggregation to other agents
(eg. ADP and PAF). The enhancement was not affected by
TP-receptor antagonists. Ranking of the agonist potency of a range
of PGE analogues suggested that the EP3-receptor could be
involved (see enclosed paper). However, there were problems
associated with the very high sensitivity of the
IP-receptor - adenylate cyclase system in this functional assay
(Jones & Wilson, 1990). For example, PGE2 gave variable results
in PRP from different donors. In some PRP's, potentiation of
aggregation was observed at low PGE2 concentrations
(10 - 100 nM) with the log concentration-response curve
becoming bell-shaped as the concentration of PGE2 was increased.
In other PRP's, inhibition of aggregation was seen, although the
log concentration-response curve was always shallow. Opposing
inhibitory and stimulatory actions on adenylate cyclase could
account for these effects.
In an attempt to overcome these difficulties I have proposed that
cyclic AMP measurements may be a better method of assessing the
potentiating effects of PGE analogues. Cyclic AMP levels in human
washed platelets were raised using a potent and stable IP-receptor
agonist, cicaprost (Skuballa et al, 1986;
Sturzebecher et al., 1986), and the abilities of PGE analogues to
inhibit the rise were measured (proposed scheme as in
Figure 3.1.3). Cicaprost was deliberately chosen as the cyclase
activator since it lacks the potent EPi-receptor agonist action of
other prostacyclin analogues such as carbacyclin and iloprost
(Dong et al., 1986). Cicaprost does have some EP3-agonist activity
as judged by its ability to inhibit the twitch response of the
guinea-pig vas deferens to electrical field stimulation
(Lawrence et al.. 1992). However, it is quite a weak agonist
(e.m.r. relative to sulprostone > 5000) and at the concentration of
8 nM used in the platelet assay, it is unlikely to interact










































Figure 3.1.2 Inhibitory agonists of platelet aggregation
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Figure 3.1.3 Interactions of prostaglandin receptors
on the human platelet
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4g disodium hydrogen citrate
- in 240 ml distilled water.
Tris - HCl 500 mM vH 7 .4
121.14 g tris(hydroxymethyl)methylamine
~ 40 ml concentrated HCl
- made up to 2 litre with distilled water.
Tris (50mM) - EDTA (4mM)
100 ml tris - HCl (500mM pH 7.4)
1.48 g ethylenediaminetetraacetic acid
(disodium salt)
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Ethanolic stock solutions (10-2 - 3 x 10 2 M) were stored at -20 °C,
and with the exception of GR 63799X, diluted with 0.9 % NaCl
solution for use. Due to the insolubility of GR 63799X in 0.9 %
NaCl, dilutions from stock were made in ethanol to ~ 2 x 10~4 M.
Cyclic AMP standards
Cyclic AMP dilutions were prepared in tris-EDTA assay buffer from
a 20 mM stock, covering a range of 0 - 100 pmoles
cyclic AMP / 50 pi for determination of the standard curve. The
solutions were stored at -18 °C for a maximum of two weeks.
Binding protein
1.5 ml B.D.H. stock cyclic AMP - dependent protein kinase
(product44199) was added to 20 ml tris-EDTA assay buffer. This
was sufficient for 200 tubes and was prepared fresh for each assay.
@-HI cuclic AMP
5 pi [8 - 3H] Adenosine 3',5' - cyclic phosphate, ammonium salt
from Amersham (TRK 304; 21.2 Ci/mmol, lmCi/ml) was added to
10 ml tris-EDTA assay buffer. This supplied 200 tubes with
0.025 pCi each and the solution was stable for at least one month at
-18 °C.
Charcoal adsorbent
0.52g B.D.H. charcoal (product 44199)
0.4g B.D.H. bovine serum albumin (product 44155)
- in 20 ml distilled water (per 200 tubes) -
Prepared fresh for each assay.
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Procedure for extraction of cuclic AMP
The fresh blood donor pool comprised 4 female and 12 male
healthy volunteers in the age range 21-46 years. No information
was available for the time-expired platelets received from BTS.
1. 180 ml fresh blood collected by venepuncture from a human
forearm was added to -20% volume of acid - citrate dextrose
solution and centrifuged at 250 g for 20 min.
2. 10 pM indomethacin was added to the platelet rich plasma
(PRP) which was centrifuged at 450 g for a further 20 min to
obtain a platelet pellet.
3. Time-expired (5-day old) human platelet concentrates
(gratefully received from Blood Transfusion Service attached to the
Royal Infirmary of Edinburgh) required only the second
centrifugation step for platelet pellet preparation.
4. The pellet was suspended in 0.05 M tris buffer pH 7.4
containing 4 mM EDTA., at 37 °C in the presence of the
TP-receptor antagonist GR 32191 (500 nM). The pellet obtained
from 180 ml blood was resuspended in approximately 45 ml
tris-EDTA buffer. Initially, quantitation of the platelet content of
the suspension involved measurement of the absorbance at 600 nm
(10 mm pathlength), giving a value of 1.4 ± 0.04 (n=16) for fresh
platelets, and 1.4 ± 0.06 (n=4) for time-expired platelets.
Subsequently, protein content was determined by the Bradford
method (1976) using Pierce Coomassie Protein Assay Reagent
(No. 23200), and gave 1.5 ± 0.1 mg/ml (n=10) for fresh platelets.
5. 0.5 ml aliquots of the platelet suspension were incubated with
the PGE analogue for 2 min, followed by 8 nM cicaprost for 1 min,
and the reaction quenched by the addition of 1 ml of ethanol.
6. The samples were centrifuged at 1000 g and 4 °C for 30 min,
the ethanol supernatant decanted, evaporated to dryness at 55 °C
under a stream of air and stored at -18 °C until assayed for cyclic
AMP content.
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3.2.1 Procedure for assay of cuclic AMP
Using the B.D.H. cyclic AMP kit and [3H]-cyclic AMP from
Amersham, the unknown samples were assayed based on the
competitive binding of tritiated cyclic AMP and unlabelled cyclic
AMP to a protein kinase isolated from bovine adrenal cortex.
Separation of protein-bound cyclic AMP from the unbound
nucleotide was achieved by adsorption of free nucleotide onto
charcoal, followed by centrifugation. An aliquot of the supernatant
was removed for liquid scintillation counting, giving an estimate of
bound [3H]-cyclic AMP. A standard curve allowed determination of
unknowns. The procedure is summarised below.
1. Samples were resuspended in 250 pi tris-EDTA buffer and
insoluble material sedimented by centrifugation at 3100 rpm
(2270g) and 4 °C for 30 min. 50 pi aliquots of the supernatant
were then assayed in duplicate.
2. The cyclic AMP assay was set up as outlined in Table 3.1. The
tubes were whirlimixed and left on ice in the cold room, for at least
two hours.
3. The charcoal adsorbent was prepared at least 30 min before
use. being continuously stirred with a magnetic stirrer and
maintained at 4 °C during this time.
4. After the incubation period, 100 pi of charcoal adsorbent was
added to 12 tubes at a time, whirlimixed and centrifuged at
3100 rpm (2270 g) and 4 °C for 2.5 min. (The charcoal should not
remain in contact with the protein-bound cyclic AMP for more
than 6 min, in order to minimise its dissociative effect on
protein-bound cyclic AMP. Adding adsorbent to only 12 tubes at a
time ensures that this time schedule is maintained).
5. A 200 pi sample of the supernatant was added to 5 ml Packard
Emulsifier Safe scintillation fluid (No. 60143389), whirlimixed and
counted on a Packard Liquid Scintillation Analyzer 1900CA.
6. A calibration curve (Figure 3.1) of % [3H]-cAMP bound vs
pmoles cyclic AMP was constructed from which unknown amounts
of cyclic AMP in the extracted samples were determined.
99













1-3 charcoal blank 150 - - 50
4-6 0 pmol cAMP 50 - - 50 100
7-9 0.3 - 50 - 50 100
10-12 0.6 - 50 - 50 100
13-15 1.25 " - 50 - 50 100
16-18 2.5 - 50 - 50 100
19-21 5 - 50 - 50 100
22-24 10 - 50 - 50 100
25-27 30 - 50 - 50 100
28-30 100 - 50 - 50 100
31, 32 unknown - - 50 50 100
33, 34 unknown - - 50 50 100
n-5-n_3 10 pmol cAMP - - - 50 100
n-2-n 1.25 " - - - 50 100
T, T, T total counts 250 - - 50 -
Note:
- The charcoal adsorbent is not 100 % efficient in removing
unbound cyclic AMP, and this is accounted for in tubes 1-3,
charcoal blank. The average DPMs remaining in these samples of
supernatant are subtracted from all the other counts.
- Two standards of cyclic AMP are included at the end of the assay
in order to ensure the efficiency of binding or adsorbing has not
altered throughout the course of the experiment.
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3.3 RESULTS
3.3.1 Efficiencu of cyclic AMP extraction and assay
Cyclic AMP levels in human washed platelet suspensions were
measured by competition with radiolabeled cyclic AMP for a cyclic
AMP - dependent protein kinase. Recovery experiments were
carried out to measure the efficiency of the extraction and assay
protocols. Adding known amounts of cyclic AMP to the human
washed platelet suspension followed by extraction and assay as
previously detailed, gave an overall % recovery of 85 ± 5 (n=5). A
known amount of [3H]-cyclic AMP was also added to the human
washed platelet suspension and an aliquot of the extracted sample
counted in scintillation fluid. The recovery for this extraction
process alone was 94 ± 3 % (n=5). The extraction and assay
procedures are therefore efficient in the determination of cyclic
AMP levels.
3.3.2 Fresh human washed platelets compared to time-expired
Due to the small size of our blood donor pool, some studies were
also conducted on 5-day old stored platelets, gratefully received
from the Blood Transfusion Service. With the exception of the
time-course (Figure 3.2), the results represent the mean increase
of cyclic AMP above basal levels, the vertical bars representing the
standard error of the mean. Differences in cyclic AMP levels were
assessed according to the Student's t -test, significance being
accepted with values of probability less than 0.05. Basal levels
were determined by incubation with saline and were
25 ± 7 pmoles cyclic AMP / ml platelets (n=6) and
7 ± 2 pmoles cyclic AMP / ml platelets (n=3) for fresh and
time-expired platelets respectively.
3.3.3 8 riM cicaprost for 1 min represents control cyclic AMP
Cicaprost elevates cyclic AMP levels in the platelet through
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interaction with the IP-receptor. The concentration-response
curve to cicaprost (Figure 3.1) illustrated there was no significant
difference between fresh and time-expired platelets at any of the
concentrations tested over the range 3 nM to 800 nM, as
represented by 54 ± 15 to 206 ± 46 pmoles / ml platelets (n=5-6)
and 51 ± 22 to 187 ± 68 pmoles / ml platelets (n=3) respectively.
To provide a sensitive system for the assessment of inhibitory
effects on cyclic AMP production, an appreciable but submaximal
level of cyclic AMP was required. 8 nM Cicaprost incubated with
the human washed platelet suspension for 1 min produced
105 ± 22 pmoles / ml platelets (n=6) representing 52 ± 5 % of the
maximum and a 5.7 ± 1.6 - fold increase over basal levels for fresh
platelets, and 95 ± 30 pmoles / ml platelets (n=3) representing
44 ± 0.01 % of the maximum and a 15 ± 7 - fold increase over basal
levels for time-expired platelets.
The time-course (Figure 3.2) demonstrated a 1 min incubation
period to produce 86 ± 7 % (n=4) of the maximum cyclic AMP
produced in a 5 min period, and the increase of cyclic AMP over
basal (82 ±27 pmoles / ml platelets) was not significantly different
from that demonstrated above for the concentration-response in
fresh platelets.
3.3.4 Inhibition of control levels of cuclic AMP
The inhibitory effects of PGE analogues were determined by a
2 min period of incubation over the range of concentrations
0.2 nM to 0.9 gM, followed by a 1 minute incubation with 8 nM
cicaprost. PGE2 and GR 63799X alone at 0.9 pM and 0.5 pM
respectively, only increased cyclic AMP levels above basal by
6.2 ± 3.5 pmoles / ml platelets (n=5) and -0.5 ±1.6 pmoles / ml
platelets (n=4) respectively.
The inhibition curves obtained with sulprostone emphasise the
similarity of response between the fresh and time-expired
platelets. The IC50 value (concentration of PGE analogue inhibiting
50 % of the cicaprost-induced elevation of cyclic AMP) for
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sulprostone in fresh platelets (Figure 3.3) was 3.0 ± 0.4 nM (n=4),
compared to that in the time-expired platelet preparation
(Figure 3.4) of 4.5 ± 0.7 nM (n=5). Sulprostone was used as the
standard agonist and in subsequent experiments was included as a
control. At 22 nM sulprostone produced an average of 16 ± 3 %
(n=10) of the cicaprost-induced elevation of cyclic AMP. This was
not significantly different from the value of 19 ± 3 % (n=10),
indicated by the sulprostone dose-response curve (Figure 3.3).
In the fresh preparations (Figure 3.3), 17-phenyl-co-trinor PGE2
was approximately 30-fold less potent than sulprostone
(IC50 = 100 ± 40 nM, n=7). lOpM AH 6809, whilst having no
significant effect alone, produced a rightward shift in both curves,
giving dose ratios of 7.3 and 3.9 for sulprostone and
17-phenyl-co-trinor PGE2 respectively. The presence of AH 6809
significantly reduced inhibition of the cicaprost-induced elevation
of cyclic AMP by 2 nM to 65 nM sulprostone and 0.3 pM
17-phenyl-co-trinor PGE2.
Figure 3.4 illustrates the 4 analogues tested on the time-expired
platelet preparations. 16,16-Dimethyl PGE2, IC50 = 4.7 ±1.7 nM
(n=4), demonstrated a potency comparable to that for sulprostone.
MB 28767 was less potent at 15 ± 6.6 nM (n=5), whilst
misoprostol in its methyl ester form was approximately 15 times
less potent than sulprostone with an IC50 of 76 ± 27 nM (n=5).
11-deoxy PGE2-I-alcohol was inhibitory at the higher
concentrations (IC50 = 720 ± 170 nM, n=4), (Figure 3.5), whilst
butaprost showed no significant inhibition of the elevated cyclic
AMP. PGE2 and GR 63799X both inhibited the rise in cyclic AMP
with IC50 values of 8.6 ± 2.0 nM (n=4) and 57 ± 8 nM (n=4)
respectively (Figure 3.6).
0C2 - Adrenoceptor agonists induce Gi-mediated inhibition of
adenylate cyclase in human platelets (Jakobs ei al., 1978). A single
experiment demonstrated that pre-incubation with 1 pM
adrenaline completely inhibited the cicaprost-induced elevation of
cyclic AMP in fresh washed human platelets. The specific
0C2 - adrenoceptor agonists oxymetazoline and UK 14304 both at
1 pM, inhibited cicaprost action by 90 % and 93 % respectively.
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3.3.5 PGE analogues in other biological sustems - a comparison
Table 3.4.1 compares the potencies of the PGE analogues tested as
inhibitors of the cicaprost-induced elevation of cyclic AMP, with
those as potentiators of PAF-induced aggregation of human
platelet-rich plasma (PRP) (see enclosed paper) and as inhibitors





Figure3.1Accum lationofcyclicMPinfreshlypreparedand time-expiredsuspensionsofhumanwashpl tel tinducby increasingonc ntrationsficaprost.
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Figure 3.3 Inhibition of cicaprost-induced elevation of
cyclic AMP in freshly prepared suspensions of human washed
platelets as % cicaprost control, by :
(a) sulprostone (n=8-10), + 10 pM AH 6809 (n=4);
(b) 17-phenyl-o)-trinor PGE2 (n=5-7), + 10 pM AH 6809 (n=5).
* denotes significant inhibition of cicaprost control (p<0.01);
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Figure3.4Inhibitionofcicaprost-inducedelevationycliAMPintime-exp rewa h dpl e ts%ica r st control,by:(a)sulprostonen=2-5);b16,16-dimethyPGE2MB28767misoprosto( ). Significantinhibitioofc caprosontrolsde o edby*(p<0.01)a d1<0.05).
Figure 3.5 Inhibition of cicaprost-induced elevation of
cyclic AMP in freshly prepared suspensions of human washed
platelets as % cicaprost control, by :
(a) 11-deoxy PGE2-1-alcohol (n=4), and
(b) butaprost (n=4).
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Figure 3.6 Inhibition of cicaprost-induced elevation of cyclic AMP
in freshly prepared suspensions of human washed platelets as
% cicaprost control, by :
(a) PGE2 (n=4-5), and
(b) GR 63799X (n=4).




Cicaprost, a stable PGI2 analogue (Skuballa et al., 1986;
Sturzebecher et al., 1986) is known to increase cyclic AMP levels
and exert its inhibitory influence on human platelets through
interaction with the IP receptor (Dong et al., 1986;
Armstrong et al., 1989). Incubation of human washed platelet
suspensions with 8 nM cicaprost for 2 min at 37 °C produced a
submaximal cyclic AMP response due to the specific IP-agonism at
this concentration, and provided a sensitive system for the
detection of PGE inhibitory effects. The pro-aggregatory activity of
the PGE analogues which prompted a study into their inhibitory
effects on cyclic AMP levels, were contemporaneous experiments
carried out by a co-worker and may be found in the enclosed
paper. The model which is being proposed for the
pro-aggregatory effect of PGE2 is shown (Figure 3.1.3).
Sulprostone, an EPi- and EP3- selective analogue
(Coleman et al., 1987a,b; Lawrence et al, 1992), was shown to be
the most potent of the PGE analogues tested in inhibiting the
cicaprost-induced elevation of cyclic AMP in both fresh and
time-expired platelet suspensions. The IC50 values are comparable
at 3.0 ± 0.4 nM and 4.5 ± 0.7 nM respectively, suggesting
EP-receptor coupling to adenylate cyclase has not altered after
5 days of storage at room temperature. The results of
pro-aggregation similarly demonstrate sulprostone to be the most
potent, at 10 nM producing a response representing 150 %
(EC 150) of the control small reversible waves to PAF. Sulprostone
has been shown to inhibit the increased cyclic AMP levels induced
by the less specific IP-receptor agonist iloprost
(Dong et al., 1986), with an IC50 of approximately 100 nM
(Thierauch & Prior, 1990). This low potency of sulprostone in
comparison to the results already presented here, may be the
result of the choice of agonist to increase the cyclic AMP level, the
shorter pre-incubation time with the PGE analogue or the fact that
PRP has been used.
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17-Phenyl-co-trinor PGE2 is predominantly an EPi-receptor
agonist, having only moderate EP3 agonist potency
(Lawrence et al, 1992) and even less activity at the EP2-receptor
(Dong et al, 1986; Lawrence et ah, 1989; Lawrence et al., 1992).
It is therefore a useful tool in assessing the contribution of
EPi-activity to the sulprostone response. In comparing IC50
values, 17-phenyl-co-trinor PGE2 (IC50 = 100 ± 40 nM) is much less
potent than sulprostone in inhibiting platelet cyclic AMP
production. This suggests the EP3 component of sulprostone
activity to be the more important in the inhibition of cyclic AMP
and is supported by studies carried out using the EPi antagonist
(Coleman et al, 1985a), AH 6809, at 10pM. Experiments with
sulprostone and 17-phenyl-co-trinor PGE2 paired in the presence
and absence of AH 6809, demonstrate a rightward shift in both
dose-response curves with dose ratios for sulprostone and
17-phenyl-co-trinor PGE2 of 7.3 and 3.9 respectively. The Schild
equation describes the relationship between the dose ratio and the
concentration of antagonist by:
dose ratio (DR) - 1 = [antagonist] / Kd antagonist.
If DR = 2, [antagonist] = Kd antagonist, therefore the
pA2 = -log (Kd antagonist). Values of pA2 for sulprostone and
17-phenyl-co-trinor PGE2 are calculated as 5.8 and 5.5 respectively.
This is in contrast to the reports of AH 6809 as an antagonist on
EPi preparations where it is 10 - 100 times more potent, as
demonstrated by a pA2 of 6.8 - 7.5 (Coleman et al, 1987c;
Eglen & Whiting 1988; Lawrence et al, 1992). The relative
potencies of sulprostone and 17-phenyl-co-trinor PGE2 and the
weak antagonistic effect of AH 6809 on each, suggests the EP3
component of sulprostone activity to be the important factor in the
inhibition of the cicaprost-induced increase in cyclic AMP levels.
Indeed, 17-phenyl-co-trinor PGE2 itself has a weak EP3 effect as
assessed by inhibition of the twitch response of the guinea-pig vas
deferens to electrical field stimulation (Lawrence et al, 1992). In
this EP3-preparation the reported e.m.r. of 17-phenyl-co-trinor
PGE2 relative to sulprostone is 45, and correlates well with the
r,->
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e.m.r. of 33 for the inhibition of cicaprost-induced elevation of
cyclic AMP reported here. Therefore the EPi component of
17-phenyl-co-trinor PGE2 and sulprostone appears to contribute
minimally if at all to their inhibitory effect. These studies are in
agreement with the functional assay where 17-phenyl-a>-trinor
PGE2 was reported to be 29 times less potent than sulprostone
(EC 150 = 10 nM) in potentiating aggregation.
GR 63799X is a novel potent selective EP3-receptor agonist which
has been tested for its inhibitory effect in this system. On
EP3-receptor containing preparations such as the guinea-pig vas
deferens (Bunce et al., 1990; see enclosed paper) and rat isolated
gastric mucosa (Bunce et al., 1990), it is 4 - 50 times more potent
than PGE2. However, in the inhibition of cyclic AMP levels,
GR 63799X is 8 times less potent than PGE2. A comparison of the
potencies in potentiation of PAF aggregation is not possible due to
the inhibitory effect observed for PGE2 (see enclosed paper). It
was however found to be 26 times less potent than sulprostone in
potentiating PAF-induced aggregation.
Three other PGE analogues with EP3 activity have been tested on
this system using time-expired washed platelets. The good
correlation between this and the fresh preparation as regards the
activity of sulprostone, support a comparison of the PGE analogues
irrespective of whether fresh or time-expired platelets.
16,16-Dimethyl PGE2, having activity at all three classified EP
subtypes (Dong et al., 1986), showed a potency comparable to that
of sulprostone as represented by IC50 = 4.7 ±1.7 nM (e.m.r. = 1.6).
This compares well with the e.m.r. for 16,16-dimethyl PGE2
relative to sulprostone of 1.3 and 0.93 in the functional assay and
the guinea-pig vas deferens respectively. The assessment of the
EP-activity of MB 28767 is complicated by its agonist action at
TP-receptors (Banerjee et al., 1985). However, this TX activity
may be blocked by routine treatment of the platelet suspensions
with 500 nM GR 32191 (Lumley et al., 1989). Under these
circumstances MB 28767 demonstrated an IC50 of 15 ± 6.6 nM in
inhibiting elevation of cyclic AMP levels. The IC50 for inhibition in
the vas deferens is similarly 5-fold greater than that for
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sulprostone, whilst the functional assay suggests a slightly less
potent effect of MB 28767 (e.m.r. = 6.8). This may be a result of
plasma protein binding of MB 28767. The aggregation
experiments with washed platelets are difficult since the platelets
lose potentiating activity, prefering their native environment.
Consequently PRP is the preferred platelet preparation for the
aggregation studies. In contrast to the three EP3-selective
analogues so far reported, misoprostol in its methyl ester form has
a relatively high IC50 of 76 ± 27 nM. This agrees with the 13-fold
less potent activity of misoprostol relative to sulprostone in
potentiating aggregation, and may reflect the free acid form to be
the more biologically active. Studies on the guinea-pig vas
deferens do however indicate a greater potency of misoprostol
(3.6-fold less) compared to sulprostone, than either of these
studies on the platelet.
The EP2-selective agonist butaprost (Gardiner, 1986) did not
display any inhibition of cicaprost-elevated cyclic AMP levels
approaching pM concentrations, whilst 11-deoxy PGE2 1-alcohol
was inhibitory at the higher concentrations with an IC50 of
720 ±170 nM. This may reflect a degree of agonism at EP3
receptors by 11-deoxy PGE2 1-alcohol, which is completely absent
in the case of butaprost (Lawrence et al, 1992). The EP2-receptor
is classically coupled to adenylate cyclase through Gs, interaction
with which results in an increase in intracellular cyclic AMP levels
(Creese & Denborough, 1981). In the pro-aggregation studies,
difficulties arose when using PGE2, butaprost and
11-deoxy PGE2 1-alcohol through inhibition of the aggregation
response. The lack of effect of the EP2-selective agonist butaprost,
supports the opinion that PGE2 and 11-deoxy PGE2 1-alcohol
display IP agonism, in the absence of an EP2-receptor on the
platelet. We reasoned that the effect of any weak IP agonism
which complicates the functional assay, would be lessened by the
increased cyclic AMP levels induced by cicaprost in this system.
Inhibition of cyclic AMP levels therefore allows for better
assessment of the potency of PGE analogues such as
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11-deoxy PGE2 1-alcohol and PGE2, where inhibition is often seen
in measuring potentiation of aggregation.
In spite of the difficulties incurred in the aggregation studies,
PGE2 is shown to be approximately 3 times less active than
sulprostone in inhibiting the elevation of cyclic AMP levels. The
greater potency of sulprostone relative to PGE2 on EP3
preparations has been reported elsewhere. For example on the
guinea-pig vas deferens sulprostone is ~7 times more potent than
PGE2 in inhibiting the twitch response to electrical field
stimulation (Lawrence et al., 1992).
Table 3.4.1 summarises these results as equipotent molar ratios of
the PGE analogues relative to sulprostone. These have been
compared with results obtained from potentiation of PAF-induced
aggregation in human PRP and inhibition of the twitch response in
the guinea-pig vas deferens to electrical field stimulation
(EP3-receptor preparation). Comparison of the ranking of agonist
potencies on these three systems suggests the PGE2-induced
potentiation of aggregation in platelets to be mediated by an
EP3-like receptor negatively coupled to adenylate cyclase.
An early report suggests coupling of an EP-receptor(s) to inhibition
of adenylate cyclase, independently of extracellular Ca2+, in the
PGE2-mediated reduction of catecholamine release from the
adrenal medulla (Gutman et al., 1979). The dual effect on cyclic
AMP levels observed for platelets was also demonstrated on
cultured cortical collecting tubule cells, where PGE2 at low
concentrations (> 10"10 M) was shown to reduce the
cyclic AMP - elevating effect of arginine vasopressin, whilst at
higher concentrations (> 10-9 M) PGE2 independently stimulated
cyclic AMP formation. Subsequently a solubilised complex of PGE
receptor and PTX-sensitive guanine nucleotide regulatory protein,
Ni, was isolated (Smith et al., 1987). PGE2 has more recently been
reported to reduce elevated platelet cyclic AMP levels induced by
PGI2, though the absence of data in this abstract precludes
comparison of a more quantitative nature (Faili et al., 1992). It was
suggested that this effect of PGE2 is the result of competition with
PGI2 for the IP-receptor, which is unlikely in view of the evidence
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presented in the introduction (section 3.1.4). supporting distinct
receptors for PGI2 and PGE2.
The PGE-inhibitory receptors are apparently linked to adenylate
cyclase through Gi (Ashby, 1986,1988). Pertussis toxin is not
effective in intact platelets, as they lack the receptor to which a
subunit of PTX binds in order to allow the catalytic unit to enter.
However, phorbol ester results in PKC-mediated phosphorylation
of Gi (Jakobs et al., 1985; Katada et al., 1985;
Watanabe et al., 1985) impairing its function and allowing the
importance of Gi to be assessed. It would obviously be of great
interest to assess the effect of such alterations to Gi in this system.
In light of the interaction between the PLC and adenylate cyclase
pathways as outlined in the introduction, there is the possibility
that the reduction in cyclic AMP levels is indirectly the result of a
stimulation of the PLC pathway. Indeed
Maclntyre & Gordon (1975) suggest the pro-aggregatory effect of
PGE2 is calcium-dependent, based on the reduced potentiation of
collagen-induced aggregation in citrated PRP as compared to
heparinised PRP, both in rat and man. Thierauch & Prior (1990)
do however find no influence of PMA-activated PKC on the
iloprost-induced increase in cyclic AMP levels in PRP or
gel-filtered platelets, nor any change in the [Ca2+h in gel-filtered
platelets. It has recently been suggested that the inhibitory effect
of PGE2 on cardiac sarcolemmal adenylate cyclase is the result of
coupling via a pertussis toxin sensitive Gi protein
(Lerner et al., 1992).
Bearing in mind the controversy over the similarity between Gi
and Gp, the results of perturbations to Gi may not actually give any
greater insight into the pathway of inhibition of adenylate cyclase.
What would be of use, is to conduct the cyclic AMP studies on
platelet membranes. The adenylate cyclase is membrane bound,
therefore if this is directly coupled to the EP receptor via Gi, a
similar effect to what is observed in intact platelets should be
obtained. However, the water-soluble products of PIP2 hydrolysis,
formed as a consequence of the membrane-bound PLC activity,
should be ineffective in the absence of the intracellular calcium
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pools in the membrane preparation, thereby abolishing any
inhibitory influence on adenylate cyclase which may occur
indirectly via the PLC pathway. Perhaps a more in depth study of
the mechanisms possible for the inhibition of elevated cyclic AMP
levels may reconcile the finding discussed below, that inhibition of
basal cyclic AMP levels do not appear to potentiate platelet
aggregation in response to submaximal doses of the aggregating
agents.
Inhibition of adenylate cyclase in the stimulation of platelets has
been reported for other agonists (reviewed in
Hourani & Cusack, 1991). ADP for instance has a role in the
secondary aggregation induced by other aggregating agents which
are responsible for its release from the granules. It inhibits
adenylate cyclase though it is not clear if this is mediated by the
same receptor which causes shape change, aggregation and the
release of granule contents in vitro. Catecholamines such as
adrenaline and noradrenaline, through an interaction with the
a-receptor may also inhibit adenylate cyclase (Jakobs et al., 1978).
However, the concentration of adrenaline required for platelet
activation in vitro (>0.1 pM) is much higher than the levels found
circulating in the blood (0.1 nM) (Culliver & Ardlie, 1981). The
role of adrenaline may therefore be similar to that of PGE2, such
that while unable itself to cause platelet aggregation, can
potentiate the platelet response to other agonists. Through the
interaction with a single ct2-receptor, adrenaline may induce
aggregation and inhibit adenylate cyclase previously stimulated by
PGI2 or PGEi, both in intact platelets and platelet membranes.
The mechanism of action of adrenaline is GTP-dependent, and the
sensitivity to PTX and proteolytic treatment of the platelet
membranes with chymotrypsin, which degrades Gj, suggests the
involvement of Gi.
There is controversy as to whether a reduction in basal
intracellular cyclic AMP concentrations as a consequence of
adenylate cyclase inhibition can lead to platelet activation. Direct
inhibition of the catalytic subunit of adenylate cyclase by
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2',5'-dideoxyadenosine in intact platelets does not cause platelet
aggregation, or even potentiation of platelet aggregation induced
by other stimuli such as ADP, vasopressin, collagen or arachidonic
acid. A decrease in the PGEi-induced inhibition of ADP-induced
platelet aggregation and the associated increases in cyclic AMP
was however shown, demonstrating the ability to inhibit adenylate
cyclase. The inhibition of adenylate cyclase is therefore thought to
be responsible for potentiating aggregation in situations where the
cyclic AMP levels have been raised. Perhaps stimulation of the
catalytic subunit by Gs is required in order for Gi to interact, since
it is only loosely associated (Levitzki, 1987). An inhibitory effect of
PGE2 on isolated bovine myometrial membrane has also been
reported (Lerner et al., 1990). Similarly, the inhibition of
adenylate cyclase at 10 ~n M was not expressed in membranes
prepared in the absence of PGE2. Alternatively, there may be pools
of cyclic AMP within the platelet, the reduction of whose content
exerting an effect whilst not reflected as a significant reduction of
total basal cyclic AMP (Salzman, 1974).
Additional signalling mechanisms have been proposed for
receptors negatively coupled to adenylate cyclase, with
experimental evidence suggesting the reduction in cyclic AMP
levels may not be the only mechanism (Limbird, 1988). For
instance, in spite of desensitisation of aspirin-treated PRP to
subsequent a2-adrenergic receptor-induced aggregation,
adrenaline-induced inhibition of PGEi-stimulated cyclic AMP
levels still occurred and adrenaline was able to inhibit basal
adenylate cyclase activity in membranes prepared from
desensitised platelets (Motulsky et al, 1986). Radioligand binding
studies also showed no change to the binding properties of the
0C2-adrenergic receptor. Possibilities for the alternative signalling
mechanisms which may be involved in situations where receptors
are negatively coupled to adenylate cyclase, include Na+ / H+
exchange, and K+ and Ca2+ channels. In a study conducted on rat
hepatocytes, the synthesis of a cyclic AMP antagonist of low
molecular weight (~ 1500) formed from PGE2 has been proposed
(Wasner, 1981). This intracellular, hormone messenger-like
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regulator is formed in hepatocytes stimulated by insulin or
adrenaline, and is reported to inhibit cyclic AMP - dependent
protein kinases and activate phosphatases. It has since been
renamed prostaglandylinositol cyclic phosphate (cyclic PIP)
(Wasner et al, 1991). There are therefore many additional
possibilities to a direct inhibition of adenylate cyclase, for the
mechanisms of stimulation and potentiation in human platelets.
Whilst there have been reports of inconsistencies between the
inhibition of adenylate cyclase and the aggregation response
tending to suggest additional mechanisms, the good correlation of
the e.m.r. of a series of PGE analogues in inhibiting the increased
cyclic AMP levels and potentiating the small reversible waves to
PAF suggests an important involvement of this mechanism in the
potentiation of aggregation in the human platelet to PGE2. In
addition, a further comparison of the activity of the analogues used
with their effect in inhibiting the twitch response of the
guinea-pig vas deferens to electrical field stimulation, suggests the
receptor may be of the EP3-subtype.
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Chapter 4
Characterisation of the PGE receptor on human
macrophage-like cells through binding studies conducted
on a purified plasma membrane preparation
4.1 INTRODUCTION
4.1.1 Prostaglandins are modulators of inflammation
Prostaglandins are widely recognised as mediators of inflammation
and inhibitors of their synthesis are therapeutically useful
anti-inflammatory agents (Ferreira et al, 1971;
Smith & Willis 1971; Vane 1971). However, depending on the
experimental situation studied, PGE2 displays either pro- or
anti- inflammatory effects (Bonta & Parnham, 1978, 1980;
reviewed in Goodwin, 1991). Indeed stable prostaglandins such as
misoprostol and PGEi acted synergistically with NSAIDs in the
inhibition of neutrophil activation (Weissmann, 1992). PGE2 may
therefore be more accurately described as a modulator of
inflammation.
Of the cells involved in inflammation, the vascular endothelial
cells, mast cells and tissue macrophages are present in the tissues,
the platelets and leucocytes gaining access from the blood. The
white blood cells or leucocytes can be subdivided into
polymorphonuclear cells, or granulocytes, and mononuclear cells.
The former consist of neutrophils, eosinophils and basophils, the
mononuclear cells comprising monocytes and lymphocytes.
Monocytes circulate in the blood for up to 1-4 days and
differentiate for example into macrophages (Kupffer cells) in liver,
into alveolar macrophages in lung and into peritoneal macrophages
in peritoneum, where they may remain for periods of up to several
months.
The inflammatory reaction consists of both immunologically
specific reactions and innate reactions having no immunological
basis. The latter involves an increase in vasodilatation and vascular
permeability, release of mediators from vascular endothelial cells,
mast cells and platelets, and phagocytosis of dead cells, tissue
debris and foreign material by leucocytes. The polymorphonuclear
cells are the first of the blood leucocytes to enter the area of the
inflammatory reaction, where they engulf, kill and digest the
invading microorganism. Macrophages secrete a range of
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substances including enzymes, plasma proteins and substances
regulating the function or growth of other cells
(Takemura & Werb, 1984). A variety of enzymes participate in a
wide range of functions, such as accelerating inflammation,
clearing up debris in inflammation sites, killing tumours and
metabolising lipoproteins and may be regulated within the
environment surrounding the macrophage by the release of
enzyme inhibitors. Plasma proteins also participate in
inflammation and are involved in tissue repair, immunoregulation
and molecular transport. Low molecular weight substances such as
reactive oxygen metabolites and bioactive derivatives of arachidonic
acids are not strictly secretory products as they are released
extracellularly after triggering by phagocytosis or chemical
stimulation. The oxygen metabolites participate primarily in the
extracellular killing of microbes and tumours.
In some tissues however, macrophages have a role in presenting
antigenic (foreign) material to the lymphocyte, thereby initiating
the specific immunological response. Those lymphocytes which
recognise the antigen, multiply and differentiate into either of the
two subsets of lymphocytes, B-cells, responsible for antibody
production, or T-cells, involved in cell-mediated reactions. This
facilitates a response more selective for the invading organisms.
The pro-inflammatory action of the prostaglandins is discussed in
Chapter 2 of this thesis. Their anti-inflammatory action is less well
recognised. In fact PGs of the E series can suppress many
parameters of the immune response, including proliferative
responses, antibody and lymphokine production and cytolysis
(reviewed in Goodwin & Webb, 1980). Such suppression of the
immune system is of great benefit in skin-grafting, where studies
suggest an increase in PGE2 may play a regulatory role in
preventing rejection through a reduced response
(Dy & Astoin, 1980). A suppressed immune system is also
important in preventing the triggering of an inappropriate immune
response in the lung, for instance, where there is daily exposure to
a considerable variety of antigens (Monick et al. 1987).
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When the host defence system functions efficiently, antigens are
disposed of without compromising host function and well-being.
However, in chronic inflammatory diseases such as rheumatoid
arthritis, granulocytes and macrophages are involved in mediating
the acute symptoms of swelling, erythema and pain, and the
chronic changes which include local connective tissue
proliferation, fibrosis and the irreversible destruction of articular
cartilage. In addition, suppressor cells have been suggested as
aetiologic or contributory in the pathogenesis of several diseases
such as cancer (Goodwin et al, 1977a) and Hodgkins' disease
(Elkashab & Lala, 1991). Research into the mechanisms of
signalling in the immune system is therefore of great interest and
potential benefit to many.
4.1.2 IL-1 facilitates the immune response
Interleukins (ILs) are involved in the signalling between cells of
the immune system (see Figure 4.1.1(a)). The macrophage
product IL-1, or lymphocyte activating factor (LAF), causes
proliferation of the lymphocytes. The mechanism of this
lymphoproliferative effect appears to be mediated by stimulation of
the release of IL-2 by T-cells in both human (Smith et al., 1980;
Maizel et al., 1981) and murine models (Smith et al., 1980). More
specifically, IL-1, is produced by macrophages and other
antigen-producing cells, acting on T-cells to induce IL-2 receptors.
IL-2, or T Cell Growth Factor produced by these activated T-cells
is necessary for their long term proliferation (Mizel, 1987),
thereby amplifying their helper and cytolytic functions. By
controlling IL-2 production then, an appropriate immune response
should be triggered.
Studies have shown an absolute requirement for ~ 1 % monocytes
for lymphocytes to produce IL-2 (Neefe et al., 1981), suggesting
depletion of monocytes from a mononuclear cell population would
inhibit IL-2 production by the lymphocytes. However, in man a
simple depletion by adherence of monocytes actually enhances
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IL-2 production. In fact excess monocytes are capable of
inhibiting IL-2 production, an effect mediated by soluble products
and blocked by treatment with indomethacin
(Chouaib & Fradelizi, 1982). Monocytes must therefore have a
regulatory role in lymphocyte IL-2 production, exerting both
stimulatory and inhibitory influences. The stimulatory component
is only demonstrated when following almost complete depletion,
achieved by a three step process of plastic adherence, filtration
through a nylon wool column and cell lysis, IL-2 production is
inhibited (Chouaib & Fradelizi, 1982).
4.1.3 FGEg inhibits mononuclear cell IL-1 production.
The IL-1 produced by the macrophage, besides inducing IL-2
production by the lymphocyte, also stimulates the release of PGE2
from other macrophages (Figure 4.1.1 (b)). Stimulation of cultured
mouse peritoneal macrophages by IL-1 resulted in a release of
arachidonic acid from both phosphatidylcholine and
phosphatidylinositol suggesting the involvement of both PLA2 and
PLC respectively (Watson & Wijelath, 1990). The PGE2 formed
from this released arachidonic acid acts as a negative feedback,
inhibiting further macrophage production of IL-1, and
consequently IL-1 induced IL-2 production
(Bonta & Parnham, 1982). IL-2 may reciprocally increase IL-1
production by both stimulated and unstimulated monocytes, and
also PGE2 production by the former (Tilden & Dunlap, 1989).
Production of E-type PGs by guinea-pig peritoneal macrophages
was shown to inhibit activation of lymphocytes, isolated from the
lymph node, and the secretion of lymphokines in response to
antigen. PGEi and PGE2 did not affect the action of preformed
lymphokine, indicating the formation rather than the action of the
lymphokine on target cells was being inhibited. It was suggested
that PGs of the E-series were produced in response to lymphokine
stimulation, thereby providing a negative feedback mechanism for
the regulation of the cellular immune response
(Gordon et al., 1976).
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Using a preparation of human peripheral blood mononuclear cells,
Goodwin et al. (1977b) showed PGEi and PGE2 at 3 x 10"8 M to
suppress mitogen stimulation as measured by [3H-thymidine]
incorporation. PGFia and PGF2a had little effect in comparison,
whilst PGA inhibited at high concentrations (3 x 10~6 M). The PG
synthetase inhibitors indomethacin and RO-20-5720 enhanced
mitogen stimulation at non-toxic doses, suggesting an endogenous
production of PGs was suppressing the [3H-thymidine]
incorporation. This enhancement by indomethacin was greatly
reduced when the mononuclear cells were depleted of adherent
cells by passing over glass wool columns. These adherent cells
must therefore be the PG-producing cells. By removing their
inhibitory influence an enhanced mitogen response was expected,
but consistent changes were not observed, suggesting a balance
between helper and suppressor effects of the adherent monocytes.
Overnight pre-incubation of peripheral blood mononuclear cells
has been shown to result in a loss of sensitivity to PGE2
(Goodwin et al., 1978), which may be the result of a loss of
receptors. When compared to fresh cells, the pre-incubated cells
show an increased response to mitogen, a loss of the enhancing
effect of indomethacin inversely related to the dose of mitogen,
and no inhibition of the mitogen response to PGE2. This supports
the role for PGs in suppressing mitogen-stimulated lymphocytes in
vitro.
More recently, PGEi and PGE2 were shown to inhibit production
of IL-2 by normal human peripheral blood mononuclear cells
(PBMC) at a pathophysiological concentration (10 ng/ml,
~ 3 x 10~8 M), whereas PGFia, PGF2a and PGA2 did not, PGAi
inhibiting at 1 mg/ml (~ 3 x 10~6 M) (Rappaport & Dodge, 1982).
Furthermore, the PG synthetase inhibitors indomethacin and
fentiazac raised IL-2 levels above basal levels, supporting the
inhibitory role for PGE. The mononuclear cell population can be
divided into adherent and non-adherent cells. Removal of these
adherent cells resulted in an increase in IL-2 production by the
non-adherent lymphocytes. In addition there was a loss of
sensitivity to the PG synthetase inhibitors, in the absence of any
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change in sensitivity to PGE2. Together, these results suggest
PGE2 produced by the adherent macrophage inhibits the IL-2
production by the lymphocytes, thereby exerting an
anti-inflammatory effect.
Experiments carried out on lipopolysacharride (LPS) -stimulated
murine resident peritoneal macrophages, indicate that LPS
stimulates IL-1 production and arachidonic acid metabolism via the
cyclooxygenase pathway, the latter giving rise to PGE2 and PGI2.
The macrophage cultures produced increased levels of PGE2 in the
presence of exogenous IL-1. Addition of exogenous PGE2 or PGI2
resulted in a dose-dependent suppression of LPS-induced
macrophage IL-1 production, whilst inhibitors of the
cyclooxygenase pathway, indomethacin, piroxicam and ibuprofen,
caused a dose-dependent increase, correlating with their
potencies as cyclooxygenase inhibitors. Bahl et al. (1989)
suggested that NSAIDs elevated IL-1 secretion by a mechanism
other than inhibition of PGE2, though the values for PGE2
represent only duplicate measurements. Arachidonic acid
metabolites formed by the cyclooxygenase pathway therefore
suppress the production of growth factors by LPS-stimulated
macrophages, IL-1 regulating its own production through the
self-induced inhibitor, PGE2 (Kunkel et al., 1986).
Mouse peritoneal macrophages are rich in arachidonic acid, having
several times a higher content than other cells (Scott et al, 1980).
Indeed, 25 % of the total fatty acid content of this cell is
composed of arachidonic acid. Similar levels are thought to be
present in both rabbit and human mononuclear phagocytes.
Following phagocytosis, 51 % of this is recovered as PGE2. Human
blood monocytes primarily produce TxB2 and PGE2
(Dudley & Burns, 1982). These arachidonic acid metabolites
participate in inflammation, hypersensitivity and
immunoregulation. The release of immunomodulatory prostanoids
by inflammatory macrophages adherent to a denatured collagen or
fibronectin surface, is significantly more than that when adherent
to tissue culture plastic or extracellular matrix
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(Gudewicz & Frewin, 1991). This may serve to suppress cytotoxic
mechanisms during wound injury.
4.1.4 Are suppressor cells involved in mediating the PGEg effect?
Identification of high-affinity binding sites for PGE on human
lymphocytes has suggested PGE2 may also exert a direct inhibitory
effect on the lymphocyte itself (Goodwin et al., 1979). Indeed, the
lymphocytes themselves produce IL-1 when stimulated by LPS, an
effect inhibited by PGE2 (Herman & Rabson, 1984). Tilden &
Balch (1982) addressed the question of whether PGE2 mediated
its inhibition of human peripheral blood mononuclear cell (PBMC)
proliferation by a direct inhibition of IL-2 responses, or indirectly
by activation of a suppressor cell. Depletion of phenotypically
defined suppressor cell populations from PBMC did not diminish
the PGE2-mediated inhibition of the phytohaemaglutinin response.
PBMC preincubated with PGE2 lacked suppressor cell function in
the absence of additional PGE2. They concluded there was no
evidence for PGE2-induced suppressor function in man.
However, inhibition of human lymphocyte IL-2 production by the
addition of PGE2 or monocytes was not observed if the
mononuclear cell preparation was pre-irradiated
(Chouaib & Fradelizi, 1982). The IL-2 producing cells were not
inhibited by the irradiation, and irradiation of monocytes did not
affect their inhibitory action. In addition, irradiation enhanced
IL-2 production by the mononuclear cell preparation regardless of
whether or not it had been depleted of adherent monocytes. This
suggests that activation of a radiosensitive lymphocyte by
monokines is required for the inhibition of IL-2 production and is
supported by the identification of a subset of T-cells that binds
PGE2, some of which may be activated into suppressor cells
(Fischer et al, 1985). In another study (Chouaib et al, 1984) it
was reported that dialysed supernatants from PGE2-induced
suppressor cells could not reproduce the suppression
phenomenon, suggesting the suppressor mechanism requires
direct cell to cell contact or a dialysable suppressor factor is
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involved. PGE2 has in fact been reported to promote the secretion
of soluble suppressor factors such as prostaglandin-induced T-cell
derived suppressor from murine glass adherent splenic T-cells
(Rogers et al, 1980,1984).
4.1.5 A PGE-independent effect of precursor fattv acids
The PGE precursors, dihomo-y-linolenic acid (DGLA) and
arachidonic acid (AA), have also been shown to inhibit IL-2
production by human PBMC. This inhibition was only partially
blocked by the cyclo-oxygenase inhibitor indomethacin in two of
three donors. Also, DGLA and AA inhibited IL-2 production by a
cell line insensitive to the inhibitory effect of PGE2 observed with
normal PBMC. It is therefore suggested that the fatty acid
precursors to PGE may exert an anti-inflammatory effect by a
PGE-independent mechanism (Santoli & Zurier, 1989). A dietary
reduction of essential fatty acids (EFA) resulted in a loss of
endogenous PG production and enhanced cellular events during
chronic inflammation (Bonta & Parnham, 1980). The
consequences of this EFA-deficiency could not be fully reversed by
exogenous PGs, supporting this notion that PG depletion is not the
only cause of the effects observed.
In addition, dietary fatty acids have been shown to alter the
number of PGE2 binding sites, possibly through a change in the
bioavailability of PGE2 from arachidonic acid (Opmeer et al, 1984).
The study involved peritoneal macrophages isolated from rats
pretreated for 4-weeks with a diet containing 12.5 % corn oil, in
which an increase in the total number of high and low affinity PGE2
binding sites in the absence of any alteration in the Kd values was
shown. This was followed by a parallel leftward shift in the
dose-response curve of PGE2-stimulated adenylate cyclase. It was
suggested that the linoleic acid present in the corn oil may have
reduced the amount of arachidonic acid released, and
consequently the level of the arachidonic acid metabolite PGE2.
The observed increase in receptor number may represent a
protective mechanism to overcome insufficient stimulation.
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Alteration of dietary fatty acids may therefore be of important use
in the treatment of inflammatory disorders.
4.1.6 HL-60 cells differentiate into human macrophagp-likp rails
Since IL-1 and IL-2 are immunomodulatory and inflammatory,
PGE2 may exert an anti-inflammatory effect through inhibition of
their release, as described. It is therefore of interest to
characterise the subtype of PGE receptor present on the
macrophage, in order to understand the molecular basis of the
inhibitory activity of PGE2 in regulating macrophage function. I
have used radioligand binding techniques on a purified plasma
membrane preparation from differentiated HL-60 cells, which
differentiate into human macrophage-like cells on exposure to
phorbol ester.
Cloning of bone marrow stem cells has indicated a common stem
cell gives rise to both monocytes and granulocytes. The
promyelocytic cell line, HL-60, is derived from a 36 year-old
Caucasian woman with acute promyelocytic leukaemia
(Collins et al., 1977) and provides a useful tool in studying the
cellular and molecular events involved in proliferation and
differentiation of normal and leukaemic cells of the granulocyte or
macrophage lineage (Collins, 1987). The cell line exists in an
arrested yet pliant state of maturation.
Spontaneous differentiation beyond the promyelocytic stage may
occur in up to 10 % of the cultured cells. However, differentiation
into macrophages or granulocytes can occur under the influence of
a series of compounds. Dimethylsulphoxide, hypoxanthine,
dimethyl formamide, actinomycin D, and retinoic acid all induce
differentiation to granulocytes. Differentiation to macrophages
occurs under the influence of phorbol ester,
1,25-dihydroxy Vitamin D3, sodium butyrate, dibutyryl cyclic AMP,
and agents which elevate cyclic AMP, such as prostaglandin E2.
In order to determine if the HL-60 population represents
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homogeneous bipotent stem cells or a mixture of cells committed
to either myeloid or monocytoid differentiation, a cloned
population of HL-60 cells has been isolated and studied. The
experiments involved the use of dimethylformamide (DMF) and
TPA which induce myeloid and monocytoid differentiation
respectively. Besides inducing differentiation of this cloned
population of cells along two distinct lines, TPA is reported to
reduce the percentage of cells exhibiting the myeloid phenotype in
response to DMF, while increasing that with the macrophage
phenotype (Fontana et al., 1981).
HL-60 cells grown in suspension culture terminally differentiate
into adherent human macrophage-like cells in the presence of
phorbol ester (Rovera et al., 1979a,b), of which
12-o-tetradecanoylphorbol 13-acetate (TPA) is the most active.
The evidence is based on the appearance of markers in
TPA-treated HL-60 cells that are specific to the monocyte /
macrophage lineage or the disappearance of myeloid markers. The
undifferentiated HL-60 cells contain a large nucleus with diffuse
chromatin and a prominent nucleolus. The Golgi apparatus is well
defined and associated with a variable number of vacuoles, many of
which have a dense core. Whilst lacking specific markers for
lymphoid cells, the HL-60 cells express surface receptors for the
Fc fragment of IgG and complement. They are, however, unable to
specifically ingest IgG-coated erythrocytes. HL-60 cells respond to
chemotactic stimuli (Gallagher et al., 1979).
Following differentiation, the TPA-treated cells become adherent
and develop pseudopodia. The nucleus is round or reniform with a
prominent nucleolus and the chromatin is condensed. Cell
proliferation is arrested but the cells are still able to synthesise
protein. In contrast to the undifferentiated form, the Golgi
apparatus is associated with small granules of uniform density, and
the extent of the rough endoplasmic reticulum and number of
mitochondria are increased. Fc-IgG receptors are present as
determined by fluorescent antibody studies. The differentiated
HL-60 cells exhibit phagocytic and microbicidal activity, but not
chemotaxis (Koeffler et al., 1981). Cellular levels of NADase, acid
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phosphatase, and non-specific esterase, enzymes reported to be
characteristic markers of monocytes and macrophages, are
markedly increased after treatment with TPA. Myeloperoxidase
activity is reduced, as would be expected since it is a myeloid
marker. More lysozyme is also found in the medium of
TPA-treated cells than in the medium of untreated cells. All of
these features closely resemble those of the human monocyte or
macrophage.
There are however limitations to the use of cell culture as a
substitute for the normal human macrophage itself. Mononuclear
phagocytes for instance should display chemotactic activity, yet the
differentiated HL-60 cells do not. However, a low level of
chemotactic activity has been demonstrated for macrophages and
monocytes in culture, and the lack of activity in the TPA-treated
cells may therefore be a consequence of the environment in which
they are maintained. The TPA-treated HL-60 cells also lack the
large digestive vacuoles or secondary lysosomes present in mature
stimulated macrophages. Newburger et al. (1981) report that
whilst TPA-induced HL-60 cells develop the morphological
appearance and enzymatic characteristics of macrophages, they
lack the functional capacities of the mature phagocytic cells.
4.1.7 Mechanism ofTPA-induced differentiation ofHL-60 cells
TPA is a tumour promoter (Diamond et al., 1980) and protein
kinase C (PKC) activator (Castagna et al., 1982), with which it
copurifies (Vandenbark et al., 1984). PKC is a calcium- and
phospholipid-dependent enzyme that is widely distributed in
numerous tissues, and which plays a crucial role in transducing
various extracellular signals across the cell membrane. In platelets
(Drummond, 1987), endogenously produced diacylglycerol (DAG)
activates PKC, increasing its affinity for calcium and phospholipid.
TPA can substitute for DAG, activating PKC without the need for PI
turnover, from which DAG is derived.
The mechanism by which TPA induces growth arrest and
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differentiation is not clear. This activation of PKC in HL-60 cells
could result in the phosphorylation of specific substrate proteins
leading to the macrophage-like phenotypic changes induced by
TPA. Studies using chick embryo fibroblasts suggest that the
particulate preparation is able to specifically bind phorbol esters at
concentrations known to induce macrophage differentiation
(Driedger & Blumberg, 1980), indicating the presence of a
receptor. The interaction of the ligand with its receptor is rapid,
fully reversible and of high affinity, with a Kd in the nanomolar
range. Phorbol esters are also reported to exert their effects while
retained at the cell surface of HL-60 cells (Cooper et al., 1982).
The high lipophilicity of TPA (Jacobson et al., 1975) causes it to
partition strongly into membranes. The amphipathic phorbol
esters may then bind nonspecifically, changing the structure and
function of the plasma membrane and thereby inducing the
observed differentiation. The low concentration at which it is
effective, however, suggests it may laterally diffuse through
biomembranes to distant receptors after binding to the bilayer
portions of the membrane.
The ability of these leukaemic cells to undergo maturation in the
presence of certain inducers, indicates that the genetic
information coding for terminal macrophage differentiation is
present and capable of expression. There is a change in the
relative abundance of certain translational products in HL-60 cells
on exposure to TPA, indicating a change in the levels of different
mRNA or the ability of mRNA to be translated, suggesting
TPA-induced signals received at the cell membrane are conveyed
to the nucleus. The changes recorded are not the same as those
following myeloid differentiation (Colbert et al, 1983). Nuclear
proto-oncogenes such as c-fos, c-jun and c-myc are examples of
immediate early genes expressed during the early phase of
responses leading to growth arrest or stimulation
(Shimizu et al., 1991). TPA can initiate rapid induction of c-fos
mRNA and protein during myelomonocytic differentiation and
macrophage differentiation (Muller et al., 1983) and is also
reported to induce c-jun expression in human myeloid leukaemia
1 33
cells (Sherman et al., 1990). Macrophage-like differentiation of
HL-60 cells is associated with a marked decrease in c-myc RNA
levels. Recent evidence indicates the expression of a novel
immediate early gene during the TPA-induced macrophagic
differentiation of HL-60 cells (Shimizu et al, 1991). The protein
derived from this novel gene may be a nuclear DNA-binding
protein which regulates transcription. The pathway leading to
induction of this gene is inhibited by the PKC inhibitor H7 and
stimulated by the PKC activator 1,2-dioctanoylglycerol (diC8). The
protein phosphatase inhibitor okadaic acid also enhances
expression. Together these results suggest the pathway of
induction of the early gene by TPA to be via PKC, and to be
controlled by protein phosphorylation.
However, activation of protein kinase C is not thought to be the
only mechanism by which phorbol esters induce differentiation of
human promyelocytic cells to macrophage-like cells.
Kreutter et al. (1985) used TPA and 1-oleoyl-2-acetylglycerol
(OAG) as activators of PKC. At similar biochemical activities, OAG
failed to induce HL-60 differentiation. The profile of protein
phosphorylation is more extensive in the presence of TPA as
compared to OAG. This may reflect the activation of a kinase other
than PKC, since both TPA and OAG activate PKC to the same
extent. However, the same group later reported
(Morin et al., 1987) that if HL-60 cells are exposed concurrently to
a cell-permeable diacylglycerol, diC8, and the calcium ionophore
A23187, at concentrations without maturational activity when used
separately, there are measurable increases in both protein
phosphorylation and the fraction of cells expressing the
differentiated phenotype. This suggests that there are specific
biochemical effects associated with TPA, in addition to the
activation of PKC, which may be important determinants for the
induction of leukaemia cell differentiation. These may include an
increased cellular permeability to calcium or mobilisation of
intracellular pools, in the light of the results obtained in the
presence of A23187.
The activation of PKC by TPA may be secondary to a stimulated
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increase in phospholipid turnover. This would result in an
increase in metabolism of DAG, an increase in the release of
arachidonic acid which itself activates PKC, and generation of
specific eicosanoids which might promote or induce leukaemia
cell differentiation. Humes et al. (1978) report on the stimulation
of release of arachidonic acid and its cyclooxygenase products from
macrophages by TPA. It has been suggested that arachidonic acid
may also be involved in the mechanism of action of TPA
(Das, 1991). Phorbol ester is concentrated largely in the lipid
phase of the cell membranes, and an early response to it is the
release from the membrane phospholipids of arachidonic acid
(Levine, 1981). Indeed an increase in cyclo-oxygenase activity, as a
result of newly synthesised enzyme, has been reported for both
monocytic and granulocytic differentiation of HL-60 cells
(Honda et al., 1990). Sanduja et al. (1988) suggest selective
metabolites rather than the entire cyclooxygenase pathway may be
increased in an inducer-specific manner, though
Dudley & Burns (1982) propose an inability of HL-60 derived
macrophages to directly utilise exogenous arachidonic acid or
mobilise endogenous subsrate for production of PGs.
Whilst the understanding of the mechanism of differentiation of
HL-60 cells remains incomplete, this cell-line allows for a constant
supply of macrophage-like cells in a controlled manner and in

















Figure 4.1.1 Interaction between mononuclear cells
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4.2 MATERIALS and METHODS
SOLUTIONS Source
Tris - HCl 500 mM pH 7 .4
121.14 g tris(hydroxymethyl)methylamine B.D.H. Chemicals
~ 40 ml concentrated HCl
- made up to 2 1 with distilled water.
Tris - HCl 50 mM pH 7.4
100 ml tris - HCl (500 mM pH 7.4)
adjust pH to 7.4 with concentrated HCl
- made up to 1 litre with distilled water.
Homoaenisation buffer
50 ml tris - HCl (50 mM pH 7.4)
42.8 g sucrose
1 mM indomethacin Sigma (I 7378)
- made up to 500 ml with distilled water.
Sucrose
0.9 M 30 g sucrose B.D.H. Chemicals
1.2 M 40 g sucrose
-in 100 ml tris - HCl 50 mM pH 7.4.
250 mM Magnesium chloride
5.1 g MgCl2-6H20
- in 100 ml tris - HCl 50 mM pH 7.4.
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SOLUTIONS continued Source
0.5 ma / ml Bovine semm albumin
5 mg BSA fraction V
- in 10 ml tris - HC1 50 mM pH 7.4
B.D.H. Chemicals
or
1 ml 2 mg / ml BSA standard
to 3 ml tris - HC1 50 mM pH 7.4.
Pierce (No. 23209)
0.1 M Sodium hydroxide
4 g NaOH B.D.H. Chemicals
in 1 1 distilled water.
2 % Sodium carbonate in 0.1 M NaOH
-in 100 ml 0.1 M NaOH.
2 % Potassium sodium tartrate
0.2 g C4H406KNa.4H20
- in 10 ml tris - HC1 50 mM pH 7.4.
1 % Copper sulphate
0.1 g CuS04.5H20
- in 10 ml tris - HC1 50 mM pH 7.4.
50 % v / u Folin & Ciocalteu's phenol reagent
10 ml Folin-Ciocalteu reagent




AH 6809 Dr. R.A. Coleman, Glaxo, U.K.
GR 32191
butaprost Dr. P. Gardiner, Bayer, U.K.
cicaprost Prof. H. Vorbruggen, Schering AG, Berlin
sulprostone
nat 11-deoxy PGEi Cayman Chemicals, U.S.A.
PGE2
[5,6,8,11,12,14,15 - 3H (N)] PGE2 NEN (NET-428)
12-o-tetradecanoylphorbol 13-acetate Sigma (P 8139)
CELL CULTURE REAGENTS Source
RPMI 1640 Gibco (041-01 / 31 870)
with L-glutamine / Glutamax
Penicillin - Streptomycin " (043-05140 )
10,000 IU/ml; 10,000 gg/ml
Heat - inactivated foetal calf serum " (031-6290 )
Hanks' balanced salt solution (HBSS) " (041-04170 )
(without calcium and magnesium)
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4.2.1 Passing ofHL-60 cells
HL-60 cells were obtained from the European Collection of Animal
Cell Cultures. All procedures required sterile technique.
The growth medium contained :
RPMI 1640 with 2 mM L-glutamine or glutamax
10 % foetal calf serum (FCS)
100 IU/ml penicillin
100 (ig/ml streptomycin
and may be stored at 4 °C for a maximium of one week.
The cells in suspension were pelleted by centrifugation at 300 g
and room temperature for 10 min. Once suspended in 50 ml fresh
growth medium in 175 cm2 plastic flasks, they were incubated at
37 °C in a humidified 5 % CO2 atmosphere. When seeded at a
concentration of 2 x 105 cells / ml, the doubling time was
approximately 1-2 days. Cell numbers were counted using a
haemocytometer, trypan blue exclusion determining viability. The
RPMI medium contained the indicator phenol red, and the cells
were passed before this was allowed to turn yellow.
4.2.2 Plasma membrane preparation from differentiated HL-60
cells
The method for the preparation of the plasma membrane - rich
fraction in differentiated HL-60 cells, has been developed from
procedures for the preparation of a similar fraction from Swiss
3T3 cells (Allergan Pharmaceuticals) and the murine
macrophage-like cell line P388Di (Fernandez-Botran, 1984 a,b).
1. 20-30 hr before preparation of the membranes, 16 nM TPA
(in acetone) was added to each of 15 cell culture flasks, containing
on average 27 ± 2 x 106 cells. An equivalent concentration of
acetone alone did not induce adherence and the HL-60 cells
remained viable as measured by trypan blue exclusion.
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2. When differentiated the cells became adherent, the culture
medium was removed by aspiration and the cells washed once with
10 ml / flask HBSS to ensure the removal of non-viable
undifferentiated HL-60 cells. The differentiated cells were
harvested by scraping into HBSS.
3. Following centrifugation at 300 g and 4 °C for 10 min, the
resultant pellet was washed once again in HBSS, and then in
homogenisation buffer. Whilst the 5 mM tris-HCl promotes
bursting of the cell membrane, 250 mM sucrose mimics the
cytoplasmic tonicity to which intracellular organelles are exposed
in order to avoid swelling and even possible disruption.
Indomethacin minimises unwanted occupancy of binding sites by
endogenously synthesised PGs.
4. The pellet was resuspended in 40 ml homogenisation buffer
and homogenised for 3 sec at setting 7 on the polytron
homogeniser (model X 1020).
5. After centrifugation at 300 g and 4 °C for 5 min, the
supernatant was removed to a clean tube.
6. The remaining pellet was once again suspended in 25 ml
homogenisation buffer, rehomogenised and centrifuged, and the
supernatant pooled with that obtained previously. The crude
homogenate preparation may be stored at -70 °C at this stage and
combined with further preparations before completing the
remainder of the plasma membrane preparation. In such a case,
the binding study was carried out without refreezing the
membrane fraction.
7. The combined supernatants were centrifuged at 177,000 g
and 4 °C for 40 min in a Kontron ultracentrifuge
(Centrikon T-2070) using a iyp TFT 50.38 (12287) fixed-angle
rotor.
8. The pellet was resuspended in 48 ml homogenisation buffer
using setting 5 on the polytron for 1 or 2 min until the pellet was
well dispersed.
141
9. This crude homogenate preparation was layered onto a
sucrose density gradient in 6 tubes, 8 ml layered over 3 ml each of
0.9.M over 1.2 M sucrose. These were then centrifuged at
112,000 g and 4 °C for 2 h in an MSE Superspeed 65
ultracentrifuge, using the swing-out rotor 43127-506.
10. The band at the interface of the 0.9 M / 1.2 M sucrose was
removed, diluted approximately 1:2 with 50 mM tris-HCl pH 7.4
and centrifuged at 304,000 g and 4 °C for 40 min.
11. The pellet was washed once with 50 mM Tris-HCl pH 7.4,
and if not frozen at the crude homogenate stage, stored at -70 °C
for future binding studies. The protein recovered in three of these
membrane preparations was sufficient for two displacement
studies, each covering 13 concentrations of competing ligand
tested in triplicate.
4.2.3 Binding studies using the purified plasma membrane
fraction.
1. The standard binding medium consisted of 2.5 mM MgCl2 in
50 mM tris-HCl pH 7.4. The plasma membrane pellet was
resuspended in 50 mM tris-HCl pH 7.4 by sonication or glass
homogenisation. Binding reactions were initiated by the addition
of 100 ml of the plasma membrane fraction (approximately 30 pg
of protein), to a reaction mixture containing [3H]-PGE2 with or
without competing ligand, to a final volume of 200 pi. Non-specific
binding was determined in each experiment by the presence of
10 pM PGE2.
2. The samples were mixed and following incubation for 1 h at
room temperature, the reaction was stopped by the addition of
ice-cold buffer. The plasma membranes were immediately
collected on Whatman glass microfibre filters under vacuum using
a Brandel cell harvester (model M-24R), and washed twice with
the ice-cold buffer.
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3. The filters were air dried, placed in scintillation vials
containing 5 ml Packard scintillation cocktail and counted on a
Packard liquid scintillation analyser 1900CA.
4. Protein content was measured initially according to the
method of Lowry (1951) (see below), and then Bradford (1976)
using Pierce Coomassie Protein Assay Reagent (No. 23200). (At
Allergan I used the Bio-Rad protein assay concentrate
(Cat. No. 500-0006) based on the Bradford method.)
4.2.4 Determination of protein content bv the Lowru method.
1. A standard curve was prepared using the volumes of
0.5 mg / ml BSA and tris-HCl 50 mM pH 7.4 detailed below.
0.5 ml of each unknown was aliquoted out. Samples were assayed
in duplicate.
Tube Volume of BSA Volume of Amount of
0.5 mg/ml (pi) tris-HCl (pi) protein (pg)
1 , 2 - 500 -
3 , 4 50 450 25
5 , 6 125 375 62.5
7 , 8 250 250 125
9 , 10 375 125 187.5
11 , 12 500 - 250
2. Reagent A was prepared as follow :
75 ml 2 % Na2C03 in 0.1 M NaOH
+ 0.75 ml 2 % potassium sodium tartrate, mix,
+ 0.75 ml 1 % CuSC>4, mix;
50 % Folin-Ciocalteu's reagent was reagent B.
3. At t=0, 2 ml of reagent A was added to each tube at 20 sec
intervals and mixed.
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4. At t=10 min, 0.25 ml of reagent B was added to each tube at
20 sec intervals and mixed.
5. At t=40 min, the absorbance at 660 nm was measured, which
is proportional to the total amount of protein and therefore allows
for the determination of the unknown protein content in the
plasma membrane samples from the standards.
144
4.3 LIGAND BINDING THEORY
R - receptor
L - ligand
RL - receptor-ligand complex
k+i - association rate constant
k_i - dissociation rate constant
Kd - equilibrium dissociation constant for ligand
B max - total number of binding sites
b - bound ligand [RL]
F - free ligand [L]
Ki - dissociation constant for an inhibitor
IC50 - concentration of inhibitor which gives 50 % inhibition of
binding of the ligand
H-l
[R] + [L] [RL]
k-i
at equilibrium k+i [R] [L] = k-i [RL]
therefore Kd = k-i / k+i = [R] [L] / [RL]
since
then
[RL] + [R] - Bmax
[RL] [L] + [R] [L] - Bmax [L]
substituting
rearranging
[RL] [L] + Kd [RL] - Bmax [L]
[RL] = Bmax [L] / [L] + Kd




therefore Kd = F
COMPETITIVE INHIBITORS OF BINDING
Displacement studies involve the use of one [3H] - ligand
concentration with increasing concentrations of competing ligand.
The relationship is described by the Cheng - Prusoff (1973)
equation :
By plotting % of control binding versus log [competing ligand], a
value for IC50 may be obtained, and consequently Ki determined.
When the [3H] - ligand and displacing ligand display the same
physical and chemical properties in the interaction with the
binding sites,
Ki = IC50 / (1 + [3H-L] / Kd)
and
Kd = Ki
IC50 = Kd + [L]
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4.4 RESULTS and development of the procedure
Initial binding studies indicated a greater specific binding in the
purified plasma membrane fraction of differentiated HL-60 cells as
compared to the crude homogenate (Table 4.1). The higher
protein concentration of the crude homogenate resulted in a
greater dpm for both total and non - specific binding, though the
dpm for specific binding was comparable to that in the purified
fraction. The sucrose density - gradient centrifugation step
therefore results in a 3-fold increase in the amount of [3H]-PGE2
bound, measured as fmoles / mg protein.
Table 4.1. Comparison of [3H]-PGE2 binding to crude
homogenate and the purified plasma membrane fraction of
differentiated HL-60 cells.
parameter crude homogenate plasma membrane
(n=8) (n=8)
total binding (DPM) 9077 ± 4481 5191 ± 2013
non-specific binding (DPM) 7419 ± 3729 3821 ± 1731
specific binding (DPM) 1658 ± 765 1370 ± 453
% specific binding of total 19 ± 4 33 ± 4
bound (fmoles/mg) 30 ± 13 105 ± 31
MgCU is required for the activation of ATP and therefore adenylate
cyclase activity which converts ATP to cyclic AMP. Since PGE2
stimulates the production of cyclic AMP in macrophages
(Bonta & Parnham, 1982) and has been shown to increase cyclic
AMP levels in both differentiated and undifferentiated HL-60 cells
(see Discussion), the effect of MgCU on PGE2 binding was tested.
Specific binding was found to fall significantly in its absence from
43 % to 20 % at 1 nM [3H]-PGE2, and 37 % to 6 % at 10 nM
[3H]-PGE2. In an experiment in which specific binding was 58 %
in the presence of 2.5 mM MgCU, a fall in specific binding of 30 %
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was observed using 0.25 mM MgCl2, whereas 25 mM showed no
improvement.
The incubation period for binding was 1 hr at room temperature.
An individual experiment showed the binding to rise from 25 %
through 36 %, 38 % to 50 % specific binding for 1 nM [3H]-PGE2
at incubation periods of 15 min, 30 min, 45 min and 60 min
respectively. The half-life (ti/2) for onset of PGE2 binding was
therefore estimated at 20 min. Considering the temperature of
incubation, two experiments demonstrated that increasing the
temperature to 37 °C did not improve the % specific binding
obtained with a 1 hr incubation at 0.1, 1 or 10 nM [3H]-PGE2. It
was decided to incubate at room temperature since the off-rate is
less than at 37 °C, thereby reducing a component of error in
separating bound and free radioligand.
As reported in the context of the MgCl2 experiments, PGE2
stimulates adenylate cyclase and binding sites should therefore
exist on the plasma membrane, in which adenylate cyclase is
embedded. Following the sucrose gradient centrifugation step to
purify the crude homogenate, the interface at which the greatest
specific binding was obtained was then taken to represent the
plasma membrane - rich fraction. These results are illustrated in
Table 4.2.
Table 4.2. Comparison of2 nM [3H]-PGE2 binding to various
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The results suggested the band on top of the 1.2 M sucrose layer to
have the greatest degree of binding. Since no appreciable specific
binding was obtained over the 0.9 M layer, this protein fraction
may contribute to non - specific binding, therefore a gradient of
0.9 M over 1.2 M sucrose was used to prepare the purified plasma
membrane fraction.
The development of this protocol for the preparation of a plasma
membrane - rich fraction allowed subsequent saturation and
displacement studies to be carried out in order to characterise the
subtype(s) of PGE receptor present on the human macrophage-like
cell. The vertical bars on the figures represent the standard error
of the mean. The statistical significance (p<0.05) of the observed
inhibitions of specific [3H]-PGE2 binding was assessed using the
paired Student's t-test. The data have been analysed according to
the theory already detailed (pages 145-146) and in addition by the
computer programs Totalfit and Fit (Barlow, 1983). The latter
analysis was provided by Dr R. Barlow, formerly Reader in Chemical
Pharmacology at the University of Bristol, to whom I am most
grateful.
Experiments carried out at Allergan Pharmaceuticals involved
determinations of the specific binding of [3H]-PGE2 over the
concentrations range 0.1 nM to 100 nM. The results are
represented as bound vs free (Figure 4.1(a),(b)), and suggest the
presence of two binding sites, a saturable high affinity site and a
lower affinity site which is not saturated at the highest radioligand
concentration used. Considering only those data points to 50 nM
(Figure 4.1(b)), at which concentration the higher affinity site
appears to be saturated, the average Kd, determined from Bmax / 2
for individual experiments, is given by 2.5 ± 0.4 nM. Using a
program based on Totalfit, this same data has been fitted to a
'binding process + chemical reaction' for those sets of data
covering the full range of concentrations (n=5), and to mass action
binding for those limited to the first saturated site (n=2). The
value of K<j is determined in each case, and the mean (n=7) is
given by 7.3 ± 2.6 nM.
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Displacement of 2 nM [3H]-PGE2 by PGE2 itself (n=4-5) revealed an
IC50 of 17 ± 1 nM, corresponding to a Kd of 15 ± 1 nM (Figure 4.2).
11-deoxy PGEi also displaced specifically bound [3H]-PGE2 with an
IC50 of 30 ± 17 nM (Figure 4.2), which may be transformed into a
Ki of 27 ± 15 nM. Surprisingly, whilst PGE2 and 11-deoxy PGEi
achieved significance (p<0.01) at concentrations equal to and
above 10"8 M and 5xl0~7 M respectively, butaprost only
significantly displaced [3H]-PGE2 to this extent at 10"5 M and
AH 13205 did not achieve significance at concentrations up to
10~5 M (Figure 4.3). In a similar manner to butaprost, sulprostone
significantly displaced [3H]-PGE2 (p<0.01) only at 10~5 M, at which
concentration AH 6809 also achieved significance though to a
lesser degree (p<0.05) (Figure 4.4). Interestingly the IP-receptor
agonist cicaprost displaced specific binding with an IC50 of
4.8 ± 1 pM, Ki of 4.2 ± 0.6 pM, (n=3-4), significant (p<0.01) at
10"5 M (Figure 4.5).
This displacement data has been analysed using the logistic fit,
developed from Fit, and with fit to two sites, developed from
2SiteInhib in Biodata handling (Barlow, 1983). In the self
displacement studies one binding site is revealed with mean Kd
given by 26 ± 5 nM. This contrasts with the two binding sites
obtained in three out of four experiments where 11-deoxy PGEi
displaced specifically bound [3H]-PGE2- The mean results for these
experiments are Kn = 12 ± 2 nM (n=3); 23 ± 11 nM (n=4) and
Ki2 = 3121 ± 87 nM. The maximum effect of the first component
of this binding is approximately 10 times that of the second.
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Figure 4.1 Saturation experiment using increasing
concentrations of [3H]-PGE2 (n=5-7), illustrating
(a) two binding sites;
(b) the saturable high affinity site.
(Curves constructed using polynomial curve fit
application in Kaleidagraph, Apple Macintosh.)
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Figure 4.2 Displacement of 2nM [3H]-PGE2 from the
human macrophage-like plasma membranes by PGE2
and the EP2 - selective agonist, 11-deoxy PGEj.
* (p<0.05) and si (p<0.01) denote significant displacement
















Figure 4.3 Displacement of 2 nM [3H]-PGE2 from the
macrophage-like plasma membranes by the EP2 - selective
agonists, butaprost and AH 13205.
* (p<0.05) and si (p<0.01) denote significant displacement
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Figure 4.4 Displacement of 2 nM [3H]-PGE2 from human
macrophage-like plasma membranes by the EP1 - &
EP3 - selective agonist sulprostone, and the EP: - selective
antagonist AH 6809.
* (p<0.05) and si (p<0.01) denote significant displacement
of specific [3H]-PGE2 bound.
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Figure 4.5 Displacement of 2 nM [3H]-PGE2 from human
macrophage-like plasma membranes by the IP - receptor
agonist, cicaprost.




Since PGs are fatty acid-like molecules, they can be expected to
associate non-specifically with hydrophobic membrane
components, regardless of a specific binding capacity. This
creates problems with PG binding studies, which may be overcome
by the preparation of a purified and concentrated plasma
membrane fraction, as detailed in the methods section. Indeed,
experiments carried out with crude homogenate produced only
half the specific binding of that following the sucrose density
gradient centrifugation step. When optimum conditions were
achieved, approximately 70 % specific binding was routinely
obtained. Insufficient protein prevented the use of fresh human
monocytes separated from whole blood by Histopaque, whilst the
use of cell culture allowed more control over reproducibility of
conditions and protein content.
Analysis of the saturation experiments conducted with 0.1 nM to
100 nM [3H]-PGE2 has suggested the presence of two receptor
binding sites on the purified plasma membrane preparation of the
differentiated HL-60 cells (Figure 4.1 (a),(b)), one of high affinity,
Kd = 2.5 ± 0.4 nM, and a second much lower affinity site. The value
of Kd determined by computer analysis is not significantly different
at 7.3 ± 2.6 nM. However, the determination of Kd from
displacement studies appears to be at odds with these findings.
Displacement of 2 nM [3H]-PGE2 by PGE2 itself, revealed an
IC50 value of 17 ± 1 nM (n=5), with > 90 % displacement
occurring over 3 log units of concentration (Figure 4.2). Given that
Kd = IC50 - [L] when [3H]-L and L have the same physical and
chemical properties (Cheng & Prusoff, 1973), Kd= 15± 1 nM.
This value of Kd is significantly different (p<0.01) from that
determined from the saturation studies. Since binding to the low
affinity site may influence estimation of the Kd by this method, the
data was analysed by computer program. In the logistic fit of the
data, if P=-l there is no point trying to look for two sites, 'P' in the
logistic equation corresponding to the Hill coefficient
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(Barlow & Blake, 1989). In the self displacement of PGE2 there is
no evidence of two sites, and Kg is represented by 26 ± 5 nM
which is not significantly different from the value determined from
the IC50. There must therefore be an alternative explanation for
the discrepancy between these results and those obtained from
analysis of the saturation data.
Whilst the effect of overestimating free ligand concentration at
equilibrium is most pronounced at the lowest ligand
concentrations, this is not likely to be of significance here, since
less than 10 % of the total ligand added is bound at any one time.
Two binding sites may have been revealed if experiments involving
displacement of a higher concentration of [3H]-PGE2 were
conducted. Nevertheless there is a 3- to 6- fold lower evaluation of
the Kg from the saturation studies performed at Allergan compared
to the displacement studies conducted at Edinburgh.
Interestingly, in the saturation binding studies representing n = 7,
the specific binding of 2 nM [3H]-PGE2 represented 77 ± 5 % of
the total binding, at 2453 ± 482 DPM and 146 ± 27 fmoles / mg
protein. In contrast, displacement studies using a fresh
subculture, whilst producing a similar degree of specific binding
represented by 69 ± 2 % at 2 nM, were equivalent to only
583 ± 52 DPM and 60 ± 9 fmoles / mg protein. This suggests a
different distribution of binding sites on the membrane
preparation prepared here, compared to that isolated from the
HL-60 cell line at Allergan. It therefore appears that whilst all
HL-60 cells originate from one source, different subcultures may
differ in their receptor binding sites. It is also interesting to note,
the different estimations of protein content according to the
method of assay. At Edinburgh, 6 protein samples were assayed by
both the Coomassie Blue (Bradford, 1976) method and the Lowry
(1951) method, giving 10 ± 2 gg and 19 ± 3 gg respectively. The
Bio-Rad technique used at Allergan is based on the Bradford
method.
In further binding studies I measured the displacement of 2 nM
[3H]-PGE2 from human macrophage-like plasma membranes by a
series of competing ligands, which are PGE analogues of differing
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selectivity for the three PGE receptor subtypes so far
characterised.
Nat 11-deoxy PGEi, an EP2-selective analogue, displaced
[3H]-PGE2 with an IC50 = 30 ± 17 nM (n=4) (Figure 4.2). The fact
that this potency, Ki = 27 ± 15 nM, was comparable to PGE2 itself
was not surprising, since PGE2 has been reported to elevate cyclic
AMP levels in the macrophage, an effect classically mediated by the
EP2-receptor subtype. The logistic fit with this data did however
suggest two receptor binding sites. Since 13 data points were
determined with 11-deoxy PGEi as compared to 7 with PGE2
itself, perhaps smaller increments in the concentration of PGE2
are necessary to demonstrate the presence of a second much
lower affinity site in this preparation. In addition the method of
filtration for separation of bound from free may not be fast enough
to prevent significant dissociation of the ligand from a lower
affinity site. Tests may be carried out using the the more rapid
method of centrifugation for separation, in order to determine if
this is indeed the case.
A contrasting profile was however observed with two other
EP2-selective analogues, butaprost and AH 13205. In the presence
of these competing ligands, displacement at a concentration of
10 pM represented that observed for PGE2 and 11-deoxy PGEi at
approximately 10 nM (Figure 4.3). Butaprost and AH 13205 were
therefore approximately 1000 times less potent than either PGE2
or 11-deoxy PGEi in displacing [3H]-PGE2 from this plasma
membrane fraction.
Gardiner (1986) has claimed butaprost to be a specific
EP2-receptor agonist. Indeed, on the cat trachea, an
EP2-receptor - containing preparation, butaprost and
11-deoxy PGEi are of similar potency (Dong et ah, 1986). However
butaprost is 500 times less potent than nat 11-deoxy PGEi in
relaxing the histamine-contracted rabbit jugular vein, suggesting
the presence of a different EP-receptor on this preparation
(Lawrence & Jones, 1992). The jugular vein is highly sensitive to
the relaxant action of PGE2 and the equipotent molar ratio (e.m.r.)
of nat 11-deoxy PGEi relative to PGE2 on this preparation is 1.4, as
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compared to 685 for butaprost. The binding studies may therefore
reflect an EP2-subtype similar to that on the rabbit jugular vein. A
measure of the relative potency of AH 13205 on the jugular vein
would be of help in further reconciling these results.
Sulprostone. an EPi- and EP3-selective agonist, also showed no
appreciable displacement of the specifically bound [3H]-PGE2 until
the 10 pM concentration (Figure 4.4). As a measure of its EP3
potency relative to PGE2, inhibition of the twitch response of
guinea-pig vas deferens to electrical field stimulation reveals an
e.m.r. of approximately 0.1 (Lawrence et al., 1992). Were there an
EP3 component involved, displacement of the [3H]-PGE2 would
therefore be expected at 10-fold lower concentrations than that
obtained for PGE2 itself. Clearly this is not the case.
AH 6809 is an EPi antagonist with a pA2 of ~ 7.0 for PGE2 on the
guinea-pig ileum and fundus and the dog fundus
(Coleman et al, 1985a). Binding studies carried out with a 10 pM
concentration revealed slight displacement of the specifically
bound [3H]-PGE2 (Figure 4.4). The pA2 value suggests an IC50 value
of approximately 100 nM, were there an EPi-receptor subtype
present on this preparation. Insufficient displacement prevented
an estimation of a value for IC50.
To test the specificity of the [3H]-PGE2, displacement studies were
also carried out with the specific IP-receptor agonist cicaprost
(Dong et al., 1986). Its potency in displacing was shown to be
approximately 300 times less than that for PGE2 (Figure 4.5)
represented by an IC50 of 4.8 ± 1 pM (n=3-4). This indicated that
[3H]-PGE2 was binding to an EP-receptor for which cicaprost had a
weak affinity, with a Ki of 4.2 ± 0.6 pM.
Following the suggestion of an additional EP-receptor subtype at
which AH 23848B may be an antagonist (Louttit et al., 1992a,b),
two representative experiments were therefore carried out in
order to determine if AH 23848B would displace the specifically
bound [3H]-PGE2 from the macrophage-like membrane
preparation. Since it is a weak antagonist, pA2 ~ 5.36, relatively
high concentrations were required in order to obtain any
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significant displacement. At 10 pM AH 23848B, no significant
displacement of the [3H]-PGE2 was obtained, two separate
experiments displacing 51 % and 46 % at 30 pM, and 91 % and
83 % at 100 pM. AH23848B was initially developed as a
thromboxane antagonist, therefore the displacing ability of the
widely used thromboxane antagonist GR 32191 was also tested in
the same two preparations. At 100 pM GR 32191 displaced the
specifically bound [3H]-PGE2 by 26 % and 29 %. These
preliminary studies indicate weak affinity of these compounds for
the EP receptor, with AH 23848B being the more potent
displacer. Further studies are required before any sound
conclusions may be drawn as regards the presence of an
EP4-receptor subtype on this preparation.
The time-course study suggests the onset of PGE2 binding is slow
(ti/2 ~ 20 min). Since
ti/2 onset = In 2 / onset rate constant
and
onset rate constant = (k+i x [L]) + k-i
then
(k+i x [L]) + k. 1 ~ 0.6x 10"3 s_1 (1)
As Kp = k-i / k+i k_i = (Kpxk+i)
= 2.5 x 10~9 x k+i (2)
Substituting (2) into (1)
3.5xl0"9xk+i ~ 0.6x 10"3 s_1
therefore k+i = 2 x 105 M^s-1
and k-i = 5 x 10~4 s-1
A forward rate constant (k+i) of 2 x 105 M^s"1 is quite low. Many
investigators use values of 106 - 107 M^s-1
(Yamamura et al., 1985). However, other workers have reported
relatively slow association of PGE2 with its receptor. Indeed
Grandt et al. (1982) showed that the slow association of PGE2 to
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hamster adipocytes was accelerated by guanine nucleotides and
monovalent cations, also more recently reported for human
myometrial PGE2 receptors (Thaler-Dao et al, 1992). Other
workers have observed a marked effect of temperature on the
association rate for binding (see Brunton et al, 1976). Rao (1974)
gives a value of 1.9 x 105 M^s-1 for the association rate constant
for the interaction of PGE2 with the bovine corpus luteum cell
membrane preparation, and a value of 3 x 105 M_1s_1 has been
reported for the porcine fundic mucosal homogenate
(Beinborn et al., 1988).
Several binding studies have previously been carried out in an
attempt to characterise the PGE receptor present on the mature
macrophage and its predecessor, the blood monocyte.
Opmeer et al. (1983a) present direct evidence for the presence of
selective binding sites for [3H]-PGE2 on rat peritoneal
macrophages with a Kd of 32 nM. The competing ligands
displaced in the manner PGE2 > PGEi > PGI2, the IC50 for PGE2
displacing 5 nM [3H]-PGE2 being 100 nM. This represents a
6-7 times lower affinity binding site than on the plasma membrane
- rich fraction of the differentiated HL-60 cells. PGI2 had a
relatively low affinity represented by an IC50 of 55 pM, hence a
Ki of 48 pM, and since it competes for [3H]-PGE2 in a non-parallel
manner compared to PGE2 itself, it is proposed to have a separate
binding site. Considering the relationship between Kd and IC50
when the [3H]-ligand and competing ligand have the same
biological profile, Kd = IC50 - [L], the IC50 for displacement of
[3H]-PGE2 by PGE2 itself represents a Kd of 95 nM, which is
three-fold greater than that obtained from the saturation
experiments. A better correlation would result if all the points are
taken into consideration in the displacement study
(Opmeer el al., 1983a, Figure 3), and would also reduce the degree
of non-parallelism between the displacement of [3H]-PGE2 by PGE2
and PGI2.
A complementary study using 20 nM [3H]-PGl2 as the ligand, was
subsequently carried out by the same group (Opmeer et al, 1983b).
PGE2 and PGI2 displaced the specifically bound [3H]-PGl2 in both
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the whole cell and membrane-enriched fractions, PGE2 being the
more potent of the two. This order of potency was also observed
for prostaglandin activation of cyclic AMP in the macrophages,
which takes into account the affinity and efficacy of the
compounds. The greater affinity of PGE2 and its stronger ability to
elevate cyclic AMP when compared to PGI2, suggests the [3H]-PGl2
to be binding to an EP receptor. It is however difficult to be
confident about any conclusions since there is no indication of the
error involved in either of the binding studies. The IC50 values
obtained for PGE2 on whole cells and membrane fractions were
2.5 nM and 2 nM respectively. In contrast, PGI2 displaced with
IC50 values of 6 nM and 400 nM, the displacement from whole
cells being biphasic. Given as before that Kd = IC50 - [L] when the
competing ligand is of the same biological activity to the
[3H] - ligand, it is difficult to determine a Kd value for PGI2 on the
whole cells when an IC50 of 6 nM is obtained in displacing 20 nM
[3H]-PGl2- The seventy-fold loss of potency on the membrane
fraction is thought to reflect a loss of PGI2 activity through
degradation or inactivation. These results may suggest the
existence of PGE2 receptors on rat peritoneal macrophages for
which PGI2 has a lower affinity, rather than separate receptors for
PGE2 and PGI2.
The PGE2 receptor on human peripheral blood monocytes has also
been characterised (Eriksen et al., 1985). Steady state binding of
[3H]-PGE2 was obtained by 30 min at 15 °C, 22 °C and 37 °C. The
observation that PGF2a and arachidonic acid were more than 4-fold
less potent than PGE2 in displacing 0.6 nM [3H]-PGE2, and did not
stimulate cyclic AMP levels, suggested the binding of [3H]-PGE2 to
be specific. Further analysis of this binding data and its
transformation to a Scatchard plot revealed a single site with a
value for Kd of 1.1 nM, and Bmax of 4.1 fmol / 107 cells. The
concentration of PGE2 producing 50 % of the maximum adenylate
cyclase response was ~ 6 nM, suggesting a relationship between
the PGE2 receptor and adenylate cyclase in the cell membrane.
The PGE receptor demonstrated on these monocytes is shown to
be of greater affinity than that isolated from differentiated HL-60
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cells. This difference may reflect changes which occur during the
course of maturation, or a whole cell preparation as compared to a
plasma membrane fraction.
In studies involving a murine macrophage-like cell line, P388 Di,
binding to intact cells revealed two PGE2-receptor binding sites
(Fernandez-Botran & Suzuki, 1984a). The high-affinity receptor
had a Kd of 1.1 nM and Bmax of 3.9 fmol / 108 cells, and the
low-affinity receptor a Kd of 20 nM and Bmax of 24 fmol / 108 cells.
Competitive binding studies indicated PGI2 and PGF2a were
respectively 10 times and 100 times less effective than PGE2 in
displacing 1 nM [3H]-PGE2 thereby confirming the presence of an
EP-receptor. The Kd for the high affinity binding site correlates
well with that on the human monocyte, though the density of
receptors is much greater on this cell line. The low affinity
receptor is comparable to that identified on the rat peritoneal
macrophage. Partially purified membrane fractions of P388Di cells
obtained by sucrose density gradient centrifugation, have been
used for the determination of adenylate cyclase activity
(Fernandez-Botran & Suzuki, 1984b). It is apparent from these
studies that the low-affinity receptor is probably the more
important for transducing the signal, since the biologic effects of
exogenously added PGE2 are at 0.1 pM to 1 pM.
In a more recent study of the PGE2 binding sites on
macrophage-like P388Di cells, IL-1 is shown to reduce the
binding capacity of both the high, 0.31 to 0.12 fmol / 106 cells,
and low affinity sites, 2.41 to 1.51 fmol / 106 cells, in a
concentration-dependent manner without altering the Kd values of
either, 2.7 nM and 40 nM respectively (Rae et al., 1992). The
desensitisation of PGE2 receptors by IL-1 on P388Di cells occurs
within the range of Kd values, suggesting a receptor-ligand
interaction. PGE2 is reported to induce desensitisation in P388Di
cells in two steps, the early homologous desensitisation whereby
only subsequent effects of PGE2 are impaired, and the later
heterologous desensitisation influencing the effects of more than
PGE2 alone (Shamma et al., 1988). It is proposed that this may
represent a mechanism by which IL-1 can overcome the
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immunosuppressive actions of PGE2, and reflects the complex
nature of the control processes functioning in the immune system.
Earlier studies demonstrated pharmacological amounts of PGEi to
suppress acute and chronic inflammation in vivo in
adrenalectomised rats (Zurier et al, 1973), and the
phosphodiesterase inhibitor theophylline to enhance the inhibitory
effect of PGEi in adjuvant-induced arthritis in rats
(Bonta et al., 1978). Indeed, PGs of the E series are known to
exert their anti-inflammatory effects through stimulation of cyclic
AMP levels in vitro (Pelus & Strausser, 1977). Secretion of IL-1
from macrophages stimulates the release of PGE2 from many cell
types, including other macrophages, the resulting elevation of
cyclic AMP due to the PG stimulation of receptor-coupled
adenylate cyclase of macrophages being associated with the
inhibition of several functions of these phagocytes
(Bonta & Parnham, 1982; Kammer, 1988).
PGE2 has been shown to have a biphasic effect on the adenylate
cyclase system of rat peritoneal macrophages, inhibiting
PGl2-induced elevation of cyclic AMP at low concentrations, and
increasing cyclic AMP levels at higher concentrations
(Adolfs & Bonta, 1982). In the presence of 1.4 nM to 12 nM PGE2,
a concentration range which is itself unable to significantly raise
cyclic AMP levels, the stimulatory response to 2.8 jiM PGI2 and a
stable synthetic analogue, DDH-carbo-PGl2, was inhibited in a
dose-dependent manner. Concentrations greater than this for
PGE2 caused a dose-dependent increase in cyclic AMP levels. At
56 nM PGE2 the inhibitory influence on DDH-carbo-PGl2 was not
evident, either not existing or being masked by the PGE2-induced
stimulation of cyclic AMP. Perhaps the initial inhibitory and later
stimulatory influence of PGE2 on adenylate cyclase reflect subtypes
of the PGE receptor, positively and negatively coupled to adenylate
cyclase. At the lower concentration range, PGE2 may occupy those
negatively coupled, thereby inhibiting the PGI2- or
DDH-carbo-PGl2- induced elevation of cyclic AMP. A threshold
concentration may be reached when EP receptors that are
positively coupled to adenylate cyclase, and for which PGI2 has a
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low affinity, are occupied. A more comprehensive study of the PGE
receptors present on the rat peritoneal macrophages is therefore
necessary for a greater understanding of the activity of PGE2.
A comparison has been made between human and rat macrophages
with regard to the regulation of cyclic AMP by the prostaglandins
(Bonta et al, 1984). Peritoneal macrophages were isolated from
the rat, and from dialysates of patients undergoing continuous
ambulatory peritoneal dialysis (CAPD). In contrast to rat peritoneal
macrophages, those isolated from humans are reported to have
separate binding sites for PGE2 and PGI2. The rat macrophages
were more sensitive to PGE2 than to DDH-carbo-PGl2 which
correlates with its greater affinity relative to PGI2 in the binding
studies already described. In contrast, whilst the potency of the
response to DDH-carbo-PGl2 was similar to that on rat cells as
measured by the elevation of cyclic AMP levels, there was a much
smaller effect in the presence of PGE2 with respect to the human
macrophages. PGE2 has been proposed as the major PG in
exerting effects of importance in governing the
cyclic AMP-mediated functions of macrophages
(Bonta & Parnham, 1982; Gemsa et al., 1982). These studies on
human macrophages suggest an important role for PGI2, though it
is not known what bearing the origin of these macrophages has on
the receptor adenylate cyclase system. However, cells from sites
of infectious inflammation show a greater increase in the
sensitivity of adenylate cyclase to PGE2 than to PGI2
(Adolfs et al, 1985). In this study, human peritoneal macrophages
were again isolated from CAPD patients, though besides the
macrophages isolated in the absence of complications, as the first
study described, macrophages were also isolated from these
patients during inflammation and after recovery. Whilst
macrophages from the uncomplicated stage of CAPD were more
responsive to DC-PGI2 than PGE2 as already reported, during
inflammation there was a marked increase in the sensitivity to PG
stimulation, especially with PGE2. Perhaps then PGE2 is
predominantly more important in conditions of inflammation.
Indeed, modulation of granulomatous inflammation by PGE2
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depends upon the period of exposure to the PG
(Parnham et al., 1979). A single daily dose of PGE2 for the first
three days enhanced the granuloma formation as measured on day
8, and inhibited the formation if administered on days 4-7.
Consequently, treatment with PGE2 during the whole time period
showed no significant change in the dry granuloma weight
indicating that the later inhibitory action of PGE2 had reversed its
early stimulatory effect. PGI2, 6-keto PGFia and PGF2a had no
significant effect on the granuloma formation when administered
over the 4-7 day period. More recently Bonta et al. (1981) have
related the effects of PGE2 on the adenylate cyclase system in vitro
to chronic inflammation in vivo. They suggest the time-dependent
increase in ex-vivo responsiveness of granuloma-derived
macrophages to PGE parallels the anti-inflammatory effect of PGE
on the granuloma tissue. A reduction in the level of cyclic AMP
during the inflammatory period was accompanied by a fall in the
endogenous synthesis of prostaglandins. In particular the effect of
PGE2 on the cyclic AMP levels was considerably more pronounced
than with macrophages isolated before this period.
The mechanism of activation of adenylate cyclase is likely to be
explained by the ternary complex model. The components of this
include the receptor, adenylate cyclase and the guanine nucleotide
regulatory protein, or G protein, which transmits the signal from
the receptor to the adenylate cyclase. Indeed PGEi requires
guanine nucleotides to stimulate the adenylate cyclase in
guinea-pig peritoneal macrophage membranes, and enhances the
GTP- and Gpp(NH)p -, a non-hydrolysable analogue of GTP,
stimulated cyclic AMP levels (Verghese & Snyderman, 1983). In
the presence of GTP, the G protein dissociates into Ga and Gp-y, as
discussed in chapter 3 of this thesis. At the same time the PGE2
binding site has been reported to be converted to both a lower
(adrenal medulla, kidney medulla, brain, hypothalamus) or higher
(adipocytes, myometrium) affinity form. Lerner et al. (1992) have
shown a nonhydrolysable form of GTP to shift [3H]PGE2 binding
from two sites, one of high affinity and the other of low affinity, to
one site of intermediate affinity. Binding studies were therefore
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carried out in the presence and absence of a non-hydrolysable
analogue of GTP to determine if the receptor was indeed G protein
linked. A preliminary study revealed no change in the IC50 value
for displacement of 2 nM [3H]-PGE2 by PGE2 itself, in the presence
of 100 pM GTP-y-s.
Additional displacement studies and assessment of the activity of
these PGE analogues on the pig saphenous vein preparation are
required for a more comprehensive EP-receptor characterisation.
This should involve the use of other analogues such as the EP2- and
EP3- selective analogue misoprostol, especially given the recent
evidence for its immunomodulatory role (Widomski et al, 1991),
and compounds active at DP-, FP- and IP-receptors to further test
the selectivity of binding.
Binding studies primarily produce estimates of affinity, the
intrinsic efficacy parameter being essentially inaccessible. The
advantage of binding over an isolated preparation is the ability to
estimate receptor density, however because of the coupling system
between receptor occupation and tissue response one cannot
assume a direct correspondence between the proportions of
heterologous receptor populations and the pharmacological
response. Such binding studies are often accompanied by second
messenger and / or functional studies to confirm the presence of a
receptor. Preliminary experiments for determination of cyclic
AMP levels in whole cells were carried out using the automated
Attflo system at Allergan Pharmaceuticals. Basal levels of cyclic
AMP in undifferentiated HL-60 cells are not elevated by PGD2 or
PGF2a indicating a degree of specificity. PGE2 and 11-deoxy PGEi
at 100 pM increased levels to approximately 105 pmoles / mg
protein and 50 pmoles / mg protein respectively. The ED50 value,
representing the concentration at which a half-maximal cyclic
AMP level is attained, was 1 pM in each case. In differentiated
cells the maximal response to PGE2 was reached at 1 pM and
represented an increase of 20 pmoles cyclic AMP / mg protein
above basal (14 ± 5 pmoles / mg). This represents only a third of
the response in the undifferentiated form, and has an ED50 of
~ 200 nM.
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Sucrose density gradient centrifugation has previously been used to
isolate plasma membranes from various cell types. In the case of
mouse lymphoid cells (Koizumi et al, 1981), electron microscopy
and measurement of the specific activities of the marker enzymes
for plasma membrane, (Na+ / K+)-ATPase, Mg2+-ATPase and
5'-nucleotidase, indicated the plasma membrane - rich fraction
had been isolated at the interface between 20 % and 40 % sucrose
in the gradients. Whilst isolating the plasma membrane - rich
fraction from the murine macrophage-like cell line P388Di
between 30 % and 45 % sucrose
(Fernandez-Botran & Suzuki, 1984a), the results of marker enzyme
activity suggested this to be only a partially purified preparation.
The interface used here between 0.9 M sucrose and 1.2 M sucrose
corresponds to that between 30 % and 40 % respectively, and
therefore falls within that already defined for plasma membrane
isolation. A further study of the adenylate cyclase activity of the
membrane fraction should confirm that it is indeed
membrane-rich, since adenylate cyclase is a membrane bound
enzyme. In addition, 5'-nucleotidase, 5'-ribonucleotide
phosphorylase, is a plasma membrane-associated enzyme that
because of its high activity in monocytes or macrophages can be
used as a marker for these cell types (Breitman, 1990). The assay
involves a measure of the capacity to release inorganic phosphate
from adenosine monophosphate.
The results discussed here suggest that a further subtype of the
EP receptor may exist. Additional binding and second messenger
studies are required in order to reconcile these results with those
found on the rabbit jugular vein and the more recently
communicated pig saphenous vein. There appear to be problems
in using different subcultures of a cell line. It is possible that the
discrepancies may be more pronounced in studies dependent on
such processes as induced differentiation. Using one source and
restricting experiments to a range of passages in which the cells




The advent of the NSAIDs and the premise that their mechanism
of action was through inhibition of cyclooxygenase activity
(Vane, 1971), suggested that the prostanoids were pro¬
inflammatory. Indeed prior to this PGE2 was identified in rat
(Willis, 1969a,b) and human (Greaves & Sondergaard, 1970;
Greaves et al, 1971) inflammatory exudate, and was also shown to
induce signs of inflammation in both (Crunkhorn & Willis,
1969,1971a). Subsequently PGE2 has been implicated as a
mediator in several models of inflammation, as discussed in
chapter 2 of this thesis. Besides this pro-inflammatory activity of
PGE2, its pro-aggregatory effect on platelets is of great interest
(chapter 3) since inflammatory mediators are released following
platelet activation.
Nonetheless, there have been indications that all the beneficial
effects of the NSAIDs are not mediated by inhibition of prostanoid
biosynthesis, such as the inhibition of neutrophil activation
(Rampart & Williams, 1986a; Weissman, 1987;
Abramson & Weissmann, 1989). In addition, as early as 1976
there was a report on the ability of PGEi and PGE2 to suppress
lymphocyte activation (Bray et al., 1976), prompting the first
suggestion that the PGEs may be more accurately described as
modulators of inflammation rather than mediators. Further
evidence for this anti-inflammatory effect of PGE2 is detailed in
chapter 4.
Distinct receptors are known to exist for each of the five naturally
occurring prostanoids PGD2, PGE2, PGF2a> PGI2 and TXA2. In
addition the PGE receptor has been further classified into at least
three subtypes (Bennet & Posner, 1971; Coleman et al, 1980;
Dong et al, 1986; Coleman et al, 1987a,b,c) believed to be coupled
to separate second messenger systems (Gutman et al, 1979;
Creese & Denborough, 1981). In the absence of specific agonists
or antagonists, the synthesis of PGE analogues showing differing
selectivity for the EPi-, EP2- and EP3- receptor subtypes has
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proved a useful tool in characterising the subtype(s) involved in a
particular system.
It has been suggested that the pro-inflammatory activity of PGE2 is
the result of its vasodilatory activity. However, we have compared
potentiation of the exudation response to bradykinin and FMLP in a
rabbit model of skin inflammation by PGE2, a range of PGE
analogues and cicaprost, a specific IP-receptor agonist, and related
this to their ability to increase local blood flow. These studies
suggest that whilst vasodilatation may have an important role in the
PGE2-induced potentiation, another mechanism may also be
involved.
Vasodilatation is associated with a rise in the second messenger
cyclic AMP, formed as a result of adenylate cyclase activity believed
to be coupled to the EP2-receptor subtype. Indeed, this may be
responsible for the potentiation observed above the 10 ng dose of
PGE2. However, an EP3-mediated effect possibly involving
chemotaxis of neutrophils may account for the potentiation at
lower doses, in the absence of any significant increase in local
blood flow.
The ability to induce vasodilatation does not necessarily result in
potentiation of plasma exudation, since ^-adrenoceptor agonists,
whilst causing vasodilatation, inhibit increased vascular
permeability (Whelan & Johnson, 1992). This is believed to be a
direct effect on the endothelial cells, and may also be a possible
mechanism for anti-inflammatory effects of PGE2. In addition,
perhaps PGE2 potentiates plasma exudation in this rabbit skin
inflammation model in part through a direct action on the
microvascular membrane, as suggested for PGEi in the canine
forelimb (Amelang et al., 1981) and previously demonstrated by
fluorescence studies with PGEi, PGE2 and PGF201 in the hamster
cheek pouch (Svensjo, 1978).
The pro-aggregatory effect of PGE2, suggested to result from an
inhibition of adenylate cyclase activity, may also be mediated by the
EP3-receptor subtype. This is supported both by potentiation of
small reversible waves to PAF and inhibition of cicaprost-induced
increases in cyclic AMP. Whilst there is no evidence for the
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presence of an EP2-receptor subtype mediating an anti-aggregatory
effect through an increase in cyclic AMP, PGE2 and the PGE
analogues may exert such an effect through interaction with the
IP-receptor at the higher concentrations. This caused some
problems with the aggregation studies, which were overcome in
the second messenger studies. The reasoning was that any small
increases in cyclic AMP induced by PGE2 or the PGE analogues
would be masked by the much greater increase induced by
cicaprost.
Whilst a pro-inflammatory effect of PGE2 is observed when
administered i.d. into rabbit skin, other models where PGEs were
administered systemically demonstrated anti-inflammatory
responses, possibly through inhibition of mediator release. In
particular, PGE2 is reported to inhibit IL-1 release from
macrophages and subsequently the IL-1 - induced IL-2 production.
This anti-inflammatory effect of PGE2 is believed to be mediated by
an EP-receptor subtype other than the EPi-, EP2- and EP3-
receptor subtypes so far classified. Binding studies were carried
out on a purified plasma membrane preparation from HL-60 cells
differentiated into human macrophage-like cells.
Only PGE2 and 11-deoxy PGEi, an EP2-selective analogue,
inhibited the specific binding of [3H]-PGE2 out of a range of PGE
analogues tested, including others also selective for the
EP2-receptor subtype. Preliminary studies using a PGE analogue
reported to be a weak antagonist at the putative EP4-receptor
subtype (Louttit et al, 1992a,b), suggest that this additional
EP-receptor subtype may indeed be involved in this
anti-inflammatory effect of PGE2. Further studies testing the full
range of PGE analogues available on the pig saphenous vein
preparation containing this novel receptor subtype would obviously
be of great benefit.
The presence of PGE-receptor subtypes can account for some of
the often opposing effects of PGE2. Characterisation of these
subtypes is important for the development of therapeutically useful
PGE analogues. There appears to be an ever expanding range of
PGE analogues selective for the three receptor subtypes so far
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characterised, and their selectivity for the putative EP4-receptor
subtype will no doubt only be a matter of time. Compounds of
greater specificity would be of tremendous benefit in prostanoid
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CHARACTERISATION OF PGE2 RECEPTORS
MEDIATING INCREASED VASCULAR PERMEABILITY
IN INFLAMMATION
R.A. Armstrong, J.S. Matthews, R.L. Jones and N.H. Wilson
Department of Pharmacology, University of Edinburgh
1 George Square, Edinburgh, EH8 9JZ, U.K.
PGE2 has little effect on vascular permeability when injected alone
into rabbit skin, but potentiates the local exudation produced by other
inflammatory mediators. This has been attributed to its vasodilator
activity (5). However, there are potential difficulties with using PGE2
as an agonist since it is known to act on (at least) three receptor sub¬
types, designated EPi, EP2 and EP3 (3,4). We have investigated the
ability ofmore selective PGE analogues to potentiate bradykinin (BK)-











FIG. 1 Specificity of action of the PGE analogues used in this study.
EPi receptors mediate contraction of the guinea-pig ileum, fundus
and trachea in vitro; the action of PGE2 is antagonised by SC 19220
and AH 6809 (2). EP2 receptors mediate relaxation of cat trachea,
guinea-pig trachea and rabbit jugular vein in vitro, and dog hind limb
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arterial vessels in vivoEP3 actions are characterised in vitro by
contraction of the chick ileum, inhibition of transmitter release in the
guinea-pig vas deferens and inhibition of secretion in the rat isolated
gastric mucosa. No antagonists are available for EP2 or EP3 receptors.
PLASMA EXUDATION BY EP2 AGONISTS
We set up the rabbit skin model in the expectation that we would
readily characterise the prostanoid receptor mediating the potentia¬
tion of exudation as an EP2 receptor, since vasodilatation is the arche¬
typal EP2 effect. However, the initial results were surprising in that
the potent EP2 agonists butaprost (1000 ng), 11-deoxy PGEi (5000 ng)
and 11-deoxy PGE2-l-alcohol (5000 ng) were poor potentiating agents,
achieving +69%, +98% and +38% of the BK control respectively. Only
misoprostol (1000 ng) could achieve the maximal potentiation seen
with PGE2 (+265% at 1000 ng) (FIG. 2). Furthermore, whereas PGE2
at only 1 ng gave a potentiation of +108%, the EP2 agonists showed
little activity below concentrations of 100-1000 ng. The weak effects
were not due to a partial agonist action, since pre-treatment with 11-
deoxy PGE2-l-alcohol (5000 ng intradermally) did not antagonise
potentiation by PGE2 or misoprostol, but produced additive effects
(n=4).
FIG 2. The ability of PGE2, misoprostol, butaprost and 11-deoxy PGE2-l-alcohol to
potentiate plasma exudation in rabbit skin induced by intradermal bradykinin
(500ng). SAL and Drug columns represent injections of saline and drug at the
highest concentration tested, but in the absence ofBK Values are the mean ± s.e.m
of at least 4 experiments.
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PLASMA EXUDATION BY EP3 AGONISTS
EP3 activity was examined using sulprostone and M&B 28,767,
whose true activity could be assessed only after its thromboxane (TP)
agonist activity had been blocked by the TP receptor antagonist GR
32191 (2 mg/kg i.v.). M&B 28,767 (1 ng) significantly increased plasma
exudation to +78% (FIG. 3) (as compared to +20% in the absence of GR
32191). Unfortunately TP receptor block is difficult to achieve in the
rabbit, and a dose-ratio of only 15 was achieved against U 46619-
induced pulmonary hypertension. While higher concentrations of
M&B 28,767 may overcome the TP block, neither M&B 28,767 nor
sulprostone showed further potentiation with higher concentrations
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FIG. 3. The ability of sulprostone and M&B 28,767 (after GR 32191) to potentiate
plasma exudation. Conditions as in FIG. 2.
DILATATION IN THE SKIN
FIG. 4 shows dilatation in the skin, measured by a 133 Xe clearance
technique (6).
Misoprostol
1 10 100 1000 10000 100000
Prostaglandin (ng)
10 100 1000 10000 100000
Prostaglandin (ng)
FIG. 4. The ability of PGE2, misoprostol, M&B 28,767 (in the presence of 2mg/kg
GR 32191) and 11-deoxy PGE2-l-alcohol to increase blood flow in rabbit skin. Drugs
were mixed with 133 Xe (5-10 |iCi per injection) and injected intradermally. Values
are the mean ± s.e.m. of at least 4 experiments.
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PGE2 and misoprostol are potent dilators, although at 1 ng PGE2
produces little dilatation. M&B 28,767( even after TP receptor block)
and sulprostone (1000 ng, n=4) did not dilate. The EP2 agonist 11-
deoxy PGE2-l-alcohol which did not potentiate BK-exudation did not
induce dilatation, and butaprost which was slightly more effective,
induced some dilatation (50% at 1000 ng,n=3)
CONCLUSIONS
Potentiation of BK-induced exudation by PGE2 may have two compo¬
nents. Neither is mediated by an EPi receptor as 17-phenyl PGE2 does
not potentiate BK in concentrations up to 1000 ng (n=4). The high
potency (1-10 ng) component may be mediated by an EP3 receptor and
appears to be unrelated to dilatation. One possibility is that dilatation
induced by BK is potentiating an EP3 receptor-mediated, leukocyte-
dependant mechanism, as has been shown with LTB4(1). The lower
potency (100-1000 ng) component may be mediated by an EP2 receptor
and does correlate with dilatation. However, the low potency of
butaprost and the inactivity of 11-deoxy PGE2-l-alcohol suggests that
the receptor differs from the conventional EP2 subtype.
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Potentiation of aggregation and inhibition of adenylate cyclase
in human platelets by prostaglandin E analogues
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Pharmacology, Chinese University of Hong Kong, Shatin, NT, Hong Kong
1 The 16-phenoxy prostaglandin E analogue sulprostone consistently potentiates primary aggregation
waves induced by adenosine 5'-diphosphate (ADP), PAF and 11,9-epoxymethano PGH, (U-46619) in
platelet-rich plasma from human donors. The effect is not blocked by the TP-receptor antagonists,
EP092 and GR 32191. The high potency of sulprostone (threshold concentration = 4-10 nM) and the
weak block of sulprostone potentiation by the EPrreceptor antagonist, AH 6809 (pA, = 4.3) suggest the
involvement of EP3-receptors as opposed to EP,- or EP,-subtypes.
2 Eight prostaglandin E (PGE) analogues were compared against sulprostone for their effects on
PAF-induced aggregation in human platelet-rich plasma (PRP) in the presence of GR 32191 and the
DP-receptor antagonist, BW A868C. PGE2 and 11-deoxy PGE,-1-alcohol showed evidence of both
potentiating and inhibitory actions and butaprost showed only inhibitory activity at high concentrations.
The remaining analogues always elicited potentiation, with the following potency ranking: sulpros¬
tone = 16,16-dimethyl PGE,>MB 28767>misoprostol >GR 63779X = 17-phenyl-co-trinor PGE2. The
results again indicate that EP3- rather than EP,- or EP2-receptors are involved. However, relative
potentiating potency could be affected by differences in plasma protein binding and the very high
sensitivity of the human platelet to prostacyclin (IP)-receptor-mediated inhibition (IC50 for the specific
IP-receptor agonist cicaprost = 0.8 nM).
3 On human washed platelet suspensions the PGE analogues, with the exception of butaprost,
inhibited the rise in adenosine 3':5'-cyclic monophosphate (cyclic AMP) induced by cicaprost (8 nM).
PGE2 produced a monophasic inhibition curve (IC50 = 5.4 nM, 92% inhibition at 600 nM). The potency
ranking was 16,16-dimethyl PGE2>sulprostone>MB 28767 = PGE,>misoprostol> GR63778X>
17-phenyl-co-trinor PGE2> 11-deoxy PGE2-1-alcohol. AH 6809 inhibited the effect of sulprostone and
17-phenyl-co-trinor PGE, with pA2 values of 5.75 and 5.32 respectively; these values are at least one log
unit lower than those found for EP,-receptor block in smooth muscle.
4 There is a statistically significant correlation between IC50 values for the PGE analogues on the
human platelet cyclic AMP assay and the guinea-pig vas deferens (standard EP, preparation): slope =
1.00, r = 0.80, P<0.05. However the correlation is far from ideal and GR 63779X in particular has a
lower potency in the cyclic AMP assay. At this time we suggest that it is prudent to describe the human
platelet receptor as 'EP3-like'.
5 We believe that our results provide further evidence for linking PGE-induced potentiation of
aggregation to inhibition of adenylate cyclase. Sulprostone is a suitable agonist for further study of this
system and in particular the nature of the G-protein linkage(s) involved. In addition the necessity to
consider potentiation of platelet aggregation in relation to the clinical use of PGE analogues in man is
emphasised.
Keywords: Prostaglandin E2; prostacyclin; sulprostone; cicaprost; potentiation of platelet aggregation; inhibition of adenylate
cyclase; EP-receptors
Introduction
In the early phase of prostanoid research, prostaglandin E,
(PGE,) was shown to inhibit platelet aggregation in platelet-
rich plasma (PRP) from man, pig and rat (Kloeze, 1967).
This effect was associated with a rise in the adenosine 3':
5'-cyclic monophosphate (cyclic AMP) level in the platelet
(Vigdahl et al., 1969; Robison et al., 1969). Following the
discovery of prostacyclin (PGI2) (Moncada et al., 1976), it
became clear that PGE, probably behaves as an agonist at
prostacyclin (IP-) receptors on platelets (Whittle et al., 1978).
This view was strengthened by the demonstration that PGE,
competes with either [3H]-PGI2 (Siegl et al., 1979; Eggerman
et al., 1986) or [3H]-iloprost (Schillinger & Losert, 1980) for a
saturable binding site on the human platelet. PGE, is about
an order of magnitude less potent than PGI2 in both func¬
tional and binding assays.
The effect of PGE, on platelet function is more variable
and more difficult to analyse. In PRP from pig and rat, PGE2
1 Author for correspondence.
potentiated adenosine diphosphate (ADP)-induced aggrega¬
tion with threshold activity present at 100 and 10 nM respec¬
tively (Kloeze, 1967). In the same studies PGE, at 5-10|xm
inhibited aggregation in human PRP and Robison and co¬
workers (1969) showed that cyclic AMP levels were raised at
these high concentrations. Inhibition of primary aggregation
and enhancement of secondary aggregation to ADP in
human PRP have been reported for PGE2 (Shio & Ramwell,
1972; McDonald & Stewart, 1974), while enhancement of
primary phase aggregation has also been observed (Andersen
et al., 1980). More recently Gresele and co-workers (1988)
showed that PGE, (0.5-5 (iM) potentiated arachidonate-
induced aggregation in human PRP from all 'non-responders
to thromboxane synthetase inhibitors', whereas aggregation
was inhibited in 80% of the 'responder" group.
It has been suggested that PGE, interacts with a specific
receptor on the platelet surface to enhance aggregation and
its variable effects are due to an opposing (albeit weak)
anti-aggregatory action operating through the IP-receptor
(Anderson et al., 1980; Tynan et al., 1984). The same
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research group (Eggerman et al., 1986) went on to provide
evidence of a specific binding site for [3H]-PGE2 on human
platelets; the radioligand was displaced equally well by PGE,
and PGE2 (IC50~10 nM) whereas PGI2 was relatively ineffec¬
tive (IC50~3 ftM). Gray & Heptinstall (1985) suggested that
activation of this receptor leads to inhibition of adenylate
cyclase. The studies of Ashby (1988) support this view and
point to the regulatory G-protein G, as the link between
receptor and cyclase molecules.
It has been known for some time that certain PGE analo¬
gues (e.g. 16-p-fluorophenoxy-o>-tetranor PGE2) can induce
irreversible aggregation of human platelets (Jones et al.,
1979; Maclntyre et al., 1978) and that this can be attributed
(at least in part) to their agonist action at thromboxane (TP-)
receptors (Jones et al., 1982). During testing of prostanoids
for potential TP agonist activity in human PRP, we observed
that another 16-phenoxy PGE analogue, sulprostone, occa¬
sionally produced a slow aggregation wave which was not
preceded by a shape change signal; the response was not
typical of a TP-receptor agonist (e.g. 11,9-epoxymethano
PGH2 (U-46619)), but was similar to that produced by
adrenaline in some PRP samples (see Hourani & Cusack,
1991). On further investigation we found that sulprostone at
low concentrations potentiated primary aggregation res¬
ponses to ADP, PAF and U-46619 in PRP from all donors
examined. This led us to suggest that sulprostone might be a
specific agonist for the 'pro-aggregation receptor' negatively
linked to adenylate cyclase. This paper describes experiments




The preparation of PRP and washed platelet suspensions
(using PGI2) from human blood and the measurement of
shape change and aggregation responses were carried out as
recently described by us (Tymkewycz et al., 1991). GR 32191
(500 nM) and BW A868C (200 nM) were added to the bulk of
the PRP at the start of the aggregation measurements. For
the study of potentiation, the PGE analogue was added to an
aliquot of PRP, 2 min before a fixed dose of the aggregating
agent and aggregation was measured for a further 1-2 min.
The concentrations of ADP (500-800 nM) and PAF (15-50
nM) were chosen to give an aggregation response between
15-20% of the maximum aggregation response for each
agent (obtained with 10 and 1 pM respectively). Sulprostone
was used as the standard potentiating agonist and a con¬
centration-response curve involving duplicate measurements
was obtained for each PGE analogue over a time period
when a submaximal potentiation response to sulprostone
remained constant. Responses were calculated as a percen¬
tage of the control response and an ECi50 value, representing
a 50% increase in aggregation response over control was
calculated. Measurements were completed within 2 h of
aspiration of the PRP. For the study of inhibition of aggre¬
gation in PRP by cicaprost, PGE, and PGE2, ADP at a
concentration of 2 pM (in a few instances 4 pM) was used to
produce a 75% maximal aggregation response.
Cyclic AMP measurements
Fresh human PRP or time-expired (5 days at room tempera¬
ture) human platelet concentrates were treated with 10pM
indomethacin and then centrifuged at 450 g for 20 min. The
pellet was suspended in sufficient 0.05 M Tris buffer pH 7.4
containing 4 mM EDTA at 37°C to give an absorbance at
600 nm of about 1.4 (10 mm pathlength). In 10 experiments
using 180 ml of fresh blood, the protein content of the
suspension (45 ml), as measured by the method of Bradford
(1976), was found to be 1.5 ± 0.1 mg ml"1 (mean ± s.e.mean).
GR 32191 (0.5 pM) was added to the platelet suspension.
Duplicate 0.5 ml aliquots of the suspension were incubated
with the varying concentrations of PGE analogue for 2 min,
followed by 8 nM cicaprost for 1 min. In each experiment a
single concentration of sulprostone (6.45 nM) was included to
ensure that the cyclase inhibitory effect was functioning.
After quenching with 1 ml ethanol, the precipitated material
was sedimented by centrifugation at about lOOOg for 30 min.
The supernatant was removed, evaporated to dryness and the
residue dissolved in 0.25 ml assay buffer. Insoluble material
was sedimented by centrifugation at 2300 g for 30 min at
4°C. The cyclic AMP content of duplicate 50 pi aliquots of
supernatant was assayed by competition with [8-3H]-cyclic
AMP ammonium salt (21 Cimmol"1, Amersham) for bind¬
ing to cyclic AMP-dependent protein kinase from bovine
adrenal cortex (BDH). Recovery of cyclic AMP (60 pmol
ml"1) added to the washed platelet suspension, extracted and
assayed as above was 85 ± 5% (« = 5). Also recovery of
radioactivity following addition of labelled cyclic AMP to the
washed platelet suspension, extraction and dissolution in
buffer was 94 ± 3% (n = 5). Log concentration-inhibition
curves were plotted and IC50 values calculated; for fresh
platelets these corresponded to 55% of control cyclic AMP
(taking maximum inhibition as 10% of control) and for
stored platelets to 60% of control (maximum = 20%).
Compounds
11-Deoxy PGE2-1-alcohol (starting material nat PGA2) and
EP 092 (rac 9a,l la-ethano-co-heptanor-13-methyl-13-phenyl-
thiocarbamoylhydrazino-prosta-5Z-enoic acid) were prepared
in our laboratory. The following compounds were gifts: sul¬
prostone, PGI2 sodium salt and cicaprost from Prof. H.
Vorbruggen, Schering AG, Berlin, Germany; MB 28767 (rac
15S- hydroxy-9-oxo-16-phenoxy-u> -tetranor-prost- 13E- enoic
acid) from Dr M. Caton, Rhone-Poulenc, U.K.; misoprostol
from Dr P. Collins, G.D. Searle, U.S.A.; butaprost from Dr
P. Gardiner, Bayer, U.K.; AH 6809 (6-isopropoxy-9-oxoxan-
thene-2-carboxylic acid), GR 32191 (9oc-(biphenylyl)methoxy-
1 ljl- hydroxy-12/5 -(N-piperidinyl)-a) -octanor- prost-4Z -enoic
acid) and GR 63799X (13-oxa-13,14-dihydro-16-phenoxy-co-
tetranor PGE2-4-(benzoylamino)phenyl ester) from Dr R.A.
Coleman, Glaxo, U.K. PGE2, 16,16-dimethyl PGE2, 17-phe-
nyl-w-trinor PGE2, 11-deoxy PGE, and U-46619 (11,9-epoxy-
methano PGH2) were purchased from Cayman Chemicals,
U.S.A. Ethanolic stock solutions of the prostanoids (10-30
mm) were stored at — 20°C and diluted with 0.9% NaCl
solution (saline) for use. Due to its low water solubility, GR
63779X was stored in ethanol at a concentration of 0.4 mm.
Saline dilutions of 20 pM and less were prepared and used for
one day only. An aliquot of a 2 mg ml"1 chloroform solution
of PAF (L-isomer, Sigma) was evaporated to dryness with a
nitrogen jet and the residue dissolved in saline to give a
10"4 m stock solution. A 10"3 m ADP stock solution was
prepared by dissolving ADP (Grade III, Sigma) in saline and
adjusting the pH to 6.8 by addition of solid NaHCO,.
Results
Potentiation of aggregation in human PRP
Initial observations on sulprostone and PGE: Shape change
and aggregation in citrated human PRP were recorded by the
conventional light scattering method. In about half of the 31
donors examined, sulprostone between 4 and 400 nM had no
effect on the oscillatory signal associated with stirring a
suspension of non-activated (discoid) platelets. In the remain¬
ing donors, 4-50 nM sulprostone also had no effect, but at
100-400 nM a slow increase in light transmission with some
decrease in oscillation was seen (see Figure la, sulprostone
100 nM). This type of response was quite different from the
rapid shape change (decrease in light transmission with loss




Control Sul 20 Sul 100 nM
ADP 500 nM
Control Sul 10 Sul 50 Sul 200 nM
Figure 1 Light transmission records showing the potentiating effect
of sulprostone (Sul) on platelet aggregation in human PRP induced
by (a) U-46619 (no antagonists present) and (b) ADP in the presence
of 1 pM EP 092. U-46619/ADP were added at (•) and sulprostone
was added 2 min before each dose of aggregating agent.
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Figure 2 Log concentration-response curves for platelet aggregation
in human platelet-rich plasma (PRP) in the presence of GR 32191
(0.5 pM). Control response = 100%. Vertical bars indicate s.e.mean.
(a) Effects of sulprostone (O) (mean of 8 donors) and prostaglandin
E2 (PGE2, •, □ , ■) (three individual donors) on small primary
waves induced by ADP. (b) Effects of cicaprost (A) (n = 8), PGEi
(A) (n = 4) and PGE2 (□) (n = 4) on 75% maximal aggregation
responses induced by ADP.
of oscillation) and reversible aggregation induced by low
concentrations of ADP (500 nM), PAF (20 nM) or U-46619
(100 nM) (Figure 1). 'Slow waves' to sulprostone were un¬
affected by the TP-receptor antagonists EP 092 (1 pM) and
GR 32919 (0.5 pM); both antagonists blocked shape change/
reversible aggregation responses to U-46619, but not those to
ADP and PAF.
Irrespective of whether slow waves were seen, sulprostone
(4-400 nM) consistently potentiated aggregation responses to
ADP, PAF and U-46619. At the lower sulprostone concen¬
trations the small reversible aggregation wave to a fixed
concentration of each aggregating agent was increased in
size. At the higher concentrations the potentiation was great
enough to elicit secondary aggregation, particulary with U-
46619 (Figure la). Although EP 092 (1 pM) and GR 32191
(0.5 pM) abolished secondary aggregation, they did not
inhibit sulprostone potentiation of primary aggregation
waves to ADP (Figure lb) and PAF. The log concentration-
response curve (mean values using PRPs from 8 donors) for
sulprostone potentiation of ADP-induced aggregation in the
presence of 0.5 pM GR 32191 is shown in Figure 2a.
Unlike sulprostone, PGE2 showed variable effects on small
primary waves induced by ADP. In PRPs from 2 of the 8
donors investigated PGE2 (10-5000 nM) only inhibited aggre¬
gation, the log concentration-response curves being rather
shallow (Figure 2a, filled squares). In the remaining 6 PRP
samples, potentiation of aggregation was seen at the lower
concentrations of PGE2 tested (10-50 nM). As the concentra¬
tion of PGE2 was increased, either a bell-shaped potentiation
curve was obtained (Figure 2a, filled circles) or a switch to
inhibition of aggregation was observed (Figure 2a, unfilled
squares).
For comparison, the effects of cicaprost (a stable pros¬
tacyclin analogue), PGE, and PGE2 on 75% maximal aggre¬
gation responses to ADP in the presence of GR 32191
(0.5 pM) are shown in Figure 2b. Cicaprost was a highly
potent inhibitor of aggregation (IC50~0.8 nM). PGE, also
inhibited aggregation, being 15-20 times less potent than
cicaprost and having a slightly shallower log concentration-
response curve. PGE2 (50-5000 nM) potentiated aggregation
such that maximum aggregation was often produced;
between 10 and 62.5 pM PGE2 always inhibited aggregation.
Effect of AH 6809 In three experiments, the EP,-receptor
antagonist, AH 6809, at 10 pM had no effect on sulprostone
potentiation of ADP-induced aggregation. With 100 pM AH
6809, there was a modest parallel shift to the right of the
sulprostone log concentration-response curve, giving dose-
ratios of 2.0, 3.2 and 4.4.
Activities of other PGE analogues Preliminary experiments
appeared to show that the potentiating effect of PGE2 was
favoured over its inhibitory effect when PAF was used as the
aggregating agent in place of ADP. The effects of nine PGE
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Figure 3 Effects of prostaglandin E (PGE) analogues on PAF-
induced aggregation in human platelet-rich plasma (PRP) in the
presence of GR 32191 (0.5 pM) and BW A868C (0.2 pM). Control
response = 100%. Vertical bars indicate s.e.mean. (a) Sulprostone
(O) (n = 6); MB 28767 (•) (n = 4); GR 63779X (□), (n = 4). (b)
16,16-dimethyl PGE, (O); misoprostol (•); 17-phenyl-co-trinor
PGE2 (□); 11-deoxy PGE2-1-alcohol (■) (all n = 4).
analogues were therefore tested for their ability to potentiate
PAF-induced aggregation in PRP. In addition to GR 32191
(0.5 ftM), BW A868C (0.2 pM) was added to prevent any
inhibition of aggregation through activation of DP-receptors.
GR 32191 was preferred to EP 092 because the block of
TP-receptors produced by the former is more difficult to
surmount (see Tymkewycz et al., 1990). Six of the analogues,
sulprostone, 16,16-dimethyl PGE,, MB 28767, misoprostol,
GR 63779X and 17-phenyl-co-trinor PGE, showed consistent
potentiating activity (Figure 3), although the log concen¬
tration-response curves for misoprostol, MB 28767 and in
particular GR 63779X and 17-phenyl-<o-trinor PGE, were
shallower than those of sulprostone and 16,16-dimethyl
PGE2. Equi-effective molar ratios (EMR) calculated at the
150% control level are given in Table 1. The testing of GR
63779X was affected by the high proportion of ethanol
required to solubilize this prostanoid. Thus 20 mM ethanol
(corresponding to 0.4 pM GR 63779X) did not affect PAF
aggregation; 100 mM ethanol (2 pM GR 63779X) reduced the
PAF response by 11 ±3% (w = 4) and 200 mM ethanol by
51 ± 6%. At the highest concentrations of misoprostol and
11-deoxy PGE2-1-alcohol used, the ethanol concentration in
the PRP was 20 mM.
PGE2 (20-1000 nM) and 11-deoxy PGE2-1-alcohol (100-
10,000 nM) still showed variable actions. In some donors,
potentiation with a shallow log concentration-response curve
was seen and in others there was evidence of inhibition of the
PAF aggregation. In the final analysis it appears that the use
of PAF may not have a significant advantage over ADP.
Butaprost (10-3000 nM) inhibited only PAF aggregation
(IC50 = 0.95, 1.3, 1.5 pM, 3 donors).
Inhibition of cyclic AMP production
Due to difficulties in obtaining large quantities of fresh
human blood, some experiments were performed on time-
expired platelet concentrates supplied by the local blood
transfusion service. Cyclic AMP levels in suspensions of the
washed platelets were measured with a radiolabelled cyclic
AMP/protein binding assay. Elevations of cyclic AMP induc¬
ed by cicaprost in the presence of 0.5 pM GR 32191 are
shown in Figure 4a; Fresh and stored platelets gave similar
log concentration-response curves; EC50 values were about 10
and 8.5 nM respectively. For all subsequent inhibition experi¬
ments, a cicaprost concentration of 8 nM was chosen to
induce a submaximal (control) rise in cyclic AMP.
The effects of pre-incubation of the PGE analogues on the
cicaprost-induced rise in cyclic AMP in the presence of
0.5 pM GR 32191 are shown in Figure 4. All of the PGE
analogues inhibited cyclic AMP accumulation with the excep¬
tion of butaprost; IC50 values and EMR are given in Table 1.
The slopes of the inhibition curves for the stored platelets
were somewhat shallower than those of the fresh platelets,
although sensitivities to sulprostone were similar (IC50 = 2.2
and 2.0 nM respectively).
AH 6809 at a concentration of 10pM shifted the log
concentration-response curves to sulprostone and 17-phenyl-
co-trinor PGE, to the right (dose-ratio = 7.2 and 3.9 respec¬
tively) (Figure 4b). pA, values calculated using the Schild
equation are 5.75 and 5.32 respectively.




aggregation in AMP in human Contraction of Inhibition of guinea-
PGE analogue human PRP washed platelets guinea-pig trachea pig vas deferens
Sulprostone 1.0 1.0 1.0 1.0
(EC150 — 10 nM) (IC50 = 2.2/2.0 nM*) (EC50 = 7 nM) (ic50 — 0.2 nM)
16,16-Dimethyl PGE2 1.3 0.34* 0.022 0.93
MB28767 6.8 2.1* >150 5.0
pge2 4 2.5 A 7.1
Misoprostol 13 10.3* t 3.6
GR 63779X 26 20 14 1.7
17-PhenyI-co-trinor PGE, 29 37 0.32 45
11-Deoxy PGE,-1-alcohol \ 180 t 79
Butaprost i >350 4 >7000
Human platelet data were obtained in the present study. Guinea-pig trachea and vas deferens values are from Lawrence et al., 1992,
except those for GR 63779X which are our unpublished values, in agreement with Bunce et al., 1990. 'Values for stored platelets.
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Figure 4 Effects of prostaglandin E (PGE) analogues on cicaprost-induced elevation of cyclic AMP in human washed platelets.
GR 32191 (0.5 fiM) was present in all experiments. Vertical bars indicate s.e.mean; n = 4 in (b) (c) and (d). (a) Elevation of cyclic
AMP by cicaprost in fresh (O) (n = 6) and stored (•) (n = 3, no error bars) platelets. B = basal condition; 8 nM cicaprost was used
in (b) (c) and (d); cyclic AMP generated = 100%. (b) Fresh platelets: inhibition curves for sulprostone (O); sulprostone in the
presence of 10 gM AH 6809 (•); 17-phenyl-co-trinor PGE2 (□) and 17-phenyl-co-trinor PGE2 in the presence of 10 pM AH 6809
(■). (c) Fresh platelets: inhibition curves for PGE2 (O); GR 63779X (•); 11-deoxy PGE2-1 -alcohol (□) and butaprost (■). (d)
Stored platelets: inhibition curves for sulprostone (O); 16,16-dimethyl PGE2 (•); misoprostol (□) and MB 28767 (■).
Discussion
We have shown that several analogues of PGE2 consistently
potentiate ADP- or PAF-induced aggregation in human PRP
in the presence of a specific TP-receptor antagonist such as
EP 092 (Armstrong et al., 1985) or GR 32191 (Lumley et al.,
1989). Sulprostone and 16,16-dimethyl PGE2 were the most
active agents, with threshold responses seen at about 2 nM in
some PRPs. However sulprostone was chosen as the standard
agonist since it is a weaker TP-receptor agonist than 16,16-
dimethyl PGE2. For example, 16,16-dimethyl PGE2 can elicit
irreversible aggregation in human PRP and is a medium
potency full agonist on the rat aorta, rabbit aorta and dog
saphenous vein (see Tymkewycz et al., 1991), whereas sulpro¬
stone does not induce typical thromboxane-like aggregation
and is a very weak agonist on the rat aorta (Coleman et al.,
1988) and rabbit aorta (R.L. Jones, unpublished observa¬
tions).
Two factors may affect estimations of the relative poten¬
tiating potencies of the PGE analogues under investigation.
First, there may be differences in the amounts of the PGE
analogues bound to plasma protein in the PRP. Secondly,
and probably of greater importance, the human platelet con¬
tains a highly sensitive IP-receptor-adenylate cyclase system
which when activated inhibits aggregation. This is illustrated
in our experiments by the high potency of cicaprost (IC50
against ADP-induced aggregation = 0.8 nM). Thus the mixed
effects of PGE2 on PAF aggregation in the presence of the
potent and specific DP-receptor antagonist BW A868C (Giles
et al., 1989) are most easily explained by a concurrent activa¬
tion of EP- and IP-receptors over the 50 nM to 5 pM concen¬
tration-range. Previous studies with the weak DP-receptor
antagonist, N-0164, have produced conflicting results for
PGE2. In the earlier study, N-0164 suppressed the platelet
inhibitory action of PGD2 and PGE2, but did not affect the
inhibitory actions of PGE, (Maclntyre & Gordon, 1977),
whereas in a later study the inhibitory actions of PGI2, PGE,
and PGE2 were unaffected (Tynan et al., 1984). The shallow¬
er log concentration-potentiation curves for MB 28767,
misoprostol, 17-phenyl-co-trinor PGE2 and 11-deoxy PGE2
1-alcohol could also reflect IP-receptor activation by these
analogues at concentrations of 1 pM and above.
Taking the EC150 as a measure of potentiating potency,
then the ranking is as follows: sulprostone = 16,16-dimethyl
PGE2> MB 28767 7* misoprostol GR 63779X = 17-
phenyl-co-trinor PGE2. The high potency of sulprostone as a
potentiator implies that an EP2-receptor is unlikely to be
involved. EP2-receptors are associated with the relaxant
actions of PGE2 on vascular and respiratory smooth muscle
and sulprostone is virtually inactive in these systems (Col¬
eman et al., 1987a,b; Lawrence & Jones, 1992). Furthermore
it is likely that the EP3 rather than the EP, subtype mediates
the potentiating effect, since sulprostone and MB 28767 are
more potent than 17-phenyl-oj-trinor PGE2 on the guinea-pig
vas deferens (EP3 preparation) and vice versa for the guinea-
pig trachea (EP, preparation) (Lawrence et al., 1992) (see
Table 1). It should be noted that we are using the guinea-pig
vas deferens as the standard EP3 preparation, since there is
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now evidence (Lawrence & Jones, 1992) that the chick ileum,
the original EP3 preparation (Coleman et al., 1987a,b), con¬
tains more than one EP-receptor.
PGE, is a highly potent EP3 agonist, being slightly more
potent than PGE2 and about 5 times less active than sulpros-
tone (see Coleman et al., 1990). But for its prostacyclin-like
activity we would expect it to potentiate aggregation at con¬
centrations of 30 nM and above. The slightly shallower inhi¬
bition curve for PGEb also observed previously by Andersen
and colleagues (1980), may reflect the existence of an oppos¬
ing potentiation.
Preliminary experiments on human washed platelets show¬
ed that sulprostone produced marked potentiation of aggre¬
gation, but mixed effects were still seen with PGE2 and
11-deoxy PGE2-l-alcohol. Because of this and the greater
difficulties of working with washed platelets, we felt that it
was hardly worthwhile attempting to obtain potentiating
potencies on washed platelets. Instead we concentrated our
efforts on developing an assay based on the putative second
messenger mechanism, namely inhibition of adenylate cyclase
in a low protein system. Our aim was to accentuate the EP
agonist action of a PGE analogue at the expense of its IP
agonist action. Cicaprost was chosen as the agent to raise the
cyclic AMP level since it is a stable and specific IP-receptor
agonist. In particular it lacks the potent EP,-receptor agonist
activity shown by other carbacyclins, such as iloprost and
6a-carba PGL (Dong et al., 1986; Lawrence et al., 1992).
Furthermore it has less EP3-agonist activity than iloprost and
carbacyclin on the guinea-pig vas deferens (Lawrence et al.,
1992). Ashby (1992) has suggested from analysis of the time
course of cyclic AMP accumulation in intact human platelets
that both iloprost and cicaprost activate an inhibitory recep¬
tor to reduce cyclic AMP accumulation. However the initial
rise in cyclic AMP is only rapidly suppressed at high concen¬
trations (3 jim) of each prostacyclin analogue and it is easily
possible that the slow fade of the cyclic AMP level seen with
lower concentrations (30 nM) is due to a mechanism other
than activation of an inhibitory receptor. In our experiments
we deliberately used a low concentration of cicaprost (8 nM,
~EC50, Figure 4a), which is unlikely to activate the EP-
receptor. In addition submaximal stimulation of adenylate
cyclase should allow the greatest opportunity for PGE-
induced inhibition of the enzyme complex. The success of our
strategy can be judged by the high sensitivities and
monophasic inhibition curves obtained for both sulprostone
and PGE2 (IC50 = 2.2 and 5.4 nM respectively).
Reconsidering the nature of the EP-receptor involved, the
low potency of 17-phenyl-w-trinor PGE2 relative to sulpros¬
tone and MB 28767 again indicates that the EP,-receptor
subtype is unlikely to be involved. Furthermore AH 6809
shows a much weaker blocking effect (pA2 = 5.3/5.76) than
would be expected for EPrreceptor antagonism (pA2 on
guinea-pig trachea = 7.35, 17-phenyl-oa-trinor PGE2 as agon¬
ist, Lawrence et al., 1992). The even lower pA2 value (~4.3)
obtained for block of sulprostone potentation by AH 6809 in
the aggregation assay is probably due to plasma protein
binding of the antagonist. Coleman and colleagues (1985)
have shown that about 98% of AH 6809 is bound to 4%
defatted bovine serum albumen. In our PRP system, 90-
95% binding of AH 6809 to the 2% total plasma protein
present would account for the difference between the pA-
values. AH 6809 is not a particularly specific EP[ antagonist
and will also block DP- and TP-receptors on human washed
platelets at a concentration of 10 ftM (pA2 = 6.3 and 5.9,
calculated from data in Keery & Lumley, 1988).
Finally, how good is the correlation between the potencies
of the PGE analogues for inhibition of adenylate cyclase in
human platelets and for inhibition of the twitch response of
the guinea-pig vas deferens, the standard EP3 preparation
(Table 1)? Using log EMRs, the least squares regression line
has a slope of 1.00 and a correlation coefficient of 0.80
(P<0.05). However, this is not a particularly convincing
correlation. The greatest discrepancy is the higher potency of
GR 63779X on the vas deferens compared to the adenylate
cyclase system (and also the aggregation assay). GR 63779X
has an agonist specificity similar to sulprostone (EP3>
EP,»EP2) (Bunce et al., 1990) and although there are
clearly difficulties in its use owing to its low water solubility,
we feel that our potency estimations are valid. Consequently
we consider it prudent to err on the side of caution and
pending further studies to refer to the EP-receptor in the
human platelet as 'EP3-like'.
It seems reasonable to propose from our experiments and
the studies of Ashby (1988) that activation of EP3-like recep¬
tors on the platelet membrane inhibits adenylate cyclase
through the intermediary of G;, and this leads to potentiation
of aggregation. Other human platelet receptors known to
operate in a similar manner are the ADP receptor (a type of
P2-purinoceptor) and the a2-adrenoceptor (see Hourani &
Cusack, 1991, for a review of this area). In an elegant study
Brass and colleagues (1988) have investigated the nature of
the G-proteins mediating pertussis toxin-sensitive phospho-
lipase C activation (Gp) and adenylate cyclase inhibition (Gi)
in human platelets. Thrombin stimulated PI hydrolysis and
inhibited cyclic AMP accumulation and this was associated
with >90% ADP-ribosylation of the extracted G-protein. In
contrast, adrenaline only inhibited cyclic AMP accumulation
in concert with 50% ADP-ribosylation; U-46619 neither inhi¬
bited cyclic AMP nor induced pertussis toxin-sensitive PI
hydrolysis. It appears that the G-proteins regulating both PI
hydrolysis and inhibition of cyclic AMP formation in this
system are very similar in nature and the possibility that they
are the same chemical species has been raised. Clearly it
would be of interest to investigate by similar methods the
nature of the G-protein(s) interacting with the EP3-like recep¬
tor of the human platelet; from our studies sulprostone
would be the most useful agonist for this purpose.
In conclusion, our results are relevant to the therapeutic
use of PGE analogues in man. TP-agonist activity in a PGE
analogue is an obvious risk factor. However, the possibility
of a PGE analogue potentiating platelet aggregation via EP3-
like receptors should also be taken into consideration.
Gifts of compounds listed in the Methods section are gratefully
acknowledged. We thank the Blood Transfusion Serivce at the Royal
Infirmary of Edinburgh for generously supplying the platelet concen¬
trates.
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